PMID,Multiple Answer,time_usage
18715920,"Here are the answers to the questions based on the provided paper:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""viral RNA was extracted from culture supernatant or virus stock"" and ""genotyping of the IN-encoding region of the pol gene of the viruses"".

Rationale: The paper reports HIV sequences from patient samples, specifically from culture supernatant or virus stock.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""antiviral assays"" and ""determination of viral p24 levels"" to measure the susceptibility of HIV-1 strains to different IN inhibitors.

Rationale: The paper reports in vitro drug susceptibility data, specifically the susceptibility of HIV-1 strains to different IN inhibitors.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not report GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals.

Rationale: The paper does not report the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the samples.

Rationale: The paper does not report the country of origin of the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not report the year of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""viral RNA was extracted from culture supernatant or virus stock"" but does not mention cloning.

Rationale: The paper does not report cloning prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""genotyping of the IN-encoding region of the pol gene of the viruses"".

Rationale: The paper reports sequencing of the IN gene.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""automated population-based full-sequence analysis (ABI Prism BigDye Terminator cycle sequencing)"".

Rationale: The paper reports using Sanger sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from culture supernatant or virus stock"".

Rationale: The paper reports sequencing of viral RNA from culture supernatant or virus stock.

Answer: Viral RNA from culture supernatant or virus stock

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virus breakthrough"" and ""virologic failure"" in the context of selecting resistant viruses.

Rationale: The paper reports sequencing of viruses from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report the patients being in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""virus breakthrough"" and ""virologic failure"" in the context of selecting resistant viruses.

Rationale: The paper reports sequencing of viruses from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""IN inhibitors"" and specifically mentions ""EVG"" and ""RAL"".

Rationale: The paper reports that individuals received IN inhibitors, specifically EVG and RAL, before sample sequencing.

Answer: IN inhibitors (EVG and RAL)

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""EVG"" and ""RAL"" as the specific drugs used in the study.

Rationale: The paper reports that individuals received EVG and RAL before sample sequencing.

Answer: EVG and RAL",62
19104010,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients. However, it does mention that the antiviral activity of GS-9160 was evaluated in HIV-1-infected MT-2 and MT-4 cell lines as well as in primary human T lymphocytes.

Rationale: Based on the information provided, it appears that the paper does not report HIV sequences from patient samples. The antiviral activity of GS-9160 was evaluated in cell lines and primary human T lymphocytes, but there is no mention of sequencing patient samples.

Answer: No.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper reports the antiviral activity of GS-9160 in HIV-1-infected MT-2 and MT-4 cell lines as well as in primary human T lymphocytes. It also mentions the EC50 values of GS-9160 in the presence of human serum and the human serum components HSA and α1-AGP.

Rationale: The paper reports in vitro drug susceptibility data, including the antiviral activity of GS-9160 in different cell types and the effect of human serum on its potency.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: Based on the information provided, it appears that the sequences from the paper were not made publicly available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report GenBank accession numbers for sequenced HIV isolates.

Rationale: Not applicable.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: Based on the information provided, it appears that the paper does not report the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: Not applicable, as the paper does not report the country of origin for the sequenced samples.

Rationale: Not applicable.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: Not applicable, as the paper does not report the year of sample collection.

Rationale: Not applicable.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: Based on the information provided, it appears that the paper does not report cloning of samples prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: Based on the information provided, it appears that the paper does not report the specific HIV genes that were sequenced.

Answer: Not reported.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: Based on the information provided, it appears that the paper does not report the sequencing method used.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: Not applicable, as the paper does not report the type of samples sequenced.

Rationale: Not applicable.

Answer: Not reported.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens.

Rationale: Based on the information provided, it appears that the paper does not report sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: Based on the information provided, it appears that the paper does not report a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention previous ARV drug use.

Rationale: Based on the information provided, it appears that the paper does not report HIV sequences from individuals who had previously received ARV drugs.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: Not applicable, as the paper does not report previous ARV drug use.

Rationale: Not applicable.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: Not applicable, as the paper does not report previous ARV drug use.

Rationale: Not applicable.

Answer: Not reported.",64
21115794,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention HIV sequences from patient samples. It mentions HIV-1 strain IIIB, HIV-1 NL432, and HIV-1 Ba-L, which are laboratory strains.

Rationale: The paper does not report HIV sequences from patient samples. It only mentions laboratory strains and site-directed mutants.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper reports in vitro drug susceptibility data, including IC50 values and fold-change in susceptibility.

Rationale: The paper reports in vitro drug susceptibility data, including IC50 values and fold-change in susceptibility, which indicates that it reports in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not mention that sequences were made publicly available, and it does not provide any accession numbers.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, and it does not mention that sequences were made publicly available.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention that samples were obtained from individuals for HIV sequencing.

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention that samples were obtained from individuals for HIV sequencing.

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention that samples were obtained from individuals for HIV sequencing.

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not mention that samples were cloned prior to sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the integrase gene.

Rationale: The paper mentions the integrase gene, which is one of the HIV genes.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not mention the sequencing method, but it mentions that the integrase region of HIV proviral DNA was amplified by PCR with specific primers.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention that samples were obtained from individuals for HIV sequencing.

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention that samples were obtained from individuals for HIV sequencing.

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that patients were in a clinical trial.

Rationale: The paper does not mention that patients were in a clinical trial, and it only mentions laboratory strains and site-directed mutants.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention that samples were obtained from individuals for HIV sequencing.

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that samples were obtained from individuals for HIV sequencing.

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that samples were obtained from individuals for HIV sequencing.

Rationale: The paper does not mention that samples were obtained from individuals for HIV sequencing, and it only mentions laboratory strains and site-directed mutants.

Answer: Not reported
""""""",64
23749954,"Here are the answers to the questions based on the provided paper:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly state that it reports HIV sequences from patient samples, but it does mention that it uses cell culture drug selections with various drugs in MT2 cells.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples, but it does describe experiments using cell culture drug selections, which may involve HIV sequences.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions cell culture drug selections with various drugs in MT2 cells and reports the selection of resistance mutations.

Rationale: The paper provides evidence of in vitro drug susceptibility data through its cell culture drug selections and reporting of resistance mutations.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals with samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals with samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions the reverse transcriptase gene.

Rationale: The paper provides evidence of sequencing the reverse transcriptase gene through its discussion of resistance mutations.

Answer: RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions cell culture drug selections in MT2 cells.

Rationale: The paper provides evidence of sequencing cell culture samples.

Answer: Cell culture
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information about virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention previous ARV drug use.

Rationale: The paper does not provide any information about previous ARV drug use.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions N(t)RTIs.

Rationale: The paper provides evidence of N(t)RTI use through its discussion of resistance mutations.

Answer: N(t)RTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions tenofovir, didanosine, stavudine, apricitabine, and abacavir.

Rationale: The paper provides evidence of these drug uses through its discussion of resistance mutations.

Answer: Tenofovir, didanosine, stavudine, apricitabine, and abacavir
""""""",53
24227862,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients. However, it does mention that ""viral RNA was extracted from plasma"" and ""viral supernatants were harvested at 48 h posttransfection, centrifuged for 5 min at 800 × *g* to remove cellular debris, filtered through a 0.45-μm-pore-size filter, aliquoted, and stored at −80°C.""

Rationale: Although the paper does not directly state that HIV sequences were obtained from patient samples, it does describe the process of extracting viral RNA from plasma and harvesting viral supernatants, which suggests that the study involved working with patient-derived samples.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility analyses of RT inhibitors"" and ""the EC ~50~ was calculated by using the GraphPad Prism program."" It also describes the use of a ""TZM-bl cell-based *in vitro* assay"" to determine the susceptibility of RT inhibitors.

Rationale: The paper explicitly states that it reports phenotypic susceptibility data, which is a type of in vitro drug susceptibility data.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to GenBank or any other public database.

Rationale: Since the paper does not mention submitting sequences to a public database, it is unlikely that the sequences are publicly available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not mention GenBank accession numbers.

Rationale: Since the paper does not mention GenBank accession numbers, it is not possible to provide an answer to this question.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly state the number of individuals who had samples obtained for HIV sequencing.

Rationale: Although the paper does not provide a specific number, it does mention that ""CBMCs were infected with viruses at the same multiplicity of infection"" and ""viral stocks of WT HIV-1 ~NL4.3~ and the E138K, E138K/N348I, and E138K/M184V/N348I mutants were harvested by transfection of HEK293T cells,"" which suggests that the study involved working with a limited number of samples.

Answer: Not reported.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: Since the paper does not provide information about the country of origin, it is not possible to provide an answer to this question.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the sequenced samples were obtained.

Rationale: Although the paper does not provide specific years, it does mention that the study was conducted over a period of 19 weeks, which suggests that the samples were obtained relatively recently.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly state whether samples were cloned prior to sequencing.

Rationale: Although the paper does not provide information about cloning, it does mention that ""site-directed mutagenesis reactions were carried out by using a QuikChange II XL site-directed mutagenesis kit,"" which suggests that the study involved working with cloned samples.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""the RT gene"" was sequenced.

Rationale: Since the paper explicitly mentions the RT gene, it is likely that this is the only gene that was sequenced.

Answer: RT.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly state the sequencing method used.

Rationale: Although the paper does not provide information about the sequencing method, it does mention that ""DNA sequencing was performed to verify the absence of spurious mutations and the presence of any desired mutation in the RT coding sequences,"" which suggests that the study involved using a standard sequencing method such as Sanger sequencing.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""viral RNA was extracted from plasma"" and ""viral supernatants were harvested at 48 h posttransfection.""

Rationale: Since the paper mentions plasma and viral supernatants, it is likely that the samples sequenced were plasma-derived.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""viral resistance mutations were selected by using increasing drug concentrations over a period of 19 weeks.""

Rationale: Since the paper mentions selecting for viral resistance mutations, it is likely that the sequences obtained were from individuals with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state whether the patients were in a clinical trial.

Rationale: Although the paper does not provide information about a clinical trial, it does mention that ""viral resistance mutations were selected by using increasing drug concentrations over a period of 19 weeks,"" which suggests that the study may have been conducted in a clinical trial setting.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""the N348I mutation is associated with the use of ZDV and NVP.""

Rationale: Since the paper mentions specific ARV drugs, it is likely that the sequences obtained were from individuals who had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""the N348I mutation is associated with the use of ZDV and NVP.""

Rationale: Since the paper mentions specific ARV drugs, it is likely that the individuals in the study received NRTIs (ZDV) and NNRTIs (NVP) before sample sequencing.

Answer: NRTIs, NNRTIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""the N348I mutation is associated with the use of ZDV and NVP.""

Rationale: Since the paper mentions specific ARV drugs, it is likely that the individuals in the study received ZDV and NVP before sample sequencing.

Answer: ZDV, NVP.",89
25637519,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"" and ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper reports HIV sequences from patient samples, including their corresponding GenBank accession numbers.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" and ""IC50"", ""EC50"", ""EC90"", ""fold-change in susceptibility"", or ""reduced susceptibility"".

Rationale: The paper reports in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"" and accession numbers for GenBank or any of the above databases.

Rationale: The sequences from the paper were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide information on whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""reverse transcriptase (RT)"".

Rationale: The paper reports that the pol gene, specifically the reverse transcriptase (RT) region, was sequenced.

Answer: Pol, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments (ABI PRISM/Applied Biosystems 310/3100/3130/3130xl/3500/3500xl/3730/3730xl/3100-Avant)"".

Rationale: The paper reports that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"".

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions ""virologic or virological failure (VF)"" and ""failing therapy or regimen"".

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ""on ART/cART/HAART"", ""ART-experienced"", ""treatment-experienced"", ""heavily pretreated"", ""salvage regimen"", or ""prior ARV exposure/regimens"".

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""NNRTI"", ""NRTI"", ""PI"", ""INSTI"", and specific drugs such as ""nevirapine"", ""efavirenz"", ""rilpivirine"", ""zidovudine"", ""abacavir"", ""lamivudine"", ""emtricitabine"", and ""tenofovir"".

Rationale: The paper reports that individuals in the study received NNRTIs, NRTIs, PIs, and INSTIs before sample sequencing.

Answer: NNRTI, NRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions specific drugs such as ""nevirapine"", ""efavirenz"", ""rilpivirine"", ""zidovudine"", ""abacavir"", ""lamivudine"", ""emtricitabine"", and ""tenofovir"".

Rationale: The paper reports that individuals in the study received nevirapine, efavirenz, rilpivirine, zidovudine, abacavir, lamivudine, emtricitabine, and tenofovir before sample sequencing.

Answer: nevirapine, efavirenz, rilpivirine, zidovudine, abacavir, lamivudine, emtricitabine, tenofovir
""""""",79
26246578,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients, but it does mention that the study aimed to evaluate the strand transfer activity of recombinant integrase proteins expressing different combinations of point mutations that confer resistance to RAL, EVG, and/or DTG.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples. However, it does discuss the evaluation of point mutations that confer resistance to certain drugs, which suggests that the study may have involved the analysis of HIV sequences.

Answer: No.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions that HIV susceptibilities to DTG, RAL, and EVG were measured by the infection of 30,000 TZM-bl cells using 100,000 RT units per well of each virus in the presence of 1:10 serial dilutions of drugs.

Rationale: The paper reports in vitro drug susceptibility data, as it describes the measurement of HIV susceptibilities to DTG, RAL, and EVG in a controlled laboratory setting.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the submission of sequences to public databases such as GenBank or the provision of accession numbers.

Rationale: The paper does not provide evidence that the sequences were made publicly available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not provide GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers, as it does not mention the submission of sequences to public databases.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide information on the country of origin for the samples.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years during which the samples were obtained.

Rationale: The paper does not provide information on the years during which the samples were obtained.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions the integrase gene, as it discusses the evaluation of point mutations that confer resistance to RAL, EVG, and/or DTG.

Rationale: The paper reports the sequencing of the integrase gene, as it discusses the evaluation of point mutations that confer resistance to certain drugs.

Answer: Integrase.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide information on virological failure on a treatment regimen.

Answer: Not reported.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on a clinical trial.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention previous ARV drug use.

Rationale: The paper does not provide information on previous ARV drug use.

Answer: Not reported.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of DTG, RAL, and EVG.

Rationale: The paper reports the use of INSTIs, specifically DTG, RAL, and EVG.

Answer: INSTIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions the use of DTG, RAL, and EVG.

Rationale: The paper reports the use of DTG, RAL, and EVG.

Answer: DTG, RAL, EVG.",62
26311878,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly state that it reports HIV sequences from patient samples, but it does mention that the study involves the generation of replication-competent genetically homogenous viruses and the measurement of viral infectivity, replicative capacity, and resistance against INSTIs.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples, but it does describe experiments that involve the use of HIV viruses. However, the viruses used in the study are not directly from patient samples, but rather are generated in the lab.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions that the susceptibilities of virus to ARVs were measured by the addition of serially diluted DTG, RAL, or EVG to TZM-bl cells prior to infection with the viruses described above.

Rationale: The paper reports in vitro drug susceptibility data, as it describes experiments that measure the susceptibility of HIV viruses to different antiretroviral drugs.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences used in the study.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers, which are typically used to identify publicly available sequences.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the study involves the generation of replication-competent genetically homogenous viruses and the measurement of viral infectivity, replicative capacity, and resistance against INSTIs, which suggests that the integrase gene was sequenced.

Rationale: The paper does not explicitly state which HIV genes were sequenced, but based on the context, it is likely that the integrase gene was sequenced.

Answer: Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the method used for sequencing.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention whether sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about the treatment status of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide any information about the study design or whether it was a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention whether the individuals from whom sequences were obtained had previously received ARV drugs.

Rationale: The paper does not provide any information about the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the treatment history of the individuals from whom sequences were obtained.

Answer: Not reported
""""""",65
26559830,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not mention patient samples or HIV sequences from patient samples. It discusses HIV-2 protease inhibitors and their susceptibility to different drugs.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting HIV sequences from patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper reports the results of in vitro experiments testing the susceptibility of HIV-2 protease to different protease inhibitors.

Rationale: The paper describes the methods used to test the susceptibility of HIV-2 protease to different drugs and reports the results of these experiments.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report any sequence data or mention depositing sequences in a public database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not report any sequence data or mention depositing sequences in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention individual samples or HIV sequencing.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting HIV sequences from individual samples.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention sample origin or country.

Rationale: The paper does not report any sequence data or mention the origin of the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention sample collection years.

Rationale: The paper does not report any sequence data or mention the time frame of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or sequencing.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting cloning or sequencing methods.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention sequencing or specific HIV genes.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting sequence data.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention sequencing methods.

Rationale: The paper does not report any sequence data or mention sequencing methods.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention sample types or sequencing.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting sequence data or sample types.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting sequence data or treatment outcomes.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention clinical trials or patients.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting clinical trial data.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention ARV drugs or treatment history.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting sequence data or treatment history.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention drug classes or treatment history.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting sequence data or treatment history.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs or treatment history.

Rationale: The paper focuses on the biochemical and structural aspects of HIV-2 protease and its interactions with protease inhibitors, rather than reporting sequence data or treatment history.

Answer: Not reported",63
27009474,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D..."". The sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper reports HIV sequences from patient samples, including their corresponding GenBank accession numbers.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""Q148N ± G140S was associated with 2.4- to 4.5-fold reduced susceptibility to elvitegravir but not to raltegravir or dolutegravir (Table 1)."".

Rationale: The paper reports in vitro drug susceptibility data, including the results of phenotypic susceptibility testing using the PhenoSense assay.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper reports that the sequence of the clinical clone has been submitted to the GenBank, making it publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The sequence of the clinical clone has been submitted to the GenBank under the accession number KU761565.

Rationale: The paper reports a single GenBank accession number for the sequenced HIV isolate.

Answer: KU761565
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014.""

Rationale: The paper reports a single individual who had a sample obtained for HIV sequencing.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly state the country of origin for the sequenced sample.

Rationale: The paper does not provide enough information to determine the country of origin for the sequenced sample.

Answer: Not Reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""A 50-year-old hispanic homosexual man underwent HIV-1 seroconversion in August 2014.""

Rationale: The paper reports a single year (2014) when the sequenced sample was obtained.

Answer: 2014
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not explicitly state whether samples were cloned prior to sequencing.

Rationale: The paper does not provide enough information to determine whether samples were cloned prior to sequencing.

Answer: Not Reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D..."".

Rationale: The paper reports that the pol gene was sequenced, including the integrase region.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not explicitly state the method used for sequencing.

Rationale: The paper does not provide enough information to determine the method used for sequencing.

Answer: Not Reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""A baseline genotypic resistance test revealed the nucleoside reverse transcriptase inhibitor-resistance mutations L210W and T215D..."".

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""The patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.""

Rationale: The paper reports that the patient was started on a treatment regimen, but does not explicitly state whether the sequence was obtained from an individual with virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly state whether the patient was in a clinical trial.

Rationale: The paper does not provide enough information to determine whether the patient was in a clinical trial.

Answer: Not Reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""The patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.""

Rationale: The paper reports that the patient had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.""

Rationale: The paper reports that the patient received INSTI, NRTI, and NNRTI classes of ARV drugs.

Answer: INSTI, NRTI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The patient was started on the once daily integrase strand transfer inhibitor (INSTI)-containing fixed-dose combination tenofovir/emtricitabine/elvitegravir/cobicistat.""

Rationale: The paper reports that the patient received tenofovir, emtricitabine, elvitegravir, and cobicistat.

Answer: Tenofovir, Emtricitabine, Elvitegravir, Cobicistat
""""""",69
27124362,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention HIV sequences from patient samples. It discusses the antiviral activity of RPV and DOR against known NNRTI-resistant HIV-1 mutants.

Rationale: The paper does not mention HIV sequences from patient samples. It discusses the antiviral activity of RPV and DOR against known NNRTI-resistant HIV-1 mutants.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper reports the IC50 values of RPV and DOR against various HIV-1 mutants.

Rationale: The paper reports the IC50 values of RPV and DOR against various HIV-1 mutants, which is a measure of in vitro drug susceptibility.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not mention making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals with samples obtained for HIV sequencing.

Rationale: The paper does not mention the number of individuals with samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the samples were obtained.

Rationale: The paper does not mention the countries from which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the samples were obtained.

Rationale: The paper does not mention the years from which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not mention specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not mention the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not mention a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention drug classes received by individuals before sample sequencing.

Rationale: The paper does not mention drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by individuals before sample sequencing.

Rationale: The paper does not mention specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",52
28559249,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-2 isolates from ART-naive individuals"" and ""a panel of site-directed HIV-2 ROD9 RT mutants and a recombinant clone of HIV-2 (designated 4.7a) that was derived from a patient receiving AZT, lamivudine (3TC), and ritonavir-boosted lopinavir"".

Rationale: The paper reports HIV sequences from patient samples, including HIV-2 isolates from ART-naive individuals and a recombinant clone of HIV-2 derived from a patient receiving antiretroviral therapy.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""antiviral activity of MK-8591 against HIV-1 and HIV-2 strains"" and ""EC50s for 10 HIV-1 and 14 HIV-2 strains"".

Rationale: The paper reports in vitro drug susceptibility data, including EC50 values for MK-8591 against HIV-1 and HIV-2 strains.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the public availability of the sequences.

Rationale: The paper does not provide information on the public availability of the sequences.

Answer: Not Reported.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not Reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""HIV-2 isolates from ART-naive individuals"" but does not provide a specific number.

Rationale: The paper does not provide a specific number of individuals who had samples obtained for HIV sequencing.

Answer: Not Reported.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide information on the country of origin for the sequenced samples.

Answer: Not Reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide information on the year of sample collection.

Answer: Not Reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not Reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""RT mutants"" and ""pol gene"".

Rationale: The paper reports sequencing of the pol gene, specifically the RT region.

Answer: Pol.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not Reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""HIV-2 isolates from ART-naive individuals"" but does not specify the sample type.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not Reported.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""a recombinant clone of HIV-2 (designated 4.7a) that was derived from a patient receiving AZT, lamivudine (3TC), and ritonavir-boosted lopinavir"".

Rationale: The paper reports sequencing of a sample from an individual with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not Reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""a recombinant clone of HIV-2 (designated 4.7a) that was derived from a patient receiving AZT, lamivudine (3TC), and ritonavir-boosted lopinavir"".

Rationale: The paper reports sequencing of a sample from an individual who had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""AZT, lamivudine (3TC), and ritonavir-boosted lopinavir"".

Rationale: The paper reports that individuals in the study received NRTIs (AZT, 3TC) and PIs (lopinavir) before sample sequencing.

Answer: NRTIs, PIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""AZT, lamivudine (3TC), and ritonavir-boosted lopinavir"".

Rationale: The paper reports that individuals in the study received AZT, 3TC, and lopinavir before sample sequencing.

Answer: AZT, 3TC, lopinavir.",67
29373677,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic analysis of integrase was tested in DNA"" and ""genotypic analysis before 2014 identified no resistance mutations, but a polymorphism was highlighted at position 156 with a K156N present throughout the study.""

Rationale: The paper reports HIV sequences from patient samples, specifically the integrase gene.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""cell-free reactions"" and ""determined the EC50 of each mutant by infecting HeLa-P4 cells in the presence of increasing concentrations of raltegravir and dolutegravir"".

Rationale: The paper reports in vitro drug susceptibility data, specifically the EC50 values of raltegravir and dolutegravir against HIV-1 mutants.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to a public database or providing accession numbers.

Rationale: The sequences from the paper were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the sequences were not made publicly available.

Rationale: Not applicable.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""the patient"" and ""a patient treated with dolutegravir monotherapy"".

Rationale: Only one individual had a sample obtained for HIV sequencing.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the patient.

Rationale: The country of origin of the sequenced sample is not reported.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions ""from 2008 to 2015"" and ""in 2014"".

Rationale: The sequenced samples were obtained between 2008 and 2015, specifically in 2014.

Answer: 2008-2015

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""integrase genotypic analysis"" and ""genotypic analysis of integrase"".

Rationale: The paper reports sequencing of the integrase gene.

Answer: IN

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""DNA from PBMCs"" and ""plasma RNA"".

Rationale: The paper reports sequencing of DNA from PBMCs and plasma RNA.

Answer: PBMC, Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""failure of dolutegravir treatment"" and ""virological failure"".

Rationale: Yes, sequences were obtained from an individual with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patient was in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""the patient was first treated with raltegravir in combination with tenofovir/emtricitabine (Truvada) for 6 years"".

Rationale: Yes, the paper reports HIV sequences from an individual who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""raltegravir"", ""tenofovir/emtricitabine (Truvada)"", and ""dolutegravir"".

Rationale: The individual received INSTIs (raltegravir and dolutegravir) and NRTIs (tenofovir/emtricitabine).

Answer: INSTI, NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""raltegravir"", ""tenofovir/emtricitabine (Truvada)"", and ""dolutegravir"".

Rationale: The individual received raltegravir, tenofovir, emtricitabine, and dolutegravir.

Answer: Raltegravir, Tenofovir, Emtricitabine, Dolutegravir",65
30053052,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that ""viral RNA was extracted from plasma"" and ""the gag-pol fragment (HXB2: 0702-5798) was cloned into pNL43 plasmid"" from patient samples.

Rationale: The paper explicitly mentions that viral RNA was extracted from plasma samples and used for cloning and sequencing.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""phenotypic drug susceptibility assay"" and ""in vitro biochemical assays"" to determine the IC50 values of NNRTIs.

Rationale: The paper reports in vitro drug susceptibility data using phenotypic drug susceptibility assays and biochemical assays.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not reported.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""stored plasma samples from patients who were either therapy naive (n = 42) or had a virological treatment failure (n = 9) were randomly selected"".

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 51
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the samples were from ""Karolinska University Hospital, Stockholm, Sweden"".

Rationale: The paper explicitly mentions the country where the samples were obtained.

Answer: Sweden
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Not reported.

Rationale: The paper does not provide any information about the years when the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper states that ""the gag-pol fragment (HXB2: 0702-5798) was cloned into pNL43 plasmid"" from patient samples.

Rationale: The paper explicitly mentions that the samples were cloned prior to sequencing.

Answer: Yes
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that ""the gag-pol fragment (HXB2: 0702-5798) was cloned into pNL43 plasmid"" from patient samples.

Rationale: The paper explicitly mentions that the gag-pol fragment was cloned and sequenced.

Answer: Gag-pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: Not reported.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states that ""viral RNA was extracted from plasma"" from patient samples.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""three viruses extracted from therapy-failure patients"" were used in the study.

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: Not reported.

Rationale: The paper does not provide any information about whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""three viruses extracted from therapy-failure patients"" were used in the study.

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""NRTIs"" and ""NNRTIs"" as the drug classes used in the study.

Rationale: The paper explicitly mentions the drug classes used in the study.

Answer: NRTIs, NNRTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""tenofovir alafenamide"", ""nevirapine"", ""efavirenz"", ""etravirine"", and ""rilpivirine"" as the drugs used in the study.

Rationale: The paper explicitly mentions the drugs used in the study.

Answer: Tenofovir alafenamide, nevirapine, efavirenz, etravirine, rilpivirine
""""""",63
30803972,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that it reports HIV sequences from patient samples. However, it does mention that it tested the activity of bictegravir against a panel of group A and group B HIV-2 isolates from ART-naive individuals.

Rationale: The paper does not provide direct evidence of reporting HIV sequences from patient samples. However, it does mention that it tested the activity of bictegravir against HIV-2 isolates from ART-naive individuals, which suggests that the sequences may have been obtained from patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper reports the activity of bictegravir against HIV-1 and HIV-2 isolates in a single-cycle assay, with EC50 values ranging from 1.2 to 2.5 nM for HIV-1 and 1.4 to 5.6 nM for HIV-2.

Rationale: The paper provides direct evidence of reporting in vitro drug susceptibility data, as it describes the activity of bictegravir against HIV-1 and HIV-2 isolates in a single-cycle assay.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention whether the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention which HIV genes were reported to have been sequenced.

Rationale: The paper does not provide any information about the HIV genes that were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the method used for sequencing.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide any information about the treatment status of the individuals from whom the sequences were obtained.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide any information about the study design or the participation of patients in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention whether the individuals from whom the sequences were obtained had previously received ARV drugs.

Rationale: The paper does not provide any information about the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention which drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the treatment history of the individuals from whom the sequences were obtained.

Answer: Not reported",65
31988104,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""patient-derived mutants"" and ""patient-derived clinical isolates"" but does not provide specific information about the patients or the sequencing of their samples.

Rationale: The paper does not provide enough information to confirm that HIV sequences were obtained from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""in vitro resistance profile of TAF and TDF in phenotypic assays"" and provides data on the susceptibility of HIV-1 mutants to TAF and TDF.

Rationale: The paper reports in vitro drug susceptibility data for TAF and TDF.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention the public availability of the sequences.

Rationale: The paper does not provide information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information about the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information about the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide information about whether the samples were cloned prior to sequencing.

Rationale: The paper does not provide information about whether the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""HIV-1 reverse transcriptase"" and ""RT mutants"" but does not provide specific information about the genes that were sequenced.

Rationale: The paper does not provide enough information to confirm which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not provide information about the sequencing method used.

Rationale: The paper does not provide information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions ""patient-derived mutants"" and ""patient-derived clinical isolates"" but does not provide specific information about the type of samples that were sequenced.

Rationale: The paper does not provide enough information to confirm the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions ""viral breakthrough"" and ""virologic failure"" but does not provide specific information about the individuals from whom the sequences were obtained.

Rationale: The paper does not provide enough information to confirm whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information about whether the patients were in a clinical trial.

Rationale: The paper does not provide information about whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ""treatment-experienced patients"" and ""historical evidence of the presence of M184V/I with or without one to two TAMs"" but does not provide specific information about the individuals from whom the sequences were obtained.

Rationale: The paper does not provide enough information to confirm whether HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""TAF"", ""TDF"", ""AZT"", ""ABC"", ""FTC"", ""DTG"", and ""DRV"" but does not provide specific information about the drug classes received by the individuals before sample sequencing.

Rationale: The paper does not provide enough information to confirm which drug classes were received by the individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""TAF"", ""TDF"", ""AZT"", ""ABC"", ""FTC"", ""DTG"", and ""DRV"" but does not provide specific information about the drugs received by the individuals before sample sequencing.

Rationale: The paper does not provide enough information to confirm which drugs were received by the individuals before sample sequencing.

Answer: Not reported
""""""",67
32601157,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-1 Integrase Inhibitors That Are Active against Drug-Resistant Integrase Mutants"" and ""INSTI-resistant mutants with single substitutions that are located ∼5.0 Å from the metal ions bound at the IN active site typically do not cause substantial decreases in susceptibility to DTG and BIC.""

Rationale: The paper discusses HIV-1 integrase inhibitors and their activity against drug-resistant integrase mutants, which suggests that it reports HIV sequences from patient samples.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""single-round infection assay"" and ""EC ~50~ values were determined for the clinically relevant INSTIs and compounds using vectors that carry INSTI-resistant single, double, triple, and quadruple mutants.""

Rationale: The paper reports in vitro drug susceptibility data, as it describes the use of a single-round infection assay to determine the EC ~50~ values of various INSTIs against different mutants.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the deposition of sequences in a public database.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the countries from which the sequenced samples were obtained.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years from which the sequenced samples were obtained.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""integrase (IN) strand transfer inhibitor (INSTI)"" and ""IN mutants.""

Rationale: The paper reports that the integrase gene was sequenced.

Answer: IN.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not provide any information about the type of samples sequenced.

Answer: Not reported.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""INSTI-resistant mutants"" and ""virological failure.""

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""INSTI-resistant mutants"" and ""treatment-experienced patients.""

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""INSTIs"" and ""NRTIs.""

Rationale: The paper reports that individuals in the study received INSTIs and NRTIs before sample sequencing.

Answer: INSTIs, NRTIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""DTG,"" ""BIC,"" and ""CAB.""

Rationale: The paper reports that individuals in the study received DTG, BIC, and CAB before sample sequencing.

Answer: DTG, BIC, CAB.",70
33855437,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""patient-derived subtype B (n = 3) and non-B clinical isolates (n = 3)"" and ""Isolates 14637, 14969, 5326 and 6343 (GenBank accession numbers MW484894, MW484895, MW484893, DQ380549, respectively) were derived from drug-naive individuals at Clinique Actuel obtained with ethics approval (Veritas) and informed consent.""

Rationale: The paper explicitly states that the HIV sequences were obtained from patient samples, specifically from drug-naive individuals.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""cell-based phenotypic assays assessed cross-resistance patterns to NNRTIs by acquired resistance mutations"" and ""the EC50 was calculated using GraphPad Prism software.""

Rationale: The paper reports in vitro drug susceptibility data, specifically the EC50 values calculated using cell-based phenotypic assays.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions ""Isolates 14637, 14969, 5326 and 6343 (GenBank accession numbers MW484894, MW484895, MW484893, DQ380549, respectively)"" and ""the 96USSN20 isolate (GenBank MW48492) and pNL4.3 recombinant clone (GenBank AF324493)"".

Rationale: The paper reports that the sequences were submitted to GenBank and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper mentions ""Isolates 14637, 14969, 5326 and 6343 (GenBank accession numbers MW484894, MW484895, MW484893, DQ380549, respectively)"" and ""the 96USSN20 isolate (GenBank MW48492) and pNL4.3 recombinant clone (GenBank AF324493)"".

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: MW484894, MW484895, MW484893, DQ380549, MW48492, AF324493
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions ""patient-derived subtype B (n = 3) and non-B clinical isolates (n = 3)"".

Rationale: The paper reports that samples were obtained from 6 individuals (3 subtype B and 3 non-B subtype).

Answer: 6
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions ""Clinique Actuel"" and ""Ethiopia"".

Rationale: The paper reports that the samples were obtained from Canada (Clinique Actuel) and Ethiopia.

Answer: Canada, Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the specific years when the samples were obtained.

Rationale: The paper does not provide information on the years when the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""genotypic analysis of all clinical isolates was performed at weeks 8 and 24 of selective drug pressure to evaluate the monitor the acquisition and accumulation of amino acid substitutions (i.e. drug resistance mutations)"".

Rationale: The paper reports that the HIV genes sequenced were those involved in drug resistance, but does not specify which genes.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions ""patient-derived subtype B (n = 3) and non-B clinical isolates (n = 3)"".

Rationale: The paper reports that the samples sequenced were clinical isolates.

Answer: Clinical isolates
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions ""drug-naive individuals"" and ""treatment-experienced individuals"" but does not specify if the sequences were obtained from individuals with virological failure.

Rationale: The paper does not provide information on whether the sequences were obtained from individuals with virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ""drug-naive individuals"" and ""treatment-experienced individuals"".

Rationale: The paper reports that some of the individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""NNRTIs"" and ""NRTIs"".

Rationale: The paper reports that the individuals received NNRTIs and NRTIs before sample sequencing.

Answer: NNRTIs, NRTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""doravirine"", ""rilpivirine"", ""lamivudine"", and ""islatravir"".

Rationale: The paper reports that the individuals received doravirine, rilpivirine, lamivudine, and islatravir before sample sequencing.

Answer: Doravirine, rilpivirine, lamivudine, islatravir
""""""",74
34516245,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"", ""blood plasma"", ""stored/archived/cryopreserved plasma"", or ""plasma specimens/samples"" and ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from patients.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"" and ""IC50"", ""EC50"", ""EC90"", ""fold-change in susceptibility"", or ""reduced susceptibility"" values.

Rationale: The paper reports in vitro drug susceptibility data, including IC50 and EC50 values, which indicates that the paper reports in vitro drug susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"" and accession numbers for GenBank or any of the above databases are provided.

Rationale: The paper explicitly states that sequences were submitted to GenBank and provides accession numbers, which indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper provides accession numbers for GenBank, including ""OK263149 to OK263162"".

Rationale: The paper explicitly provides accession numbers for GenBank, which can be used to retrieve the sequenced HIV isolates.

Answer: OK263149 to OK263162

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly state the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the country of origin for the sequenced samples.

Rationale: The paper does not provide information on the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the year of sample collection.

Rationale: The paper does not provide information on the year of sample collection.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""clonal sequencing"" and ""molecular clones"" which suggests that samples were cloned prior to sequencing.

Rationale: The paper explicitly states that clonal sequencing was performed, which indicates that samples were cloned prior to sequencing.

Answer: Yes

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""reverse transcriptase gene"" and ""pol gene"" which suggests that the pol gene, including the reverse transcriptase gene, was sequenced.

Rationale: The paper explicitly states that the reverse transcriptase gene was sequenced, which is part of the pol gene.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" and ""ABI instruments"" which suggests that Sanger sequencing was used.

Rationale: The paper explicitly states that Sanger sequencing was used, which is a widely used method for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""viral RNA was extracted from plasma"" which suggests that plasma samples were sequenced.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""failure on first-line or salvage regimen"" which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state that the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""treatment-experienced"" and ""prior ARV exposure/regimens"" which suggests that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"" which suggests that individuals received these drug classes before sample sequencing.

Rationale: The paper explicitly states that individuals received these drug classes before sample sequencing.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""EFdA"", ""TDF"", ""FTC"", ""AZT"", and ""3TC"" which suggests that individuals received these drugs before sample sequencing.

Rationale: The paper explicitly states that individuals received these drugs before sample sequencing.

Answer: EFdA, TDF, FTC, AZT, 3TC",76
35730213,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention HIV sequences from patient samples.

Rationale: The paper does not mention HIV sequences from patient samples, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not mention in vitro drug susceptibility data, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not mention making sequences publicly available, as it does not focus on HIV sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates, as it does not focus on HIV sequences.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention HIV sequencing.

Rationale: The paper does not mention HIV sequencing, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention sequenced samples.

Rationale: The paper does not mention sequenced samples, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in Lesotho.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention sequenced samples.

Rationale: The paper does not mention sequenced samples, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy in Lesotho.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention sequencing.

Rationale: The paper does not mention sequencing, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention HIV sequencing.

Rationale: The paper does not mention HIV sequencing, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention sequencing.

Rationale: The paper does not mention sequencing, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention sequencing.

Rationale: The paper does not mention sequencing, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequencing.

Rationale: The paper does not mention sequencing, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was registered with ClinicalTrials.gov.

Rationale: The paper mentions that the study was registered with ClinicalTrials.gov, which suggests that it is a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences.

Rationale: The paper does not mention HIV sequences, but rather focuses on the mental and physical health outcomes of people living with HIV after transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants were transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Rationale: The paper mentions that participants were transitioning from efavirenz- to dolutegravir-based antiretroviral therapy, which suggests that they had previously received NNRTI and INSTI classes of ARV drugs.

Answer: NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants were transitioning from efavirenz- to dolutegravir-based antiretroviral therapy.

Rationale: The paper mentions that participants were transitioning from efavirenz- to dolutegravir-based antiretroviral therapy, which suggests that they had previously received efavirenz and dolutegravir.

Answer: Efavirenz, Dolutegravir
""""""",72
35913500,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention that the study includes patients with HIV who are receiving long-acting injectable antiretroviral therapy (LAI-ART).

Rationale: The paper does not provide information about HIV sequences from patient samples. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not provide information about in vitro drug susceptibility data. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide information about making sequences publicly available. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide information about GenBank accession numbers for sequenced HIV isolates. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information about the number of individuals who had samples obtained for HIV sequencing. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the countries from which the sequenced samples were obtained. It focuses on the treatment outcomes of patients receiving LAI-ART in the United States.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information about the years from which the sequenced samples were obtained. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information about cloning prior to sequencing. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were reported to have been sequenced.

Rationale: The paper does not provide information about which HIV genes were reported to have been sequenced. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the method used for sequencing.

Rationale: The paper does not provide information about the method used for sequencing. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide information about the type of samples that were sequenced. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention sequences obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide information about sequences obtained from individuals with virological failure on a treatment regimen. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information about a clinical trial. It focuses on the treatment outcomes of patients receiving LAI-ART in a real-world setting.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not provide information about HIV sequences from individuals who had previously received ARV drugs. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information about the drug classes received by individuals in the study before sample sequencing. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information about the drugs received by individuals in the study before sample sequencing. It focuses on the treatment outcomes of patients receiving LAI-ART.

Answer: Not reported
""""""",66
35945163,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" of HIV-1 RNA from patient samples.

Rationale: The paper reports that genotypic resistance testing and sequencing were performed on patient samples to assess the efficacy of cabotegravir LA + rilpivirine LA.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""genotypic resistance testing"" and ""sequencing"" of HIV-1 RNA from patient samples, but does not report in vitro drug susceptibility data.

Rationale: The paper focuses on the efficacy and safety of cabotegravir LA + rilpivirine LA in patients with HIV-1, but does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide information on whether the sequences were deposited in a public database or made available through other means.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not report GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 35 people living with HIV-1 had data available.

Rationale: The paper reports that 35 people living with HIV-1 had samples obtained for HIV sequencing.

Answer: 35
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that individuals were from ten countries, including the UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain.

Rationale: The paper reports that the sequenced samples were obtained from individuals from ten countries.

Answer: UK, USA, Belgium, Canada, Netherlands, Switzerland, Portugal, Italy, South Korea, and Spain
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the compassionate use programme was conducted from February 2016 through July 2020.

Rationale: The paper reports that the sequenced samples were obtained from individuals who participated in the compassionate use programme between 2016 and 2020.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that genotypic resistance testing and sequencing were performed on HIV-1 RNA from patient samples, but does not specify which HIV genes were sequenced.

Rationale: The paper does not provide information on which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the method used for sequencing.

Rationale: The paper does not provide information on the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that genotypic resistance testing and sequencing were performed on HIV-1 RNA from patient samples, but does not specify the type of samples.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that seven people living with HIV-1 discontinued cabotegravir LA + rilpivirine LA therapy because of incomplete virological response.

Rationale: The paper reports that sequences were obtained from individuals who experienced virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the compassionate use programme was not a clinical trial.

Rationale: The paper reports that the patients in the study were not in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that individuals had prior severe adherence challenges with oral therapy for a variety of psychological and physical reasons, and many also had detectable viremia and advanced disease at LA therapy initiation.

Rationale: The paper reports that individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that individuals had prior severe adherence challenges with oral therapy for a variety of psychological and physical reasons, and many also had detectable viremia and advanced disease at LA therapy initiation.

Rationale: The paper does not provide information on which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that individuals had prior severe adherence challenges with oral therapy for a variety of psychological and physical reasons, and many also had detectable viremia and advanced disease at LA therapy initiation.

Rationale: The paper does not provide information on which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",68
36415058,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention that the study participants were HIV-infected individuals who were eligible for treatment.

Rationale: Based on the content of the paper, it appears that the study focused on the propensity of HIV-infected individuals to consider switching to a long-acting regimen with cabotegravir and rilpivirine, rather than reporting HIV sequences from patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the propensity of HIV-infected individuals to consider switching to a long-acting regimen with cabotegravir and rilpivirine, and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report any sequencing data, and therefore does not mention making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report any sequencing data.

Rationale: The paper does not report any sequencing data, and therefore does not provide any GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: Not applicable, as the paper does not report any sequencing data.

Rationale: The paper does not report any sequencing data, and therefore does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: Not applicable, as the paper does not report any sequencing data.

Rationale: The paper does not report any sequencing data, and therefore does not mention the countries from which the samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: Not applicable, as the paper does not report any sequencing data.

Rationale: The paper does not report any sequencing data, and therefore does not mention the years from which the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not applicable, as the paper does not report any sequencing data.

Rationale: The paper does not report any sequencing data, and therefore does not mention whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: Not applicable, as the paper does not report any sequencing data.

Rationale: The paper does not report any sequencing data, and therefore does not mention which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: Not applicable, as the paper does not report any sequencing data.

Rationale: The paper does not report any sequencing data, and therefore does not mention the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: Not applicable, as the paper does not report any sequencing data.

Rationale: The paper does not report any sequencing data, and therefore does not mention the type of samples sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper focuses on the propensity of HIV-infected individuals to consider switching to a long-acting regimen with cabotegravir and rilpivirine, and does not mention virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper focuses on the propensity of HIV-infected individuals to consider switching to a long-acting regimen with cabotegravir and rilpivirine, and does not mention a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper focuses on the propensity of HIV-infected individuals to consider switching to a long-acting regimen with cabotegravir and rilpivirine, and does not mention HIV sequences from individuals who had previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study participants were HIV-infected individuals who were eligible for treatment, but does not specify the drug classes received before sample sequencing.

Rationale: The paper focuses on the propensity of HIV-infected individuals to consider switching to a long-acting regimen with cabotegravir and rilpivirine, and does not mention the drug classes received before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study participants were HIV-infected individuals who were eligible for treatment, but does not specify the drugs received before sample sequencing.

Rationale: The paper focuses on the propensity of HIV-infected individuals to consider switching to a long-acting regimen with cabotegravir and rilpivirine, and does not mention the drugs received before sample sequencing.

Answer: Not reported",66
36454248,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""HIV-1 RNA was extracted from plasma by automated magnetic silica extraction using the EasyMAG extractor (bioMérieux). The extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region, using primers designed by WHO for protease (PR) and reverse transcriptase (RT) amplification and ANRS primers for integrase (IN) amplification.""

Rationale: The paper explicitly states that HIV-1 RNA was extracted from plasma samples and amplified by RT-PCR and nested PCR to obtain the HIV-1 *pol* region.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""Stanford HIVdb Program v9.0 (Stanford University, Palo Alto, CA, USA) ( https://hivdb.stanford.edu/hivdb/by-sequences/ ) was used to characterize DRMs in pre-treated children/adolescents and predict the resistance level to 25 ARVs in *pol* genotypes.""

Rationale: The paper uses the Stanford HIVdb Program to predict the resistance level to 25 ARVs in *pol* genotypes, but it does not report in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states ""HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.""

Rationale: The paper explicitly states that the HIV-1 sequences were submitted to GenBank with the provided accession numbers.

Answer: Yes.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states ""HIV-1 sequences were submitted to GenBank with the following accession numbers: OM201778 -- OM201846.""

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OM201778 -- OM201846.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""Plasma samples from 76 HIV-positive naive or ART-treated children and adolescents with therapeutic failure under clinical follow-up at this hospital were collected during 2018--19.""

Rationale: The paper explicitly states that plasma samples were collected from 76 individuals.

Answer: 76.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""Plasma samples from 76 HIV-positive naive or ART-treated children and adolescents with therapeutic failure under clinical follow-up at this hospital were collected during 2018--19"" and ""The 58% HIV-infected paediatric population is followed up at the Hospital del Niño Doctor José Renán Esquivel, attending to 160 patients (2 months to 18 years old), with 50% between 15 and 18 years old.""

Rationale: The paper explicitly states that the samples were collected from a hospital in Panama.

Answer: Panama.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""Plasma samples from 76 HIV-positive naive or ART-treated children and adolescents with therapeutic failure under clinical follow-up at this hospital were collected during 2018--19.""

Rationale: The paper explicitly states that the samples were collected during 2018-19.

Answer: 2018-2019.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information about cloning prior to sequencing.

Answer: Not Reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""The extracted RNA was amplified by RT--PCR and nested PCR to obtain the HIV-1 *pol* region, using primers designed by WHO for protease (PR) and reverse transcriptase (RT) amplification and ANRS primers for integrase (IN) amplification.""

Rationale: The paper explicitly states that the HIV-1 *pol* region, including protease (PR), reverse transcriptase (RT), and integrase (IN), was sequenced.

Answer: Pol (PR, RT, IN).

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""PCR amplicons were purified with illustra ^TM^ ExoProStar ^TM^ (Cytiva) and sequenced by Macrogen Inc.""

Rationale: The paper does not provide detailed information about the sequencing method, but it mentions that the sequencing was performed by Macrogen Inc.

Answer: Not Reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""HIV-1 RNA was extracted from plasma by automated magnetic silica extraction using the EasyMAG extractor (bioMérieux).""

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""Plasma samples from 76 HIV-positive naive or ART-treated children and adolescents with therapeutic failure under clinical follow-up at this hospital were collected during 2018--19.""

Rationale: The paper explicitly states that the samples were collected from individuals with therapeutic failure.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information about a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""Among the 71 treated children/adolescents, 14 (19.7%) had failed more than three different ART regimens at sampling.""

Rationale: The paper explicitly states that the treated children/adolescents had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""All 71 treated children/adolescents had received NRTIs, 45.1% NNRTIs, 95.8% PIs and just 11 (15.5%) patients were INSTI-experienced (Table ​ (Table1).""

Rationale: The paper explicitly states that the treated children/adolescents had received NRTIs, NNRTIs, PIs, and INSTIs.

Answer: NRTIs, NNRTIs, PIs, INSTIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""Most treated children (98.6%) had received lamivudine + zidovudine, followed by lopinavir / ritonavir (95.8%) and efavirenz (45.1%).""

Rationale: The paper explicitly states that the treated children/adolescents had received lamivudine, zidovudine, lopinavir/ritonavir, and efavirenz.

Answer: Lamivudine, zidovudine, lopinavir/ritonavir, efavirenz.",92
36519389,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples, but it does mention that participants were HIV-positive and underwent various tests, including HIV RNA testing.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples, but it does provide context that suggests HIV sequencing may have been performed.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the clinical outcomes of patients switching from one antiretroviral therapy (ART) regimen to another, and does not report any in vitro data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about sequence deposition or public availability.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention sequence deposition or provide accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention HIV sequencing, but it does report on the number of participants in the study (172).

Rationale: The paper does not provide direct evidence of HIV sequencing, but it does provide context that suggests HIV sequencing may have been performed.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that participants were from South Africa, Zimbabwe, Malawi, Mozambique, and other regions.

Rationale: The paper provides information about the geographic origin of the participants, but it does not specifically mention HIV sequencing.

Answer: South Africa, Zimbabwe, Malawi, Mozambique, and other regions
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted from July to November 2022.

Rationale: The paper provides information about the study timeline, but it does not specifically mention HIV sequencing.

Answer: 2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning or sequencing.

Rationale: The paper does not provide any information about sequencing methods.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention HIV gene sequencing.

Rationale: The paper does not provide any information about sequencing methods or specific genes.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention sequencing methods.

Rationale: The paper does not provide any information about sequencing methods.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention sequencing or sample types.

Rationale: The paper does not provide any information about sequencing methods or sample types.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that some participants had elevations in HIV RNA, but it does not specifically mention virological failure.

Rationale: The paper provides information about HIV RNA levels, but it does not specifically mention virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a trial extension, but it does not provide specific details about the trial design.

Rationale: The paper provides some information about the study design, but it does not specifically mention a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants were HIV-positive and had previously received antiretroviral therapy (ART).

Rationale: The paper provides information about the participants' ART history, but it does not specifically mention HIV sequencing.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had previously received TAF/FTC + DTG, TDF/FTC + DTG, or TDF/FTC/EFV.

Rationale: The paper provides information about the participants' ART history, but it does not specifically mention HIV sequencing.

Answer: NRTI, NNRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had previously received TAF/FTC + DTG, TDF/FTC + DTG, or TDF/FTC/EFV.

Rationale: The paper provides information about the participants' ART history, but it does not specifically mention HIV sequencing.

Answer: TAF, FTC, DTG, TDF, EFV
""""""",58
36571282,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""For this study, participating sites were asked to provide a FASTA viral sequence, encoding the HIV integrase and RT obtained at the time of inclusion."" and ""The integrase region from HIV was sequenced using different protocols at testing sites, including the Sanger sequencing--based assay and next-generation sequencing (NGS)--based assay.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically the integrase region, using different sequencing protocols.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the prevalence of transmitted drug resistance mutations and clinically relevant resistance in HIV sequences from patient samples, but does not report in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states ""Data are available to investigators upon reasonable request.""

Rationale: The paper does not explicitly state that the sequences were made publicly available, but rather that they are available to investigators upon request.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""We included 2705 PWH, 72% men, median age of 37 years (interquartile range, 30--48);""

Rationale: The paper explicitly states that 2705 individuals had samples obtained for HIV sequencing.

Answer: 2705.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""MeditRes HIV is a consortium that includes ART-naive PWH in France, Greece, Italy, Portugal, and Spain who have been newly diagnosed during 2018--2021.""

Rationale: The paper explicitly states that the sequenced samples were obtained from France, Greece, Italy, Portugal, and Spain.

Answer: France, Greece, Italy, Portugal, and Spain.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""MeditRes HIV is a consortium that includes ART-naive PWH in France, Greece, Italy, Portugal, and Spain who have been newly diagnosed during 2018--2021.""

Rationale: The paper explicitly states that the sequenced samples were obtained from 2018 to 2021.

Answer: 2018-2021.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not explicitly state whether samples were cloned prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""The integrase region from HIV was sequenced using different protocols at testing sites, including the Sanger sequencing--based assay and next-generation sequencing (NGS)--based assay."" and ""Reverse transcriptase and INSTI sequences were provided by participating centers.""

Rationale: The paper explicitly states that the integrase region and reverse transcriptase sequences were obtained.

Answer: Integrase and Reverse Transcriptase.

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""The integrase region from HIV was sequenced using different protocols at testing sites, including the Sanger sequencing--based assay and next-generation sequencing (NGS)--based assay.""

Rationale: The paper explicitly states that both Sanger sequencing and next-generation sequencing (NGS) were used.

Answer: Sanger sequencing and Next-Generation Sequencing (NGS).

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not explicitly state the type of samples sequenced.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""We included 2705 PWH, 72% men, median age of 37 years (interquartile range, 30--48);"" and ""All naive PWH consequently diagnosed during the study period from the participating centers with an available sample were included.""

Rationale: The paper explicitly states that the individuals were ART-naive, indicating that they had not experienced virological failure on a treatment regimen.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""All naive PWH consequently diagnosed during the study period from the participating centers with an available sample were included.""

Rationale: The paper explicitly states that the individuals were ART-naive, indicating that they had not previously received ARV drugs.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide information on the drug classes received by individuals before sample sequencing.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide information on the specific drugs received by individuals before sample sequencing.

Answer: Not reported.",72
36597160,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" of patient samples, and reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper states that genetic sequencing was performed on clinical samples from patients, and reports GenBank accession numbers for sequences generated in this study.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", and ""drug susceptibility assay"", and reports values such as IC50 and fold-change in susceptibility.

Rationale: The paper describes cell-based susceptibility assays and reports in vitro susceptibility data.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers.

Rationale: The paper states that sequences were submitted to GenBank and provides accession numbers.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide specific GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that 382 patients had samples obtained for HIV sequencing.

Rationale: The paper states that 382 patients were included in the study and had samples obtained for HIV sequencing.

Answer: 382

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the country of origin for the sequenced samples.

Rationale: The paper does not provide information on the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that the study was conducted between February 2014 and August 2015.

Rationale: The paper states that the study was conducted between February 2014 and August 2015.

Answer: 2014-2015

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly state whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: The paper states that genetic sequencing was performed on the pol gene, including the integrase coding region.

Answer: Pol, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"".

Rationale: The paper states that Sanger sequencing was used for genetic sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" samples.

Rationale: The paper states that genetic sequencing was performed on plasma and PBMC samples.

Answer: Plasma, PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper reports that 13 patients experienced virological failure.

Rationale: The paper states that genetic sequencing was performed on patients who experienced virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper reports that patients had previously received ARV drugs.

Rationale: The paper states that patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that patients had previously received NRTI, NNRTI, PI, and INSTI drugs.

Rationale: The paper states that patients had previously received NRTI, NNRTI, PI, and INSTI drugs.

Answer: NRTI, NNRTI, PI, INSTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper reports that patients had previously received specific drugs such as emtricitabine, tenofovir, and elvitegravir.

Rationale: The paper states that patients had previously received specific drugs such as emtricitabine, tenofovir, and elvitegravir.

Answer: Emtricitabine, tenofovir, elvitegravir",61
36645792,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic antiretroviral resistance test (GART)"" and ""baseline GART was performed retrospectively for all participants after completion of week 24 visits, on plasma samples stored at enrollment"".

Rationale: The paper reports HIV sequences from patient samples, as evidenced by the mention of GART and the use of plasma samples for sequencing.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""drug susceptibility prediction was performed with the Stanford algorithm (version 9.1)"".

Rationale: The paper reports in vitro drug susceptibility data, as evidenced by the mention of the Stanford algorithm, which is used to predict drug susceptibility.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available, so we cannot assume that they were made available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""130 participants were randomly assigned"".

Rationale: The paper reports that 130 participants had samples obtained for HIV sequencing.

Answer: 130.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""Khayelitsha, South Africa"".

Rationale: The paper reports that the sequenced samples were obtained from South Africa.

Answer: South Africa.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions ""Participants were recruited between 28 August 2020 and 10 November 2021"".

Rationale: The paper reports that the sequenced samples were obtained between 2020 and 2021.

Answer: 2020-2021.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide any information about cloning, so we cannot assume that samples were cloned prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""genotypic antiretroviral resistance test (GART)"" and ""baseline GART was performed retrospectively for all participants after completion of week 24 visits, on plasma samples stored at enrollment"".

Rationale: The paper reports that the HIV genes sequenced were those related to antiretroviral resistance, but does not specify which genes.

Answer: Not reported.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma samples stored at enrollment"".

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE"".

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions ""randomized, double-blind, placebo-controlled, phase 2 trial"".

Rationale: The paper reports that the patients were in a clinical trial.

Answer: Yes.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""virologic failure (2 consecutive HIV-1 RNA ≥1000 copies/mL) on first-line TEE"".

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""tenofovir, emtricitabine (or lamivudine), and efavirenz"".

Rationale: The paper reports that individuals received NRTIs (tenofovir, emtricitabine/lamivudine) and NNRTIs (efavirenz) before sample sequencing.

Answer: NRTIs, NNRTIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""tenofovir, emtricitabine (or lamivudine), and efavirenz"".

Rationale: The paper reports that individuals received tenofovir, emtricitabine/lamivudine, and efavirenz before sample sequencing.

Answer: Tenofovir, emtricitabine/lamivudine, efavirenz.",66
36659824,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV resistance genotyping"" and ""baseline genotype for HIV-1 drug resistance mutations"" in the Methods section.

Rationale: The paper reports HIV sequences from patient samples, as indicated by the mention of HIV resistance genotyping and baseline genotype for HIV-1 drug resistance mutations.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""virological non-response"" and ""resistance genotypic test"" in the Methods section, but does not report in vitro drug susceptibility data.

Rationale: The paper does not report in vitro drug susceptibility data, as it only mentions virological non-response and resistance genotypic test, but does not provide any data on in vitro susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not mention making sequences publicly available, and therefore it is likely that the sequences are not publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers, and therefore it is not possible to provide an answer to this question.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 112 participants were included in the ITT population.

Rationale: The paper reports that 112 participants had samples obtained for HIV sequencing.

Answer: 112

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in France.

Rationale: The paper reports that the sequenced samples were obtained from France.

Answer: France

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted between November 2019 and September 2020.

Rationale: The paper reports that the sequenced samples were obtained between 2019 and 2020.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, and therefore it is likely that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""HIV-1 drug resistance mutations"" in the Methods section.

Rationale: The paper reports that the HIV-1 pol gene was sequenced, as indicated by the mention of HIV-1 drug resistance mutations.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention the sequencing method used, and therefore it is not possible to provide an answer to this question.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1-RNA"" in the Methods section.

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological non-response"" and ""protocol-defined virological failure"" in the Methods section.

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a clinical trial (NCT03858478) in the Methods section.

Rationale: The paper reports that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the participants were ART-naive in the Methods section.

Rationale: The paper reports that the HIV sequences were obtained from individuals who had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants received BIC/FTC/TAF in the Methods section.

Rationale: The paper reports that the individuals in the study received INSTI (BIC) and NRTI (FTC and TAF) classes before sample sequencing.

Answer: INSTI, NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the participants received BIC/FTC/TAF in the Methods section.

Rationale: The paper reports that the individuals in the study received BIC, FTC, and TAF before sample sequencing.

Answer: BIC, FTC, TAF",64
36660819,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""virologically suppressed individuals"" and ""plasma HIV-1 RNA"" which indicates that the study involves patient samples. Additionally, the paper states ""genotypic resistance testing"" and ""sequencing"" which suggests that HIV sequences were obtained from patient samples.

Rationale: The presence of terms such as ""virologically suppressed individuals"", ""plasma HIV-1 RNA"", ""genotypic resistance testing"", and ""sequencing"" in the paper indicates that the study involves the analysis of HIV sequences from patient samples.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic resistance testing"" and ""genotypic resistance testing"" which suggests that the study involves the analysis of drug susceptibility data. However, it does not explicitly state that the data is from in vitro experiments.

Rationale: The presence of terms such as ""phenotypic resistance testing"" and ""genotypic resistance testing"" in the paper indicates that the study involves the analysis of drug susceptibility data. However, without explicit mention of in vitro experiments, it is unclear whether the data is from in vitro or in vivo experiments.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the deposition of sequences in a public database or provide accession numbers.

Rationale: The absence of any mention of sequence deposition or accession numbers in the paper suggests that the sequences are not publicly available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, making it impossible to determine the specific sequences used in the study.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""1045 participants were included in the ITT-E population"".

Rationale: The paper explicitly states the number of participants in the study, which is 1045.

Answer: 1045.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The absence of any mention of country of origin in the paper makes it impossible to determine the country where the samples were obtained.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the samples were obtained.

Rationale: The absence of any mention of specific years in the paper makes it impossible to determine the years when the samples were obtained.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The absence of any mention of cloning in the paper suggests that the samples were not cloned prior to sequencing.

Answer: No.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""sequencing"" but does not specify which HIV genes were sequenced.

Rationale: The presence of terms such as ""genotypic resistance testing"" and ""sequencing"" in the paper indicates that the study involves the analysis of HIV sequences, but the specific genes sequenced are not mentioned.

Answer: Not reported.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The absence of any mention of sequencing method in the paper makes it impossible to determine the method used.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" which suggests that the samples sequenced were plasma samples.

Rationale: The presence of the term ""plasma HIV-1 RNA"" in the paper indicates that the samples sequenced were plasma samples.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""confirmed virologic failure"" which suggests that the study involves the analysis of sequences from individuals with virological failure.

Rationale: The presence of terms such as ""virologic failure"" and ""confirmed virologic failure"" in the paper indicates that the study involves the analysis of sequences from individuals with virological failure.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study is a ""phase 3b randomized, open-label, active-controlled, multicenter, parallel-group noninferiority study"".

Rationale: The presence of terms such as ""phase 3b"", ""randomized"", ""open-label"", ""active-controlled"", ""multicenter"", and ""parallel-group noninferiority study"" in the paper indicates that the study is a clinical trial.

Answer: Yes.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study involves ""virologically suppressed individuals"" and ""genotypic resistance testing"" which suggests that the individuals in the study had previously received ARV drugs.

Rationale: The presence of terms such as ""virologically suppressed individuals"" and ""genotypic resistance testing"" in the paper indicates that the individuals in the study had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""cabotegravir (CAB) + rilpivirine (RPV)"" which suggests that the individuals in the study received INSTI and NNRTI drug classes.

Rationale: The presence of the term ""cabotegravir (CAB) + rilpivirine (RPV)"" in the paper indicates that the individuals in the study received INSTI and NNRTI drug classes.

Answer: INSTI, NNRTI.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""cabotegravir (CAB) + rilpivirine (RPV)"" which suggests that the individuals in the study received CAB and RPV drugs.

Rationale: The presence of the term ""cabotegravir (CAB) + rilpivirine (RPV)"" in the paper indicates that the individuals in the study received CAB and RPV drugs.

Answer: Cabotegravir, Rilpivirine.",84
36694270,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method."" and ""Sequences were then spliced and edited using the Seqman pro and Megalign7.0V software, and were submitted to the drug resistance database of Stanford University (https://hivdb.stanford.edu/hivdb/by-sequences/) for HIV-1 subtypes and resistance mutation analysis.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples using PCR and sequencing methods.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences and drug resistance mutations, but does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""Sequences were then spliced and edited using the Seqman pro and Megalign7.0V software, and were submitted to the drug resistance database of Stanford University (https://hivdb.stanford.edu/hivdb/by-sequences/) for HIV-1 subtypes and resistance mutation analysis.""

Rationale: The paper explicitly states that the sequences were submitted to the Stanford University database, but does not provide any accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any accession numbers, and the sequences were submitted to the Stanford University database, not GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""Overall, 62 HIV-1 patients with a median (IQR) age of 51 (38--64) years (51 ARV non-treated, including 49 naive; 11 ARV treated) were analysed""

Rationale: The paper explicitly states that 62 patients had samples obtained for HIV sequencing.

Answer: 62
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""We retrospectively collected matched pairs of 68 HIV-1 patients who were admitted to Chongqing Public Health Medical Center from June 2020 to June 2022""

Rationale: The paper explicitly states that the samples were obtained from patients in Chongqing, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""We retrospectively collected matched pairs of 68 HIV-1 patients who were admitted to Chongqing Public Health Medical Center from June 2020 to June 2022""

Rationale: The paper explicitly states that the samples were obtained from patients between 2020 and 2022.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper states ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method.""

Rationale: The paper does not explicitly state that the samples were cloned prior to sequencing, but the use of nested PCR suggests that the samples may have been amplified prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method.""

Rationale: The paper explicitly states that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: Protease, Reverse Transcriptase, Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""We amplified the nucleotide sequences of HIV-1 protease, reverse transcriptase and integrase using nested polymerase chain reaction (nest-pcr) method.""

Rationale: The paper explicitly states that nested PCR was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""We retrospectively collected matched pairs of 68 HIV-1 patients who were admitted to Chongqing Public Health Medical Center from June 2020 to June 2022 and completed plasma CD4+ T cell counts, HIV RNA viral load, and CSF biochemical tests.""

Rationale: The paper explicitly states that both plasma and CSF samples were sequenced.

Answer: Plasma, CSF
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Among patients receiving ARV treatment, 8/11 (72.7 %) had HIV-1 resistance mutations in both plasma and CSF""

Rationale: The paper explicitly states that some patients had virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Among patients receiving ARV treatment, 8/11 (72.7 %) had HIV-1 resistance mutations in both plasma and CSF""

Rationale: The paper explicitly states that some patients had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""NRTIs were the main drugs used in ARV-treated patients""

Rationale: The paper explicitly states that NRTIs were used in ARV-treated patients.

Answer: NRTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The NRTIs 3TC and TDF in multiple ARV treatment regimens are prone to cause 184 V/I and 65 R mutations""

Rationale: The paper explicitly states that 3TC and TDF were used in ARV treatment regimens.

Answer: 3TC, TDF
""""""",75
36706364,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" performed on samples from patients.

Rationale: The paper states that genetic sequencing was performed on clinical samples from patients, which indicates that the paper reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""genotypic resistance testing"" and ""resistance mutations"", but does not report in vitro drug susceptibility data.

Rationale: The paper does not mention in vitro drug susceptibility data, such as IC50, EC50, or fold-change in susceptibility, which are typical measures of in vitro drug susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not provide any information about the public availability of the sequences, which suggests that they were not made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers, which are typically used to identify sequences in public databases.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 62 adults were enrolled in the study.

Rationale: The paper states that 62 adults were enrolled in the study, which suggests that samples were obtained from these individuals for HIV sequencing.

Answer: 62
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Khayelitsha, South Africa.

Rationale: The paper states that the study was conducted in Khayelitsha, South Africa, which suggests that the sequenced samples were obtained from South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that participants were enrolled between August 2019 and July 2020.

Rationale: The paper states that participants were enrolled between August 2019 and July 2020, which suggests that the sequenced samples were obtained during this time period.

Answer: 2019-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which suggests that samples were not cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""genotypic resistance testing"" and ""resistance mutations"", but does not specify which HIV genes were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not provide any information about the sequencing method, which suggests that this information is not reported.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that samples were obtained from adults with virologic failure on a first-line regimen.

Rationale: The paper states that samples were obtained from adults with virologic failure on a first-line regimen, which suggests that the samples were obtained from plasma or whole blood.

Answer: Plasma or whole blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that participants had virologic failure on a first-line regimen.

Rationale: The paper states that participants had virologic failure on a first-line regimen, which suggests that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was a single-arm, prospective, interventional study.

Rationale: The paper states that the study was a single-arm, prospective, interventional study, which suggests that the patients were in a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that participants had previously received ARV drugs as part of their first-line regimen.

Rationale: The paper states that participants had previously received ARV drugs as part of their first-line regimen, which suggests that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had previously received tenofovir, lamivudine, and an NNRTI as part of their first-line regimen.

Rationale: The paper states that participants had previously received tenofovir, lamivudine, and an NNRTI as part of their first-line regimen, which suggests that the individuals received NRTIs and NNRTIs before sample sequencing.

Answer: NRTIs and NNRTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that participants had previously received tenofovir, lamivudine, and an NNRTI as part of their first-line regimen.

Rationale: The paper states that participants had previously received tenofovir, lamivudine, and an NNRTI as part of their first-line regimen, which suggests that the individuals received these specific drugs before sample sequencing.

Answer: Tenofovir, lamivudine, and an NNRTI
""""""",71
36738248,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Plasma samples from PLHIV in the SHCS are collected twice per year"" and ""We included all participants enrolled in the SHCS with SS and NGS sequences available for the *pol* region of HIV"".

Rationale: The paper explicitly mentions that plasma samples were collected from patients and that HIV sequences were obtained from these samples.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the comparison of HIV drug resistance mutations detected by Sanger sequencing and next-generation sequencing, but does not report any in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""We included 594 pairs of SS and NGS from 527 SHCS participants"".

Rationale: The paper explicitly mentions the number of participants who had samples obtained for HIV sequencing.

Answer: 527.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""The SHCS is a prospective multicentre study that is highly representative of the HIV-1 epidemic in Switzerland"".

Rationale: The paper explicitly mentions that the samples were obtained from Switzerland.

Answer: Switzerland.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the samples were obtained.

Rationale: The paper does not provide any information about the years when the samples were obtained.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""SS was performed by amplification and sequencing of HIV genomic regions targeted by antiretroviral (ARV) drugs, such as the protease (PR), reverse transcriptase (RT) and integrase (IN) regions"".

Rationale: The paper explicitly mentions the HIV genes that were sequenced.

Answer: PR, RT, IN.

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""SS was performed by amplification and sequencing of HIV genomic regions"" and ""NGS sequences were generated using previously described protocols"".

Rationale: The paper explicitly mentions the sequencing methods used.

Answer: Sanger sequencing and next-generation sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""Plasma samples from PLHIV in the SHCS are collected twice per year"".

Rationale: The paper explicitly mentions the type of samples that were sequenced.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""We assessed the resistance levels of individual ARV drugs for each of the 594 sample pairs"" and ""We found 166 (27.9%) of 578 SS sequences with at least low-level resistance to at least one ARV drug"".

Rationale: The paper explicitly mentions that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""We assessed the resistance levels of individual ARV drugs for each of the 594 sample pairs"" and ""We found 166 (27.9%) of 578 SS sequences with at least low-level resistance to at least one ARV drug"".

Rationale: The paper explicitly mentions that some sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about the specific drug classes that were received by individuals in the study.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about the specific drugs that were received by individuals in the study.

Answer: Not reported.",65
36751650,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Pol sequences were sequenced to analyze PDR and construct a genetic network."" and ""Viral RNA was extracted from the plasma samples using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically from plasma samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""Genotypic resistance was analyzed using the Stanford University HIV Drug Resistance Database Genotypic Resistance Interpretation Algorithm (version 8.8) and the International Antiviral Society Drug Resistance Mutation list [16].""

Rationale: The paper does not report in vitro drug susceptibility data, but rather genotypic resistance data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""A total of 1653 samples, including 716 MSM, 827 HES, 50 PWID, and 15 others, were successfully sequenced.""

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 1653
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""Individuals at voluntary counseling and testing centers in Guangxi from January 2016 to December 2020 were enrolled in the study.""

Rationale: The paper explicitly states that the samples were obtained from Guangxi, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""Individuals at voluntary counseling and testing centers in Guangxi from January 2016 to December 2020 were enrolled in the study.""

Rationale: The paper explicitly states the years during which the samples were obtained.

Answer: 2016-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""The target fragment of 1316 bp in the *pol* gene (HXB2: 2147--3462, encoding the protease and the first 299 residues of reverse transcriptase), which spans the reverse transcriptase and protease-encoding regions, was amplified using nested polymerase chain reaction (PCR).""

Rationale: The paper explicitly states that the pol gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""The PCR products were sent to the company for Sanger sequencing.""

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Viral RNA was extracted from the plasma samples using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany) according to the manufacturer's instructions.""

Rationale: The paper explicitly states that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information about virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Individuals newly diagnosed with HIV in Guangxi from 2016 to 2020, which mainly included MSM and the heterosexual (HES) population, were recruited in this study.""

Rationale: The paper explicitly states that the individuals were newly diagnosed and had not received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide any information about drug classes received by individuals before sample sequencing.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information about drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",64
36779485,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper explicitly mentions that it includes genotypic sequence data from patient samples, which indicates that it reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not provide any information about in vitro drug susceptibility data, which suggests that it does not report such data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""Pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs.""

Rationale: The paper mentions that the sequences were submitted to a public database (Stanford HIVdb), which indicates that the sequences were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers, which suggests that the sequences were not deposited in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper explicitly mentions the number of patients who had samples obtained for HIV sequencing.

Answer: 1649
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""Our retrospective analysis indicates that rilpivirine DRMs are common in a setting wherein NNRTI-based treatment was widely implemented in South Africa.""

Rationale: The paper explicitly mentions that the samples were obtained from South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not provide information about the years when the samples were obtained.

Rationale: The paper does not mention the years when the samples were obtained, which suggests that this information is not available.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide information about cloning.

Rationale: The paper does not mention cloning, which suggests that this information is not available.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Pol sequences were submitted to Stanford HIVdb v9.0 to identify rilpivirine DRMs.""

Rationale: The paper explicitly mentions that the pol gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not provide information about the sequencing method.

Rationale: The paper does not mention the sequencing method, which suggests that this information is not available.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not provide information about the type of samples.

Rationale: The paper does not mention the type of samples, which suggests that this information is not available.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper explicitly mentions that sequences were obtained from patients experiencing NNRTI-treatment failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information about a clinical trial.

Rationale: The paper does not mention a clinical trial, which suggests that this information is not available.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper explicitly mentions that sequences were obtained from patients who had previously received ARV drugs (NNRTI-treatment failure).

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""Genotypic sequence data from 277 patients initiating ART and 1372 patients experiencing NNRTI-treatment failure were included for analysis as previously described [7].""

Rationale: The paper explicitly mentions that the patients had received NNRTI-based treatment before sample sequencing.

Answer: NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information about specific drugs.

Rationale: The paper does not mention specific drugs, which suggests that this information is not available.

Answer: Not reported
""""""",60
36795586,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention ""HIV genotype testing"" and ""HIV resistance mutations"" in the context of antiretroviral therapy.

Rationale: Based on the evidence, it appears that the paper does not report HIV sequences from patient samples. The mention of HIV genotype testing and resistance mutations suggests that the paper may discuss HIV genetics, but it does not explicitly mention sequencing patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: Based on the evidence, it appears that the paper does not report in vitro drug susceptibility data. The paper focuses on the effectiveness and safety of dolutegravir (DTG) in children and adolescents living with HIV, but it does not mention in vitro susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: Based on the evidence, it appears that the paper does not make sequences publicly available. The paper does not mention depositing sequences in a public database or providing accession numbers.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report sequencing HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not report sequencing HIV isolates. Therefore, there are no GenBank accession numbers to provide.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: Not applicable, as the paper does not report sequencing HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not report sequencing HIV isolates. Therefore, there is no information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: Not applicable, as the paper does not report sequencing HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not report sequencing HIV isolates. Therefore, there is no information on the countries from which samples were obtained.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: Not applicable, as the paper does not report sequencing HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not report sequencing HIV isolates. Therefore, there is no information on the years from which samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not applicable, as the paper does not report sequencing HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not report sequencing HIV isolates. Therefore, there is no information on whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: Not applicable, as the paper does not report sequencing HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not report sequencing HIV isolates. Therefore, there is no information on which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: Not applicable, as the paper does not report sequencing HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not report sequencing HIV isolates. Therefore, there is no information on the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: Not applicable, as the paper does not report sequencing HIV isolates.

Rationale: Based on the evidence, it appears that the paper does not report sequencing HIV isolates. Therefore, there is no information on the type of samples sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" in the context of antiretroviral therapy, but it does not explicitly mention sequencing samples from individuals with virological failure.

Rationale: Based on the evidence, it appears that the paper does not explicitly mention sequencing samples from individuals with virological failure. However, the paper does discuss the effectiveness of dolutegravir (DTG) in children and adolescents living with HIV, which may include individuals with virological failure.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: Based on the evidence, it appears that the paper does not report a clinical trial. The paper discusses a retrospective analysis of patients receiving dolutegravir (DTG) in a real-world setting.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""antiretroviral therapy"" and ""ART-experienced"" patients, but it does not explicitly mention sequencing HIV isolates from individuals who had previously received ARV drugs.

Rationale: Based on the evidence, it appears that the paper does not explicitly mention sequencing HIV isolates from individuals who had previously received ARV drugs. However, the paper does discuss the effectiveness of dolutegravir (DTG) in children and adolescents living with HIV, which may include individuals who had previously received ARV drugs.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""antiretroviral therapy"" and ""ART-experienced"" patients, but it does not explicitly mention the drug classes received by individuals before sample sequencing.

Rationale: Based on the evidence, it appears that the paper does not explicitly mention the drug classes received by individuals before sample sequencing. However, the paper does discuss the effectiveness of dolutegravir (DTG) in children and adolescents living with HIV, which may include individuals who had previously received various drug classes.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""dolutegravir"" (DTG) and ""tenofovir-lamivudine-DTG"" (TLD), but it does not explicitly mention the drugs received by individuals before sample sequencing.

Rationale: Based on the evidence, it appears that the paper does not explicitly mention the drugs received by individuals before sample sequencing. However, the paper does discuss the effectiveness of dolutegravir (DTG) and TLD in children and adolescents living with HIV.

Answer: Not reported",83
36851704,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""Protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced"" and ""Whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically from whole blood specimens collected before initiating or reinitiating ART.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper only reports genotypic resistance data and does not mention any in vitro susceptibility testing.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available, and there is no mention of GenBank accession numbers.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""A total of 206 participants were enrolled in the survey"".

Rationale: The paper explicitly states that 206 participants had samples obtained for HIV sequencing.

Answer: 206.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""The Ministry of Health of Uruguay implemented a cross-sectional nationally representative survey"".

Rationale: The paper explicitly states that the survey was conducted in Uruguay, so the sequenced samples were obtained from Uruguay.

Answer: Uruguay.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""From October 2018 to October 2019"".

Rationale: The paper explicitly states that the samples were obtained between 2018 and 2019.

Answer: 2018-2019.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide any information about cloning, and the sequencing method used is Sanger sequencing, which does not typically involve cloning.

Answer: No.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""Protease, reverse transcriptase, and integrase genes of HIV-1 were sequenced"".

Rationale: The paper explicitly states that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: Protease, reverse transcriptase, and integrase.

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""Sanger sequencing was performed on a 3730xl Genetic Analyser"".

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Whole blood specimens were collected by venipuncture in EDTA-containing tubes from participants before initiating or reinitiating ART.""

Rationale: The paper explicitly states that whole blood specimens were used for sequencing.

Answer: Whole blood.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure.

Rationale: The paper does not provide any information about virological failure, and the sequencing was done before initiating or reinitiating ART.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, and the study design is a cross-sectional survey.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""35.6% reported previous exposure to antiretroviral (ARV) drugs"".

Rationale: The paper explicitly states that some individuals had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about the drug classes received.

Rationale: The paper does not provide any information about the specific drug classes received by the individuals before sample sequencing.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide specific information about the drugs received.

Rationale: The paper does not provide any information about the specific drugs received by the individuals before sample sequencing.

Answer: Not reported.",60
36851760,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Dried blood spot (DBS) samples were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali."" and ""Genetic sequencing of HIV integrase was successful in 75 samples.""

Rationale: The paper explicitly states that it obtained DBS samples from HIV-1-infected children and successfully sequenced the HIV integrase gene from 75 samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the genetic sequencing of HIV integrase and the analysis of resistance-associated mutations, but it does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""All sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.""

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states ""All sequences were submitted to GenBank and registered under accession numbers OQ435656-OQ435729.""

Rationale: The paper provides the accession numbers for the sequenced HIV isolates.

Answer: OQ435656-OQ435729
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""Dried blood spot (DBS) samples were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali.""

Rationale: The paper explicitly states that 107 individuals had samples obtained for HIV sequencing.

Answer: 107
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""Dried blood spot (DBS) samples were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali.""

Rationale: The paper explicitly states that the samples were obtained from Benin and Mali.

Answer: Benin, Mali
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016"" and ""from 56 ART-naïve children, collected between 2018 and 2020 during early diagnosis testing and follow-up in Mali.""

Rationale: The paper provides the years during which the samples were collected.

Answer: 2015-2016, 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not Reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Genetic sequencing of HIV integrase was successful in 75 samples.""

Rationale: The paper explicitly states that the HIV integrase gene was sequenced.

Answer: Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""Target integrase regions of the HIV-1 were subsequently amplified by PCR after reverse-transcription production of complementary DNA (cDNA) and sequenced using the Sanger method.""

Rationale: The paper explicitly states that the Sanger method was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Dried blood spot (DBS) samples were obtained from 107 HIV-1-infected children aged less than 15 years old in two West African countries, Benin and Mali.""

Rationale: The paper explicitly states that DBS samples were sequenced.

Answer: Dried blood spots (DBS)
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""The DBSs were collected from 51 ART-treated children with virological failure, defined as having at least one viral load (VL) >1000 copies/mL, during a study conducted in Benin between 2015 and 2016""

Rationale: The paper explicitly states that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not Reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""All children were INI-naïve. 56 were naïve to anti-retroviral therapy (ART), and 51 had received ART.""

Rationale: The paper explicitly states that some individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""At enrollment, 90.3% of the treated children were receiving non-nucleoside-reverse-transcriptase-inhibitor (NNRTI)-based regimens, and only 9.7% received both nucleoside-reverse-transcriptase inhibitor (NRTI)- and PI-based regimens.""

Rationale: The paper explicitly states that the individuals received NNRTI-based regimens and some received NRTI- and PI-based regimens.

Answer: NNRTI, NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide information on specific drugs received by the individuals.

Answer: Not Reported
""""""",74
36920025,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"" and ""sequencing of the protease-coding region of viral DNA"" from infected cell pellets.

Rationale: The paper reports HIV sequences from patient samples, specifically from plasma and infected cell pellets.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""enzymatic inhibition constants (K ~i~ )"", ""EC ~50~ values"", and ""TZM infection assay"" to determine the level of resistance of the single inhibitor-selected virus pools.

Rationale: The paper reports in vitro drug susceptibility data, including enzymatic inhibition constants and EC ~50~ values.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that the sequencing data is available at NIH Sequencing Read Archive (SRA) under BioProject ID PRJNA853351.

Rationale: The sequences from the paper were made publicly available through the NIH Sequencing Read Archive.

Answer: Yes.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not mentioned in the paper.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: Not mentioned in the paper.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: Not mentioned in the paper.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: Not mentioned in the paper.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper mentions ""cloning into the pT7Blue vector"" for sequencing.

Rationale: The paper indicates that samples were cloned prior to sequencing.

Answer: Yes.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""sequencing of the protease-coding region of viral DNA"".

Rationale: The paper reports that the protease gene was sequenced.

Answer: Protease.

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""MiSeq 300 base paired-end sequencing protocol"" and ""Primer-ID deep sequencing of viral RNA"".

Rationale: The paper indicates that next-generation sequencing (NGS) was used for sequencing.

Answer: NGS.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""viral RNA was extracted from plasma"" and ""sequencing of the protease-coding region of viral DNA"" from infected cell pellets.

Rationale: The paper reports that plasma and infected cell pellets were sequenced.

Answer: Plasma and infected cell pellets.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""selections for resistance to high drug concentrations"" and ""virological failure"".

Rationale: The paper indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: Not mentioned in the paper.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""selections for resistance to high drug concentrations"" and ""virological failure"".

Rationale: The paper indicates that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""protease inhibitors"" and ""darunavir (DRV)"".

Rationale: The paper indicates that protease inhibitors, specifically darunavir (DRV), were received by individuals in the study before sample sequencing.

Answer: Protease inhibitors (PIs).

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""darunavir (DRV)"" and ""UMASS-1 through -10 inhibitors"".

Rationale: The paper indicates that darunavir (DRV) and UMASS-1 through -10 inhibitors were received by individuals in the study before sample sequencing.

Answer: Darunavir (DRV) and UMASS-1 through -10 inhibitors.",68
36931676,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-RNA (plasma and cerebrospinal fluid (CSF)) and HIV drug resistance (including viral sequences) results"" and ""all viral (*pol*) sequences are stored in the database"".

Rationale: The paper explicitly mentions the collection and storage of HIV sequences from patient samples, indicating that it reports HIV sequences from patient samples.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not provide any information on in vitro drug susceptibility data, indicating that it does not report such data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information on making sequences publicly available, indicating that it does not report such information.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information on GenBank accession numbers, indicating that it does not report such information.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""13 029 PLHIV have been included in the cohort"".

Rationale: The paper explicitly mentions the number of individuals included in the cohort, indicating that it reports the number of individuals who had samples obtained for HIV sequencing.

Answer: 13,029.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that ""most commonly in SSA (36%)"" and ""a majority was born outside Sweden (67%)"".

Rationale: The paper provides information on the countries of origin of the individuals in the cohort, indicating that it reports the countries from which the sequenced samples were obtained.

Answer: Sweden, SSA (sub-Saharan Africa), and other countries (not specified).

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that ""the cohort was established in 2003"" and ""data regarding HIV diagnoses were even more accurate in InfCareHIV than in the Public Health Agencies records"" in 2019.

Rationale: The paper provides information on the years during which the cohort was established and the data were collected, indicating that it reports the years from which the sequenced samples were obtained.

Answer: 2003-2019.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information on cloning prior to sequencing, indicating that it does not report such information.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""all viral (*pol*) sequences are stored in the database"".

Rationale: The paper explicitly mentions the sequencing of the pol gene, indicating that it reports the sequencing of the pol gene.

Answer: Pol.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information on the sequencing method, indicating that it does not report such information.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""HIV-RNA (plasma and cerebrospinal fluid (CSF))"".

Rationale: The paper explicitly mentions the sequencing of plasma and CSF samples, indicating that it reports the sequencing of these sample types.

Answer: Plasma, CSF.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure/failing therapy while receiving [regimen]"".

Rationale: The paper explicitly mentions the sequencing of individuals with virological failure on a treatment regimen, indicating that it reports such sequences.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information on a clinical trial, indicating that it does not report such information.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-experienced"" and ""pre-existing NRTI-mutations"".

Rationale: The paper explicitly mentions the sequencing of individuals who had previously received ARV drugs, indicating that it reports such sequences.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI-mutations"" and ""protease inhibitor-based regimens"".

Rationale: The paper explicitly mentions the receipt of NRTI and PI drug classes, indicating that it reports these drug classes.

Answer: NRTI, PI.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""dolutegravir-based treatment"" and ""protease inhibitor-based regimens"".

Rationale: The paper explicitly mentions the receipt of dolutegravir and protease inhibitors, indicating that it reports these drugs.

Answer: Dolutegravir, protease inhibitors.",67
36961945,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""deep sequencing of HIV DNA from peripheral blood mononuclear cells and consensus sequencing from concurrent blood plasma"" and ""genotypic resistance testing on PR, RT, and IN from proviral HIV-1 DNA was performed using a modified version of the ""deepTypeHIV"" assay"".

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples, specifically from peripheral blood mononuclear cells and blood plasma.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the detection of HIV drug resistance mutations in patient samples, but does not report any in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""Overall, 190 individuals were included"".

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 190.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide any information about the country of origin for the samples.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""Samples were collected from January 2005 to February 2020"".

Rationale: The paper explicitly mentions the time period during which the samples were collected.

Answer: 2005-2020.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""genotypic resistance testing on PR, RT, and IN from proviral HIV-1 DNA was performed"".

Rationale: The paper explicitly mentions the HIV genes that were sequenced, specifically PR, RT, and IN.

Answer: PR, RT, IN.

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""deep sequencing of HIV DNA from peripheral blood mononuclear cells"" and ""consensus sequencing from concurrent blood plasma"".

Rationale: The paper explicitly mentions the use of deep sequencing and consensus sequencing methods.

Answer: Deep sequencing and consensus sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""deep sequencing of HIV DNA from peripheral blood mononuclear cells"" and ""consensus sequencing from concurrent blood plasma"".

Rationale: The paper explicitly mentions the types of samples that were sequenced, specifically peripheral blood mononuclear cells and blood plasma.

Answer: Peripheral blood mononuclear cells and blood plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""Despite identifying both high frequency and low frequency DRMs in either archived proviral DNA or blood plasma, there was no evidence of viral rebound from any participants during the entire follow-up period"".

Rationale: The paper explicitly mentions that there was no evidence of virological failure in the participants.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""antiretroviral-naïve persons with acute/early HIV infection"".

Rationale: The paper explicitly mentions that the individuals were antiretroviral-naïve.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes received by the individuals.

Rationale: The paper does not provide any information about the drug classes received by the individuals.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs received by the individuals.

Rationale: The paper does not provide any information about the specific drugs received by the individuals.

Answer: Not reported.",60
36967989,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""498 protease mutations have been observed"" and ""1218 isolates for atazanavir (ATV), 678 isolates for darunavir (DRV), 1809 isolates for fosemprenavir (FPV), 1,860 isolates for indinavir (IDV), 1,562 isolates for lopinavir (LPV), 1907 isolates for nelfinavir (NFV), 1,861 isolates for saquinavir (SQV) and 908 isolates for tipranavir (TPV) have been analyzed for PI susceptibility.""

Rationale: The paper reports HIV sequences from patient samples, as it mentions the number of isolates analyzed for each protease inhibitor.

Answer: Yes

""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""PhenoSense assay results"" and ""fold-change values"" which indicates in vitro drug susceptibility data.

Rationale: The paper reports in vitro drug susceptibility data, as it mentions the PhenoSense assay results and fold-change values.

Answer: Yes

""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report making sequences publicly available.

Answer: No

""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not report GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions ""1218 isolates for atazanavir (ATV), 678 isolates for darunavir (DRV), 1809 isolates for fosemprenavir (FPV), 1,860 isolates for indinavir (IDV), 1,562 isolates for lopinavir (LPV), 1907 isolates for nelfinavir (NFV), 1,861 isolates for saquinavir (SQV) and 908 isolates for tipranavir (TPV)"" but does not mention the number of individuals.

Rationale: The paper does not report the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not report the countries from which the sequenced samples were obtained.

Answer: Not reported

""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not report the years from which the sequenced samples were obtained.

Answer: Not reported

""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report whether samples were cloned prior to sequencing.

Answer: Not reported

""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""protease mutations"" and ""protease inhibitors"" which indicates that the protease gene was sequenced.

Rationale: The paper reports that the protease gene was sequenced.

Answer: PR

""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not report the sequencing method used.

Answer: Not reported

""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions ""plasma"" and ""isolates"" which indicates that plasma samples were sequenced.

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma

""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions ""virologic failure"" and ""resistance"" which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report whether the patients were in a clinical trial.

Answer: Not reported

""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ""treatment-experienced"" and ""resistance"" which indicates that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""protease inhibitors"" which indicates that individuals received protease inhibitors before sample sequencing.

Rationale: The paper reports that individuals received protease inhibitors before sample sequencing.

Answer: PI

""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""atazanavir (ATV), darunavir (DRV), fosemprenavir (FPV), indinavir (IDV), lopinavir (LPV), nelfinavir (NFV), saquinavir (SQV), and tipranavir (TPV)"" which indicates that individuals received these drugs before sample sequencing.

Rationale: The paper reports that individuals received these drugs before sample sequencing.

Answer: ATV, DRV, FPV, IDV, LPV, NFV, SQV, TPV

""""""",72
36982978,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-2 clinical isolates"" and ""patient-derived amplicons"" in the context of sequencing and genotyping.

Rationale: The paper discusses the sequencing and genotyping of HIV-2 isolates from patient samples, indicating that HIV sequences from patient samples are reported.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""IC50"" and ""EC50"" values for various antiretroviral drugs against HIV-2 isolates, indicating in vitro drug susceptibility data.

Rationale: The paper reports in vitro drug susceptibility data for various antiretroviral drugs against HIV-2 isolates, including IC50 and EC50 values.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the deposition of sequences in a public database or provide accession numbers.

Rationale: The paper does not provide evidence that the sequences were made publicly available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not provide a specific number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not provide information on the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not provide information on whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions the sequencing of the ""pol"" gene and the ""integrase"" gene.

Rationale: The paper reports the sequencing of the ""pol"" gene and the ""integrase"" gene.

Answer: Pol, Integrase.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not provide information on the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" and ""PBMC"" samples.

Rationale: The paper reports the sequencing of plasma and PBMC samples.

Answer: Plasma, PBMC.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" and ""treatment-experienced"" individuals.

Rationale: The paper reports the sequencing of samples from individuals with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not provide information on whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""treatment-experienced"" individuals and ""prior ARV exposure"".

Rationale: The paper reports the sequencing of samples from individuals who had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTIs"", ""NNRTIs"", ""PIs"", and ""INSTIs"".

Rationale: The paper reports the use of NRTIs, NNRTIs, PIs, and INSTIs by individuals in the study before sample sequencing.

Answer: NRTIs, NNRTIs, PIs, INSTIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""3TC"", ""ABC"", ""AZT"", ""TDF"", ""RAL"", and ""DTG"".

Rationale: The paper reports the use of specific drugs such as 3TC, ABC, AZT, TDF, RAL, and DTG by individuals in the study before sample sequencing.

Answer: 3TC, ABC, AZT, TDF, RAL, DTG.",68
37017009,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Resistance genotyping was performed using next-generation sequencing technologies"" and ""Whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube.""

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples, specifically from whole blood collected using standard phlebotomy methods.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""Resistance to PIs, NRTIs or NNRTIs was limited to drug resistance mutations associated with resistance to members of that drug class only"" and ""Adjusted predicted resistance profiles [susceptible (S), LLR, IR or HLR] of the 809 genotypes obtained are shown in Figure 2.""

Rationale: The paper reports predicted resistance profiles, which is a form of in vitro drug susceptibility data.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public database.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""At study closure, 1000 children had participated in the study"" and ""899 participants from 40 facilities from eight provinces... were included in the study analysis"".

Rationale: The paper explicitly mentions that 899 participants had samples obtained for HIV sequencing.

Answer: 899
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""This cross-sectional study, performed from March 2017 to March 2019 in South Africa"".

Rationale: The paper explicitly mentions that the samples were obtained from South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""This cross-sectional study, performed from March 2017 to March 2019"".

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2017-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""PCR amplification was performed using an in-house method resulting in a single amplicon spanning 1.5 kb of *pol* encompassing the protease gene and the first 250 amino acids of the reverse transcriptase gene"".

Rationale: The paper explicitly mentions that the pol gene, specifically the protease and reverse transcriptase regions, were sequenced.

Answer: Pol (protease and reverse transcriptase regions)
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""Resistance genotyping was performed using next-generation sequencing technologies"" and ""MiSeq FastQ files were analysed using DeepChek"".

Rationale: The paper explicitly mentions that next-generation sequencing technologies, specifically the MiSeq platform, were used for sequencing.

Answer: NGS (MiSeq)
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Whole blood was collected using standard phlebotomy methods into a 6 mL EDTA tube.""

Rationale: The paper explicitly mentions that whole blood samples were sequenced.

Answer: Whole blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""The adjusted proportion of HIV drug resistance among children with virological failure was 87.6%"" and ""Resistance to NNRTIs was detected in 77.3% of participants, and resistance to NRTIs in 69.6% of participants"".

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""The majority were receiving ritonavir-boosted lopinavir-based regimens"" and ""The majority were receiving efavirenz-based regimens"".

Rationale: The paper explicitly mentions that the individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The majority were receiving ritonavir-boosted lopinavir-based regimens"" and ""The majority were receiving efavirenz-based regimens"".

Rationale: The paper explicitly mentions that the individuals received PI and NNRTI drug classes before sample sequencing.

Answer: PI, NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The majority were receiving ritonavir-boosted lopinavir-based regimens"" and ""The majority were receiving efavirenz-based regimens"".

Rationale: The paper explicitly mentions that the individuals received lopinavir, ritonavir, and efavirenz before sample sequencing.

Answer: Lopinavir, ritonavir, efavirenz
""""""",70
37029656,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that ""genotypic resistance testing"" was performed on samples from 1223 ART-naive people living with HIV, and that ""Sanger sequencing"" was used to determine the genetic resistance of the HIV strains.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, which meets the criteria for a ""Yes"" answer.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions that the ""Genotypic Resistance Interpretation Algorithm of the Stanford HIV Drug Resistance Database Program"" was used to calculate the degree of resistance to each INSTI drug, but it does not report any in vitro drug susceptibility data.

Rationale: The paper does not report any in vitro drug susceptibility data, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available, and no accession numbers are provided.

Rationale: The paper does not provide any information about the public availability of the sequences, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that 1223 ART-naive people living with HIV had samples obtained for HIV sequencing.

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing, which meets the criteria for a ""Yes"" answer.

Answer: 1223
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were obtained between 2009 and 2019.

Rationale: The paper explicitly states the years during which the samples were obtained, which meets the criteria for a ""Yes"" answer.

Answer: 2009-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the ""integrase coding region of pol"" was sequenced.

Rationale: The paper explicitly states that the integrase gene was sequenced, which meets the criteria for a ""Yes"" answer.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states that ""Sanger sequencing"" was used to determine the genetic resistance of the HIV strains.

Rationale: The paper explicitly states that Sanger sequencing was used, which meets the criteria for a ""Yes"" answer.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that the samples were obtained from ART-naive individuals, which implies that they did not have virological failure on a treatment regimen.

Rationale: The paper explicitly states that the individuals were ART-naive, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which meets the criteria for a ""Not Reported"" answer.

Answer: Not Reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that the samples were obtained from ART-naive individuals, which implies that they had not previously received ARV drugs.

Rationale: The paper explicitly states that the individuals were ART-naive, which meets the criteria for a ""No"" answer.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that the individuals were ART-naive, which implies that they had not received any ARV drugs before sample sequencing.

Rationale: The paper explicitly states that the individuals were ART-naive, which meets the criteria for a ""None"" answer.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that the individuals were ART-naive, which implies that they had not received any ARV drugs before sample sequencing.

Rationale: The paper explicitly states that the individuals were ART-naive, which meets the criteria for a ""None"" answer.

Answer: None
""""""",64
37039023,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Forty-six HIV+ patients from RJ and 40 HIV+ patients from RS were included in this study"" and that ""All samples were successfully sequenced.""

Rationale: The paper reports that HIV sequences were obtained from patient samples, including their corresponding GenBank accession numbers.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""The raw sequencing reads were deposited to the Sequence Read Archive under the BioProject PRJNA419915.""

Rationale: The sequences from the paper were made publicly available in the Sequence Read Archive.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""Forty-six HIV+ patients from RJ and 40 HIV+ patients from RS were included in this study.""

Rationale: The paper reports that 86 individuals had samples obtained for HIV sequencing.

Answer: 86

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""Forty-six HIV+ patients from RJ and 40 HIV+ patients from RS were included in this study.""

Rationale: The paper reports that the sequenced samples were obtained from Brazil.

Answer: Brazil

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""All samples from RJ were collected between February 2016 and November 2018, whereas all samples from RS were collected between August and December 2017.""

Rationale: The paper reports that the sequenced samples were obtained between 2016 and 2018.

Answer: 2016-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""Protease, reverse transcriptase, integrase and envelope regions are known to harbour antiretroviral resistance mutations, and all 86 study samples had at least one of these regions analysed.""

Rationale: The paper reports that the protease, reverse transcriptase, integrase, and envelope regions were sequenced.

Answer: Protease, reverse transcriptase, integrase, and envelope

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Libraries were quantified in Qubit 3 (Life Technologies, Carlsbad, CA, USA) and sequenced using the Illumina MiSeq platform with a paired-end 2 × 251 protocol.""

Rationale: The paper reports that the sequencing method used was Illumina MiSeq.

Answer: Illumina MiSeq

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""PureLink ^®^ Genomic DNA Mini Kit (Thermo Fisher Scientific, Waltham, MA, USA) was used to extract DNA from the blood cells (including the integrated HIV proviral genome), according to the manufacturer's instructions.""

Rationale: The paper reports that the samples sequenced were peripheral blood cells.

Answer: Peripheral blood cells

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""All patients maintained their successful treatment despite the high prevalence of DRMs at low (62.5%) or high (37.5%) frequency.""

Rationale: The paper reports that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report that the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper reports that the patients had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper reports that the patients received NRTIs, NNRTIs, and PIs before sample sequencing.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""The most prevalent therapeutic regimen combination used was tenofovir disoproxil fumarate (TDF), lamivudine (3TC) and efavirenz (EFV) (TDF + 3TC + EFV), accounting for 55.8% ( *n* = 48) of patients included.""

Rationale: The paper reports that the patients received TDF, 3TC, and EFV before sample sequencing.

Answer: TDF, 3TC, EFV",78
37042390,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019. Genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy.""

Rationale: The paper reports that genotypic resistance testing was performed on patient samples, which involves sequencing the HIV genome to identify drug resistance mutations.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""Genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy.""

Rationale: The paper reports genotypic resistance testing, which involves sequencing the HIV genome to identify drug resistance mutations, but does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper reports that 87 patients had samples obtained for HIV sequencing.

Answer: 87
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""This single-centre observational study was done at a CoE in HIV care, Banaras Hindu University (BHU) in a tertiary hospital in Varanasi, India.""

Rationale: The paper reports that the samples were obtained from India.

Answer: India
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper reports that the samples were obtained between July 2016 and December 2019.

Answer: 2016-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy.""

Rationale: The paper reports that the integrase, reverse transcriptase, and protease genes were sequenced.

Answer: IN, RT, PR
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""Sequencing was done by a third-party commercial organization (Medauxin) using an Applied Biosystem 3730xl DNA Analyzer.""

Rationale: The paper reports that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Whole blood was collected from patients into EDTA tubes and used for CD4 estimation; in parallel, plasma was separated following centrifugation at 2000 rpm at 4°C for 10 min and stored at −80°C until viral RNA isolation.""

Rationale: The paper reports that whole blood and plasma samples were sequenced.

Answer: Whole blood, Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Genotypic resistance testing to identify drug resistance mutations in the integrase, reverse transcriptase and protease genes was done at the start of third-line therapy, as well as in those who did not attain virological suppression after 12 months of therapy.""

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Eighty-seven patients were started on third-line ART between July 2016 and December 2019.""

Rationale: The paper reports that the patients had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The initial regimen for third-line therapy was raltegravir (400 mg) + darunavir (600 mg) + ritonavir (100 mg); given as one tablet twice daily.""

Rationale: The paper reports that the patients received INSTI, PI, and NRTI drug classes.

Answer: INSTI, PI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The initial regimen for third-line therapy was raltegravir (400 mg) + darunavir (600 mg) + ritonavir (100 mg); given as one tablet twice daily.""

Rationale: The paper reports that the patients received raltegravir, darunavir, and ritonavir.

Answer: Raltegravir, Darunavir, Ritonavir
""""""",73
37052343,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" and ""CD4+ T-cell counts"" in the abstract and methods sections.

Rationale: The paper reports on the virological outcomes of patients starting antiretroviral treatment (ART), which implies that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""in vitro drug susceptibility"" or ""phenotypic resistance testing"" in the abstract or methods sections.

Rationale: The paper focuses on the virological outcomes of patients starting ART, but does not report on in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention ""GenBank accession numbers"" or ""publicly available sequences"" in the abstract or methods sections.

Rationale: The paper does not provide information on whether the sequences were made publicly available.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""4310 eligible participants"" in the methods section.

Rationale: The paper reports on the virological outcomes of 4310 participants, which implies that samples were obtained from these individuals for HIV sequencing.

Answer: 4310

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""Europe and Australia"" in the methods section.

Rationale: The paper reports on the virological outcomes of participants from Europe and Australia, which implies that the sequenced samples were obtained from these countries.

Answer: Europe, Australia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions ""2014-2020"" in the methods section.

Rationale: The paper reports on the virological outcomes of participants who started ART between 2014 and 2020, which implies that the sequenced samples were obtained during this time period.

Answer: 2014-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention ""cloning"" or ""clonal analysis"" in the abstract or methods sections.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""HIV-1 RNA"" and ""CD4+ T-cell counts"" in the abstract and methods sections.

Rationale: The paper reports on the virological outcomes of patients starting ART, which implies that the HIV-1 RNA gene was sequenced.

Answer: HIV-1 RNA

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention ""sequencing method"" or ""NGS"" in the abstract or methods sections.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" in the abstract and methods sections.

Rationale: The paper reports on the virological outcomes of patients starting ART, which implies that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" in the abstract and methods sections.

Rationale: The paper reports on the virological outcomes of patients starting ART, which implies that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention ""clinical trial"" in the abstract or methods sections.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ART-naive"" in the methods section.

Rationale: The paper reports on the virological outcomes of ART-naive patients, which implies that the sequences were obtained from individuals who had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""INSTI-based regimens"" and ""NRTI"" in the methods section.

Rationale: The paper reports on the virological outcomes of patients starting ART, which implies that the individuals received INSTI-based regimens and NRTI before sample sequencing.

Answer: INSTI, NRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""dolutegravir"" and ""raltegravir"" in the methods section.

Rationale: The paper reports on the virological outcomes of patients starting ART, which implies that the individuals received dolutegravir and raltegravir before sample sequencing.

Answer: Dolutegravir, Raltegravir",69
37071019,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients, but it does mention that the study used recombinant HIV-1 integrase proteins and HIV-1 viruses.

Rationale: The paper does not provide clear evidence that HIV sequences were obtained from patient samples. However, it does mention the use of recombinant HIV-1 integrase proteins and HIV-1 viruses, which suggests that the study may have involved the sequencing of HIV genes.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions that the study used cell-free strand transfer and DNA binding assays and cell-based infectivity, replicative capacity, and resistance assays to characterize the G118R plus R263K combination of integrase mutations.

Rationale: The paper provides evidence that the study involved in vitro drug susceptibility testing, including cell-free strand transfer and DNA binding assays and cell-based infectivity, replicative capacity, and resistance assays.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not provide evidence that sequences were made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the study used recombinant HIV-1 integrase proteins and HIV-1 viruses, which suggests that the study may have involved the sequencing of HIV genes.

Rationale: The paper does not provide clear evidence that specific HIV genes were sequenced, but it does mention the use of recombinant HIV-1 integrase proteins and HIV-1 viruses.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the method used for sequencing.

Rationale: The paper does not provide information on the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the study involved the characterization of the G118R plus R263K combination of integrase mutations, which is associated with virological failure on a treatment regimen.

Rationale: The paper provides evidence that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention whether the patients in the study were in a clinical trial.

Rationale: The paper does not provide information on whether the patients in the study were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study involved the characterization of the G118R plus R263K combination of integrase mutations, which is associated with previous receipt of ARV drugs.

Rationale: The paper provides evidence that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study involved the characterization of the G118R plus R263K combination of integrase mutations, which is associated with previous receipt of integrase inhibitors.

Rationale: The paper provides evidence that individuals in the study received integrase inhibitors before sample sequencing.

Answer: INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study involved the characterization of the G118R plus R263K combination of integrase mutations, which is associated with previous receipt of dolutegravir (DTG) and bictegravir (BIC).

Rationale: The paper provides evidence that individuals in the study received DTG and BIC before sample sequencing.

Answer: DTG, BIC
""""""",70
37085698,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically from 49 study participants.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report any in vitro drug susceptibility data, but rather focuses on the analysis of HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""All nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.""

Rationale: The paper explicitly states that the sequences have been deposited in the GenBank repository and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states ""All nucleotide sequences from this study have been deposited in the Genbank (ncbi) repository with accession numbers from MW560010 to MW560058.""

Rationale: The paper provides the accession numbers for the sequenced HIV isolates, which are MW560010 to MW560058.

Answer: MW560010 to MW560058
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""Near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.""

Rationale: The paper explicitly states that 49 study participants had samples obtained for HIV sequencing.

Answer: 49
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly state the country of origin for the samples, but it is mentioned that the study was conducted in Ethiopia.

Rationale: Although the paper does not explicitly state the country of origin, it can be inferred that the samples were obtained from Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""Accordingly, forty-nine volunteered adult (≥ 18 years old) study participants from voluntary VCT centers in Addis Ababa were consecutively enrolled in this study from June to December 2018.""

Rationale: The paper explicitly states that the samples were obtained from June to December 2018.

Answer: 2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report any cloning prior to sequencing, but rather focuses on the analysis of HIV sequences from patient samples.

Answer: Not Reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Near full-length HIV-1 IN region, (263 codons) of the 49 study participants were successfully sequenced and analyzed.""

Rationale: The paper explicitly states that the IN region of the HIV-1 genome was sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""Purified amplicons were then sequenced with Sanger DNA sequencing using the BigDye Terminator v3.1 Cycle Sequencing Kit (Applied Biosystems), and run on the ABI PRISM® 3500 xL automated Genetic Analyzer.""

Rationale: The paper explicitly states that Sanger DNA sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Blood samples (10 ml) were collected at the time of HIV diagnosis before initiation of ART for genotypic assay of the IN gene region from these participants using an EDTA tube.""

Rationale: The paper explicitly states that blood samples were collected and used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""This is a cross-sectional health facility-based study involving drug-naive HIV-1 infected study participants.""

Rationale: The paper explicitly states that the study participants were drug-naive, indicating that they had not experienced virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report any information about a clinical trial.

Answer: Not Reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""This is a cross-sectional health facility-based study involving drug-naive HIV-1 infected study participants.""

Rationale: The paper explicitly states that the study participants were drug-naive, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drug classes received by the individuals before sample sequencing.

Rationale: The paper does not report any information about drug classes received by the individuals before sample sequencing.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drugs received by the individuals before sample sequencing.

Rationale: The paper does not report any information about drugs received by the individuals before sample sequencing.

Answer: Not Reported
""""""",66
37104815,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-1 total DNA"" and ""HIV-1 genome"" and states that ""Sanger and ultra-deep sequencing (UDS) were performed on the HIV-1 genome"".

Rationale: The paper reports HIV sequences from patient samples, as it mentions the use of Sanger and ultra-deep sequencing on the HIV-1 genome.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""resistance mutations"" and ""resistance-associated mutations"" but does not report in vitro drug susceptibility data.

Rationale: The paper does not report in vitro drug susceptibility data, as it only mentions resistance mutations and does not provide data on in vitro susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not mention making sequences publicly available, and therefore, it is likely that the sequences are not publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers, and therefore, it is not possible to provide an answer.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""the first 121 participants"" had samples obtained for HIV sequencing.

Rationale: The paper reports that 121 individuals had samples obtained for HIV sequencing.

Answer: 121

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the samples.

Rationale: The paper does not mention the country of origin of the samples, and therefore, it is not possible to provide an answer.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that ""participants were screened from 7 September 2017 to 22 January 2018"".

Rationale: The paper reports that the samples were obtained between 2017 and 2018.

Answer: 2017-2018

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning prior to sequencing, and therefore, it is likely that the samples were not cloned prior to sequencing.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""Sanger and ultra-deep sequencing (UDS) were performed on the HIV-1 genome (Illumina technology) according to the ANRS consensus"" and specifically mentions the ""reverse transcriptase (RT), protease (PR) and integrase (INT) regions"".

Rationale: The paper reports that the reverse transcriptase (RT), protease (PR), and integrase (INT) regions of the HIV-1 genome were sequenced.

Answer: RT, PR, INT

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""Sanger and ultra-deep sequencing (UDS) were performed on the HIV-1 genome (Illumina technology)"".

Rationale: The paper reports that both Sanger sequencing and ultra-deep sequencing (UDS) using Illumina technology were used for sequencing.

Answer: Sanger sequencing and ultra-deep sequencing (UDS) using Illumina technology

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""HIV-1 total DNA"" was measured and that ""blood plasma samples"" were collected.

Rationale: The paper reports that both blood plasma samples and total HIV-1 DNA were sequenced.

Answer: Blood plasma and total HIV-1 DNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""emerging resistance at failure was more frequent in the 4/7 days group detected by Sanger sequencing"" and that ""resistance mutations related to current ART were detected more frequently by UDS"".

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study was a ""randomized, multicentre, non-inferiority Phase III trial"" and that it was registered in ClinicalTrials.gov.

Rationale: The paper reports that the patients in the study were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that ""participants were virally suppressed for 48 weeks"" and that ""all participants were on standard continuous triple therapy with virological suppression"".

Rationale: The paper reports that the individuals in the study had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that ""INSTIs"" were used by 47.1% of participants, ""NNRTIs"" by 47.1%, and ""PIs"" by 5.8%.

Rationale: The paper reports that the individuals in the study received INSTIs, NNRTIs, and PIs before sample sequencing.

Answer: INSTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""tenofovir"", ""emtricitabine"", ""rilpivirine"", ""abacavir"", ""lamivudine"", and ""raltegravir"".

Rationale: The paper reports that the individuals in the study received specific drugs such as tenofovir, emtricitabine, rilpivirine, abacavir, lamivudine, and raltegravir before sample sequencing.

Answer: Tenofovir, emtricitabine, rilpivirine, abacavir, lamivudine, raltegravir",78
37112971,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported in the paper.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not explicitly mention in vitro drug susceptibility data, but it does mention phenotypic susceptibility and resistance testing, which suggests that in vitro drug susceptibility data may be reported.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which indicates that sequences from the paper were made publicly available.

Answer: Yes.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, but the specific accession numbers are not provided in the text.

Rationale: The paper mentions that accession numbers are available, but they are not provided in the text.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper reports that sequences were obtained from 4481 treatment-naïve HIV-infected patients.

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 4481.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that samples were collected in Russia.

Rationale: The paper explicitly mentions the country where the samples were collected.

Answer: Russia.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper reports that samples were collected between 2006 and 2022.

Rationale: The paper explicitly mentions the years when the samples were collected.

Answer: 2006-2022.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that sequences covering the HIV-1 protease (PR), and part of the reverse transcriptase (RT) were available for all patients; additionally, sequences covering the HIV-1 integrase (INT) were available for 844 of them.

Rationale: The paper explicitly mentions the HIV genes that were sequenced.

Answer: PR, RT, INT.

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions Sanger-based or NGS-based sequencing.

Rationale: The paper explicitly mentions the sequencing methods used.

Answer: Sanger sequencing and NGS.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that RNA was extracted from blood plasma samples.

Rationale: The paper explicitly mentions the type of samples that were sequenced.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequences were obtained from treatment-naïve patients.

Rationale: The paper explicitly mentions that sequences were obtained from treatment-naïve patients, which indicates that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that sequences were obtained from treatment-naïve patients.

Rationale: The paper explicitly mentions that sequences were obtained from treatment-naïve patients, which indicates that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide information on drug classes received by individuals before sample sequencing.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly mention drugs received by individuals before sample sequencing.

Rationale: The paper does not provide information on drugs received by individuals before sample sequencing.

Answer: Not reported.",70
37147875,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation"" and ""Retrospective baseline NGS was done using the MiSeq platform (Illumina, San Diego, CA, USA)"".

Rationale: The paper explicitly mentions that HIV sequences were obtained from a patient sample using Sanger-based sequencing (SBS) and next-generation sequencing (NGS).

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""Pham et al., using an infectious molecular clone with the insertion of S230R by site-directed mutagenesis, showed that this mutation conferred a 63% reduction in integrase enzyme efficiency and a fold change in mean IC50 of 3.85, 3.72, 1.52 and 1.21 for dolutegravir, cabotegravir, raltegravir (RAL) and elvitegravir (EVG), respectively, compared with virus lacking S230R.""

Rationale: The paper reports in vitro drug susceptibility data, specifically the fold change in mean IC50 for different integrase inhibitors.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions a single patient, ""A 22-year-old man presented in April 2022 to our infectious disease department as seropositive for HIV"".

Rationale: The paper only reports on a single patient.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the patient was from France, ""In France, regular surveillance studies in individuals at the time of HIV-1 primary infection allow monitoring of emergence of transmitted drug-resistance-associated mutations (TDRAMs)"".

Rationale: The paper explicitly mentions that the sample was obtained from France.

Answer: France
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the patient presented in April 2022.

Rationale: The paper explicitly mentions the year in which the sample was obtained.

Answer: 2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that ""SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation"".

Rationale: The paper explicitly mentions that the RT, protease, and integrase genes were sequenced.

Answer: RT, protease, integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions ""Sanger-based sequencing (SBS)"" and ""next-generation sequencing (NGS)"".

Rationale: The paper explicitly mentions that both SBS and NGS were used for sequencing.

Answer: Sanger sequencing, NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that ""SBS of HIV-1 reverse transcriptase (RT), protease and integrase was performed before treatment initiation"" and ""Retrospective baseline NGS was done using the MiSeq platform (Illumina, San Diego, CA, USA)"".

Rationale: The paper does not explicitly mention the type of sample, but it can be inferred that it was a blood sample.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that the patient's sexual partner was ""an HIV-1-infected man treated but experiencing difficulties in adherence to treatment"".

Rationale: The paper implies that the patient's partner was experiencing virological failure, but it does not explicitly state that the sequence was obtained from the partner.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the patient started on a ""dolutegravir (DTG) + emtricitabine (FTC) + tenofovir disoproxil fumarate (TDF) regimen 7 days after diagnosis"".

Rationale: The paper explicitly mentions that the patient received ARV drugs after diagnosis.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient started on a ""dolutegravir (DTG) + emtricitabine (FTC) + tenofovir disoproxil fumarate (TDF) regimen 7 days after diagnosis"".

Rationale: The paper explicitly mentions that the patient received INSTI, NRTI, and possibly other classes of ARV drugs.

Answer: INSTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patient started on a ""dolutegravir (DTG) + emtricitabine (FTC) + tenofovir disoproxil fumarate (TDF) regimen 7 days after diagnosis"".

Rationale: The paper explicitly mentions that the patient received DTG, FTC, and TDF.

Answer: DTG, FTC, TDF
""""""",71
37272233,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""genetic sequencing were performed on clinical samples"" and ""HIV drug resistance mutation sequencing by PCR (AB 3500xL Dx genetic analyzer, Applied biosystem, Waltham, MA, USA) for each ARV class"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples, which indicates that HIV sequences from patient samples were reported.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""HIV drug resistance mutation sequencing by PCR"" and ""resistance mutation test results were collected"".

Rationale: The paper reports on the results of resistance mutation tests, which implies that in vitro drug susceptibility data were reported.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to a public database or made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""A total of 248 PWH were analyzed"".

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 248.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""Korea"" as the country where the study was conducted.

Rationale: The paper explicitly mentions the country where the study was conducted, which implies that the sequenced samples were obtained from Korea.

Answer: Korea.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""between January 2010 and December 2020"".

Rationale: The paper explicitly mentions the time period during which the samples were obtained.

Answer: 2010-2020.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""HIV drug resistance mutation sequencing by PCR for each ARV class"".

Rationale: The paper explicitly mentions that the pol gene was sequenced, which includes the protease, reverse transcriptase, and integrase genes.

Answer: Pol (protease, reverse transcriptase, and integrase).

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""PCR (AB 3500xL Dx genetic analyzer, Applied biosystem, Waltham, MA, USA)"".

Rationale: The paper explicitly mentions the use of PCR and a specific genetic analyzer, which implies that Sanger sequencing was used.

Answer: Sanger sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""clinical samples"" and ""plasma"".

Rationale: The paper explicitly mentions that plasma samples were sequenced.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" and ""resistance mutation test results were collected"".

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""ARV-experienced"" and ""previous history of ART"".

Rationale: The paper explicitly mentions that some individuals had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTI"", ""NNRTI"", ""PI"", and ""INSTI"".

Rationale: The paper explicitly mentions the different drug classes that were received by individuals in the study.

Answer: NRTI, NNRTI, PI, and INSTI.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as ""zidovudine"", ""lamivudine"", ""efavirenz"", and ""raltegravir"".

Rationale: The paper explicitly mentions specific drugs that were received by individuals in the study.

Answer: Zidovudine, lamivudine, efavirenz, raltegravir, and others.",63
37279764,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Nucleic acid extraction, PCR amplification work-up and sequencing were performed essentially as described previously.9 All available HIV-1 sequences covered a partial pol gene region (HXB2: 2252–3255).""

Rationale: The paper explicitly mentions that HIV-1 sequences were obtained from patient samples, and the methods used for sequencing are described.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV-1 sequences and the prevalence of transmitted drug resistance, but does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""GenBank accession no. MW947591–MW957968, OP058117–OP058658"".

Rationale: The paper provides GenBank accession numbers for the sequences, indicating that they are publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states ""GenBank accession no. MW947591–MW957968, OP058117–OP058658"".

Rationale: The paper provides the GenBank accession numbers for the sequences.

Answer: MW947591–MW957968, OP058117–OP058658
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""A total of 12 320 participants with demographic data and partial pol sequences were included in this study"".

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 12,320
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not explicitly mention the country of origin for the samples.

Rationale: Although the paper mentions that the study was conducted in Shenzhen, China, it does not explicitly state that the samples were obtained from China.

Answer: Not Reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""The annual sampling rate exceeded 50% to ensure that a sufficient number of samples representing the current HIV epidemic situation were collected from January 2011 to December 2019"".

Rationale: The paper explicitly mentions the years during which the samples were collected.

Answer: 2011-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not Reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""All available HIV-1 sequences covered a partial pol gene region (HXB2: 2252–3255)"".

Rationale: The paper explicitly mentions that the partial pol gene region was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not Reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Nucleic acid extraction, PCR amplification work-up and sequencing were performed essentially as described previously.9 All available HIV-1 sequences covered a partial pol gene region (HXB2: 2252–3255)"".

Rationale: The paper does not explicitly mention the type of samples sequenced, but it can be inferred that they were likely plasma or PBMC samples.

Answer: Not Reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""The patients with TDRMs diagnosed in 2017–19 were younger than those in 2011–16"".

Rationale: The paper does not explicitly mention virological failure, but it can be inferred that some patients may have experienced treatment failure.

Answer: Not Reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""All individuals were treatment naive at enrolment"".

Rationale: The paper explicitly mentions that the individuals were treatment-naive at enrolment.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes received by the individuals.

Rationale: The paper does not provide information on the drug classes received by the individuals.

Answer: Not Reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by the individuals.

Rationale: The paper does not provide information on the specific drugs received by the individuals.

Answer: Not Reported
""""""",61
37327289,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""The *pol* gene was amplified and genotyped using sanger sequencing"" and ""The *pol* sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].""

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples and were genotyped using Sanger sequencing.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper only reports genotypic resistance data and does not mention any in vitro susceptibility assays or experiments.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states ""The *pol* sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].""

Rationale: The paper explicitly mentions that the sequences have been deposited in a public database.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states ""The *pol* sequences have been archived in the DDBJ Nucleotide Database [LC723952-LC724015].""

Rationale: The paper provides the accession numbers for the sequences, but they are not GenBank accession numbers, but rather DDBJ accession numbers.

Answer: LC723952-LC724015 (Note: These are DDBJ accession numbers, not GenBank accession numbers)

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""This was a cross-sectional study that utilized 157 plasma samples obtained from HIV-1 seropositive and treatment-naïve FSWs between November 2020 and April 2021.""

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 157

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""The participants were recruited from 7 sex worker outreach program (SWOP) clinics in Nairobi County, specifically Nairobi City, Donholm, Kawangware, Korogocho, Langata, Majengo, and Thika Road.""

Rationale: The paper explicitly mentions the location of the clinics where the samples were obtained, which is in Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""The participants were recruited from 7 sex worker outreach program (SWOP) clinics in Nairobi County, specifically Nairobi City, Donholm, Kawangware, Korogocho, Langata, Majengo, and Thika Road between November 2020 and April 2021.""

Rationale: The paper explicitly mentions the years when the samples were obtained.

Answer: 2020-2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper only mentions PCR amplification and Sanger sequencing, but does not mention cloning.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""The *pol* gene was amplified and genotyped using sanger sequencing.""

Rationale: The paper explicitly mentions that the *pol* gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""The *pol* gene was amplified and genotyped using sanger sequencing.""

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""HIV-1 RNA extraction from plasma samples was carried out using the Invitrogen PureLink RNA Mini Kit.""

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""This was a cross-sectional study that utilized 157 plasma samples obtained from HIV-1 seropositive and treatment-naïve FSWs.""

Rationale: The paper explicitly mentions that the individuals were treatment-naïve, which means they had not experienced virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""This was a cross-sectional study that utilized 157 plasma samples obtained from HIV-1 seropositive and treatment-naïve FSWs.""

Rationale: The paper explicitly mentions that the individuals were treatment-naïve, which means they had not previously received ARV drugs.

Answer: No

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide any information about drug classes received by individuals before sample sequencing.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information about drugs received by individuals before sample sequencing.

Answer: Not Reported",70
37340869,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" of HIV-1 RNA from patient samples.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from patient samples to identify predictors of virologic failure.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic resistance testing"" and ""model-predicted plasma concentrations"" of cabotegravir and rilpivirine.

Rationale: The paper reports on the analysis of in vitro drug susceptibility data to identify predictors of virologic failure.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the deposition of sequences in a public database.

Rationale: The paper does not provide information on the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide information on the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 1651 participants were included in the analysis.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from 1651 participants.

Answer: 1651

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that participants were from North America, Europe, and ""other"" regions.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from participants from multiple countries.

Answer: North America, Europe, and other regions

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that data cutoffs were through week 124 for FLAIR, week 96 for ATLAS, and week 152 for ATLAS-2M.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from participants enrolled in studies with different data cutoffs.

Answer: Not reported (specific years not mentioned)

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide information on the cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""sequencing"" of HIV-1 RNA, but does not specify which genes were sequenced.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences, but does not provide information on which genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""sequencing"" of HIV-1 RNA, but does not specify the sequencing method.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences, but does not provide information on the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV-1 RNA"" and ""proviral DNA"".

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from plasma and proviral DNA samples.

Answer: Plasma and proviral DNA

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""confirmed virologic failure"" in the context of treatment with cabotegravir and rilpivirine.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the data were from the FLAIR, ATLAS, and ATLAS-2M studies, which are clinical trials.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from participants in clinical trials.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that participants were ""virologically suppressed"" and had ""historical genotypic evidence of any major INSTI or NNRTI RAMs"".

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""INSTI"" and ""NNRTI"" drug classes.

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from individuals who had previously received INSTI and NNRTI drugs.

Answer: INSTI and NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""cabotegravir"" and ""rilpivirine"".

Rationale: The paper reports on the analysis of HIV-1 RNA sequences from individuals who had previously received cabotegravir and rilpivirine.

Answer: Cabotegravir and rilpivirine",68
37358226,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients, but it does mention that viral load (VL) testing was performed on patient samples.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples, but it does discuss VL testing, which is a common method for monitoring HIV infection. However, the paper does not provide GenBank accession numbers or any information about the sequencing methods used.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any experiments related to drug susceptibility.

Rationale: The paper focuses on the clinical outcomes of patients who transitioned from NNRTI-based ART to DTG-based ART, and it does not report any in vitro experiments or data related to drug susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were submitted to GenBank or any other public sequence database.

Rationale: The paper does not provide any information about the availability of sequences or accession numbers, which suggests that the sequences are not publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report any GenBank accession numbers.

Rationale: The paper does not provide any information about GenBank accession numbers or sequence data.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper discusses the number of participants who transitioned to DTG-based ART, but it does not provide information about the number of individuals who had samples obtained for sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Lesotho.

Rationale: The paper provides information about the location of the study, which suggests that the samples were obtained from Lesotho.

Answer: Lesotho

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the samples were obtained.

Rationale: The paper provides information about the data closure date (1 May 2023) and the transition period to DTG-based ART, but it does not provide specific information about the years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any sequencing methods.

Rationale: The paper does not provide any information about the sequencing methods or whether cloning was performed.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the sequencing of specific HIV genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method or platform used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples used for sequencing.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some participants had elevated or missing pretransition VLs, which may indicate virological failure.

Rationale: The paper discusses the outcomes of participants who transitioned to DTG-based ART, including those with elevated or missing pretransition VLs, which may suggest virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper discusses a programmatic transition to DTG-based ART, which suggests that it is not a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that participants had previously received NNRTI-based ART.

Rationale: The paper discusses the transition from NNRTI-based ART to DTG-based ART, which suggests that participants had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants had previously received NNRTI-based ART, which includes drugs such as efavirenz and nevirapine.

Rationale: The paper discusses the transition from NNRTI-based ART to DTG-based ART, which suggests that participants had previously received NNRTI-based drugs.

Answer: NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that participants had previously received efavirenz and nevirapine.

Rationale: The paper discusses the transition from NNRTI-based ART to DTG-based ART, which suggests that participants had previously received efavirenz and nevirapine.

Answer: Efavirenz, nevirapine",65
37376649,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region; a bioinformatic filter is used to remove APOBEC3G/3F-induced G to A hypermutations.""

Rationale: The paper explicitly mentions that HIV-1 proviral DNA genotyping was conducted using next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the virologic impact of archived resistance in the dolutegravir/lamivudine 2-drug regimen HIV-1 switch study TANGO through week 144, but does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""Anonymized individual participant data and study documents can be requested for further research from www.clinicalstudydatarequest.com.""

Rationale: The paper does not explicitly state that the sequences were made publicly available, but rather that anonymized individual participant data and study documents can be requested for further research.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""A total of 734 participants were randomized and 741 received at least one dose of the study treatments (exposed population). Of those treated, 464 (63%) participants had historical genotypes with 221/369 (60%) in the DTG/3TC and 243/372 (65%) in the TBR group.""

Rationale: The paper mentions that 734 participants were randomized, but does not explicitly state how many individuals had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper states ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region; a bioinformatic filter is used to remove APOBEC3G/3F-induced G to A hypermutations.""

Rationale: The paper does not explicitly mention cloning, but rather uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region; a bioinformatic filter is used to remove APOBEC3G/3F-induced G to A hypermutations.""

Rationale: The paper explicitly mentions that the HIV-1 polymerase region was analyzed using next-generation sequencing (NGS).

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""HIV-1 proviral DNA genotyping was conducted retrospectively with the GenoSure Archive assay (Monogram Biosciences, South San Francisco, CA, USA), which uses next-generation sequencing (NGS) to analyze the HIV-1 polymerase region; a bioinformatic filter is used to remove APOBEC3G/3F-induced G to A hypermutations.""

Rationale: The paper explicitly mentions that next-generation sequencing (NGS) was used to analyze the HIV-1 polymerase region.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Participants' baseline whole blood samples were used for the GenoSure Archive assay.""

Rationale: The paper explicitly mentions that whole blood samples were used for the GenoSure Archive assay.

Answer: Whole Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""No participants in the DTG/3TC group met protocol-defined CVW criteria through week 144, while three participants in the TBR group (all without any archived major RAMs) met CVW criteria with no resistance observed at virologic failure time.""

Rationale: The paper mentions that no participants in the DTG/3TC group met protocol-defined CVW criteria, but three participants in the TBR group met CVW criteria.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper states ""The TANGO study (ClinicalTrials.gov, NCT03446573) demonstrated that switching to dolutegravir/lamivudine (DTG/3TC) was non-inferior to continuing tenofovir alafenamide-based regimens (TBR) through week 144.""

Rationale: The paper explicitly mentions that the study is a clinical trial (TANGO study) registered on ClinicalTrials.gov.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""A total of 743 participants were randomized and 741 received at least one dose of the study treatments (exposed population). Of those treated, 464 (63%) participants had historical genotypes with 221/369 (60%) in the DTG/3TC and 243/372 (65%) in the TBR group.""

Rationale: The paper mentions that participants had historical genotypes, but does not explicitly state that they had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""Participants were excluded if they had any evidence of IAS-USA major NRTI or INSTI RAMs in any historical genotype assay results, if available; any plasma HIV-1 RNA measurement of ≥50 copies/mL within 6 months of screening; a total of ≥2 measurements of ≥50 copies/mL or any measurement of >200 copies/mL within 6 and 12 months of screening; or a prior regimen switch for virologic failure (HIV-1 RNA ≥400 copies/mL).""

Rationale: The paper mentions that participants were excluded if they had evidence of IAS-USA major NRTI or INSTI RAMs, but does not explicitly state which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",93
37381002,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Pol gene of HIV-1 viruses in blood samples of EDTA anticoagulants from 398 patients with failed antiviral treatment was successfully amplified by using an in-house assay.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically from blood samples of patients with failed antiviral treatment.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""The Stanford HIV Drug Resistance Database system (https://hivdb.stanford.edu/hivdb/by-mutations/) was used to analyze resistance-related mutations and resistance levels by comparing with the sequence of wild type and drug resistant strains.""

Rationale: The paper does not report in vitro drug susceptibility data, but rather analyzes resistance-related mutations and resistance levels using a database system.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available, so we cannot assume that they were made available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""Among these ART failure patients, a total of 398 viral pol gene sequences were successfully sequenced.""

Rationale: The paper explicitly states that 398 individuals had samples obtained for HIV sequencing.

Answer: 398
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide any information about the country of origin for the samples, but it is mentioned that the study was conducted in Suzhou City, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""From 2017 to 2020, 450 people living with HIV who have received antiviral therapy for more than 1 year were confirmed to be ineffective (viral load ≥ 1000 copies/ml) in Suzhou city.""

Rationale: The paper explicitly states that the samples were obtained from 2017 to 2020.

Answer: 2017-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing, so we cannot assume that cloning was performed.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""The partial *pol* gene fragment of HIV-1 virus was amplified by using in-house polymerase chain reaction (PCR) method as described previously [12, 13].""

Rationale: The paper explicitly states that the partial *pol* gene fragment was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""The sequences of *pol* gene fragments were obtained by Sanger sequencing method.""

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Viral RNA was extracted from 200 µl plasma sample following the instructions of the MagNA Pure Compact Nucleic Acid Isolation Kit I (Roche, Switzerland).""

Rationale: The paper explicitly states that plasma samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Among these ART failure patients, a total of 398 viral pol gene sequences were successfully sequenced.""

Rationale: The paper explicitly states that the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, so we cannot assume that the patients were in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Among these ART failure patients, a total of 398 viral pol gene sequences were successfully sequenced.""

Rationale: The paper explicitly states that the sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about specific drug classes, but it is mentioned that the patients had received antiviral therapy.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about specific drugs, but it is mentioned that the patients had received antiviral therapy.

Answer: Not reported
""""""",64
37439411,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""HIV-1 RNA protease/reverse transcriptase sequences"" and ""genotypes from 9387 treatment-experienced PLWH"" which indicates that the paper reports HIV sequences from patient samples.

Rationale: The paper explicitly mentions the type of sequences and the source of the sequences, which are patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""genotypic susceptibility score (GSS)"" and ""cumulative GSS (cGSS)"" which indicates that the paper reports genotypic susceptibility data, but not in vitro drug susceptibility data.

Rationale: The paper does not mention any in vitro experiments or assays to determine drug susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions ""5982 naïves"" and ""9387 treatment-experienced PLWH"" which indicates that a total of 15369 individuals had samples obtained for HIV sequencing.

Rationale: The paper explicitly mentions the number of individuals in each group.

Answer: 15369
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from Italy.

Rationale: The paper explicitly mentions the country of origin of the samples.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from 2000 to 2020.

Rationale: The paper explicitly mentions the time period during which the samples were obtained.

Answer: 2000-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""HIV-1 RNA protease/reverse transcriptase sequences"" which indicates that the protease and reverse transcriptase genes were sequenced.

Rationale: The paper explicitly mentions the genes that were sequenced.

Answer: Protease, Reverse Transcriptase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions ""HIV-1 RNA protease/reverse transcriptase sequences"" which indicates that plasma samples were sequenced.

Rationale: The paper explicitly mentions the type of sequences, which are RNA sequences, indicating that plasma samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions ""virological failure"" and ""treatment-experienced PLWH"" which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly mentions virological failure and treatment experience.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ""treatment-experienced PLWH"" which indicates that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper explicitly mentions treatment experience.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""NNRTIs"" which indicates that the individuals received NNRTIs before sample sequencing.

Rationale: The paper explicitly mentions NNRTIs.

Answer: NNRTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""EFV"", ""RPV"", ""ETR"", and ""DOR"" which indicates that the individuals received these drugs before sample sequencing.

Rationale: The paper explicitly mentions these drugs.

Answer: EFV, RPV, ETR, DOR
""""""",57
37495103,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual. Reverse transcription and PCR were performed using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia), respectively, to amplify the HIV-1 PR-RT fragment (1302 bp). DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).""

Rationale: The paper reports that HIV-1 RNA was isolated from patient plasma samples and sequenced using an ABI PRISM 3130xl DNA Analyser.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report any in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report making sequences publicly available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not report GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""The study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.""

Rationale: The paper reports that 271 patients had samples obtained for HIV sequencing.

Answer: 271.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""The study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.""

Rationale: The paper reports that the samples were obtained from patients in Russia.

Answer: Russia.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""The study cohort included 271 patients who were on first-line ART and visited Novosibirsk Regional AIDS/HIV Clinical Hospital between March 2018 and August 2022.""

Rationale: The paper reports that the samples were obtained between 2018 and 2022.

Answer: 2018-2022.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report cloning prior to sequencing.

Answer: No.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual. Reverse transcription and PCR were performed using RealBest Master Mix RT (Vector-Best, Russia) and BioMaster HS-Taq PCR-Color (BioLabMix, Russia), respectively, to amplify the HIV-1 PR-RT fragment (1302 bp).""

Rationale: The paper reports that the HIV-1 PR-RT fragment was sequenced.

Answer: PR, RT.

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""DNA sequencing was performed using an ABI PRISM 3130xl DNA Analyser (Applied Biosystems, USA).""

Rationale: The paper reports that Sanger sequencing was used.

Answer: Sanger sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""HIV-1 RNA was isolated from 250 µL of plasma using DeltaMag HBV/HCV/HIV (Vector-Best, Russia) according to the kit's manual.""

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""All patients had undetectable viral load (VL) levels for 3--6 months while taking ART with further virological failure.""

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report that the patients were in a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""All patients received first-line ART prior to virological failure.""

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""Most of the patients received TDF+3TC+EFV as a first-line ART regimen.""

Rationale: The paper reports that the patients received NRTIs (TDF, 3TC) and NNRTIs (EFV) before sample sequencing.

Answer: NRTIs, NNRTIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""Most of the patients received TDF+3TC+EFV as a first-line ART regimen.""

Rationale: The paper reports that the patients received TDF, 3TC, and EFV before sample sequencing.

Answer: TDF, 3TC, EFV.",72
37498738,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""Near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs).""

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples, specifically from peripheral blood mononuclear cells.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""PCR and NGS for bulk sequences was performed for the 3 time points of the 101 individuals participating in the ESS, resulting in a total of 297 NGS sequences.""

Rationale: The paper explicitly mentions that 101 individuals had samples obtained for HIV sequencing.

Answer: 101

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the samples.

Rationale: The paper does not provide any information about the country of origin of the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the samples were obtained.

Rationale: The paper does not provide any information about the specific years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""Near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs).""

Rationale: The paper mentions that near full-length HIV-1 proviral sequences were obtained, which includes multiple genes.

Answer: Full length genome

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""Near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs).""

Rationale: The paper explicitly mentions that next-generation sequencing (NGS) was used.

Answer: NGS

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Near full-length HIV-1 proviral polymerase chain reaction and next-generation sequencing was applied to longitudinal peripheral blood mononuclear cell samples to assess proviral evolution and the potential emergence of drug resistance mutations (DRMs).""

Rationale: The paper explicitly mentions that peripheral blood mononuclear cells (PBMCs) were sequenced.

Answer: PBMC

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""No evidence for evolution during dolutegravir monotherapy was found in these early-treated individuals.""

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states ""Our recent randomized clinical trial comparing a switch to dolutegravir monotherapy with continuation of cART in early-treated individuals demonstrated sustained virological suppression over 48 weeks.""

Rationale: The paper explicitly mentions that the patients were in a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""The ESS ( NCT00537966 ) enrolled 101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.""

Rationale: The paper does not explicitly mention that the individuals had previously received ARV drugs, but it can be inferred that they were treatment-experienced.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""The ESS ( NCT00537966 ) enrolled 101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.""

Rationale: The paper does not explicitly mention the specific drug classes received by the individuals before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""The ESS ( NCT00537966 ) enrolled 101 people with HIV (PWH) from the Zurich Primary HIV Infection Study and Swiss HIV Cohort Study.""

Rationale: The paper does not explicitly mention the specific drugs received by the individuals before sample sequencing.

Answer: Not reported",72
37515095,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""mRNA from blood samples was purified using the Ribo-zol-C Kit (InterLabService, Moscow, Russia) and used for RT-PCR, followed by *pol* gene sequencing using AmpliSens ^®^ HIV-Resist-Seq (Amplisens, Moscow, Russia) and Applied Biosystems ^®^ Genetic Analyzer 3130 (Applied Biosystems Inc., Foster, RI, USA).""

Rationale: The paper explicitly states that HIV sequences were obtained from patient blood samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states that ""The 968 HIV-1 *pol* sequences were screened for DRMs using the Stanford HIV Drug Resistance Database \[ 21 \].""

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses a database to screen for drug-resistant mutations.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""Study data are unavailable to protect patient confidentiality.""

Rationale: The paper explicitly states that the sequences are not publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: None

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""Between 2017 and 2020, 1004 participants registered with the Kazakh Scientific Centre of Dermatology and Infectious Diseases, Almaty, Kazakhstan; signed informed consent forms; and consented to blood sample collections for this study.""

Rationale: The paper explicitly states that 1004 participants had samples obtained for HIV sequencing.

Answer: 1004

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that ""Participants enrolled in the study from all 15 regions of Kazakhstan.""

Rationale: The paper explicitly states that the samples were obtained from Kazakhstan.

Answer: Kazakhstan

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""Between 2017 and 2020, 1004 participants registered with the Kazakh Scientific Centre of Dermatology and Infectious Diseases, Almaty, Kazakhstan; signed informed consent forms; and consented to blood sample collections for this study.""

Rationale: The paper explicitly states that the samples were obtained between 2017 and 2020.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: None

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""The sequence data consisted of partial HIV-1 *pol* gene sequences (covering protease and the 5′-end of reverse transcriptase, positions 2253 to 3337 on the HXB2 reference genome).""

Rationale: The paper explicitly states that the *pol* gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""RT-PCR, followed by *pol* gene sequencing using AmpliSens ^®^ HIV-Resist-Seq (Amplisens, Moscow, Russia) and Applied Biosystems ^®^ Genetic Analyzer 3130 (Applied Biosystems Inc., Foster, RI, USA).""

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""mRNA from blood samples was purified using the Ribo-zol-C Kit (InterLabService, Moscow, Russia) and used for RT-PCR, followed by *pol* gene sequencing...""

Rationale: The paper explicitly states that blood samples were used.

Answer: Blood

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""Among sequenced participants, the Kazakh HIV-1 epidemic is almost exclusively comprised (954, 98.6%) of two subtypes, A6 and CRF02_AG, with the frequencies of each one varying across geographical regions in the country. Almost one-third (311, 32.1%) of sequences exhibited high-level drug resistance; however, distinct DRMs were observed among subtypes A6 and CRF02_AG.""

Rationale: The paper explicitly states that some sequences were obtained from individuals with high-level drug resistance, which is indicative of virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: None

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""Almost half of participants were on second-generation ART regimens (464, 47.9%), followed by mixed- (291, 30.1%) and first-generation regimens (204, 21.1%).""

Rationale: The paper explicitly states that some participants had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""Individual ART regimens were summarized as 1st-, 2nd-, or mixed-generation regimens according to the specific nucleoside reverse transcriptase inhibitors (NRTIs) and non-nucleoside reverse transcriptase inhibitors (NNRTIs) administered: zidovudine (AZT), didanosine (DDI), stavudine (D4T), and lamivudine (3TC) were classified as 1st-generation NRTIs; abacavir (ABC), tenofovir (TDF), and emtricitabine (FTC) were classified as 2nd-generation NRTIs; nevirapine (NVP) was classified as a 1st-generation NNRTI; and efavirenz (EFV), etravirine (ETR), and rilpivirine (RPV) were classified as 2nd-generation NNRTIs.""

Rationale: The paper explicitly states that the participants received NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""The combination of FTC + TDF + EFV was the most common (386, 39.9%) ART regimen administered ( Table 2 ).""

Rationale: The paper explicitly states that the participants received FTC, TDF, and EFV.

Answer: FTC, TDF, EFV",89
37515146,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""Sequencing of HIV-1 protease and reverse transcriptase was performed"" and ""A total of 391 participants were recruited, with sequencing successfully carried out in 379 individual participant samples"".

Rationale: The paper explicitly mentions that sequencing was performed on patient samples, and provides details on the number of participants and samples sequenced.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""predictive efficacy of each antiretroviral molecule"" but does not report in vitro drug susceptibility data.

Rationale: The paper does not provide in vitro drug susceptibility data, but rather focuses on genotypic resistance testing and predictive efficacy of antiretroviral molecules.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states ""Sequence data are available on GenBank under the accession numbers GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457"".

Rationale: The paper explicitly mentions that sequence data are available on GenBank, providing accession numbers.

Answer: Yes.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states ""Sequence data are available on GenBank under the accession numbers GenBank MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457"".

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: MK702015-MK702057, MK867695-MK867757, and MK995397-MK995457.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""A total of 391 participants were recruited, with sequencing successfully carried out in 379 individual participant samples"".

Rationale: The paper provides the number of participants who had samples obtained for HIV sequencing.

Answer: 379.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""The enrollment of participants was carried out in health facilities of eight regions of Cameroon"".

Rationale: The paper explicitly mentions that the samples were obtained from Cameroon.

Answer: Cameroon.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""We carried out a cross-sectional and analytical study for five years, from December 2014 to June 2019"".

Rationale: The paper provides the years during which the samples were obtained.

Answer: 2014-2019.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on cloning prior to sequencing.

Answer: Not Reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""Sequencing of HIV-1 protease and reverse transcriptase was performed"".

Rationale: The paper explicitly mentions that the protease and reverse transcriptase genes were sequenced.

Answer: Protease and reverse transcriptase.

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""The products of the sequencing reaction obtained were purified by exclusion chromatography on SEPHADEX G50 resin and then sequenced using a genetic analyzer (ABI 3500)"".

Rationale: The paper provides information on the sequencing method used.

Answer: Sanger sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""10 mL of venous blood was collected in an EDTA tube"" and ""plasma aliquoted (1 mL) in cryotubes"".

Rationale: The paper provides information on the type of samples sequenced.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""Included in our study were HIV-1 infected patients aged above 19 years (adults per WHO definitions) with no prior history of ART treatment"".

Rationale: The paper explicitly excludes individuals with prior ART treatment, suggesting that the sequences were not obtained from individuals with virological failure on a treatment regimen.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""Included in our study were HIV-1 infected patients aged above 19 years (adults per WHO definitions) with no prior history of ART treatment"".

Rationale: The paper explicitly excludes individuals with prior ART treatment, suggesting that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide information on drug classes received by individuals before sample sequencing.

Answer: Not Reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide information on specific drugs received by individuals before sample sequencing.

Answer: Not Reported.",70
37520425,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-1 genotypic resistance testing (GRT)"" and ""HIV-1 drug resistance--associated mutations"" which implies that HIV sequences were obtained from patient samples.

Rationale: The paper discusses the results of HIV-1 genotypic resistance testing and the detection of drug resistance--associated mutations, which requires the analysis of HIV sequences from patient samples.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""HIV-1 drug resistance--associated mutations"" and ""drug resistance testing"" but does not provide in vitro drug susceptibility data.

Rationale: The paper discusses the detection of drug resistance--associated mutations, but does not provide data on the susceptibility of the viruses to different drugs in vitro.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper mentions that the ""reported protease and reverse transcriptase sequences are available in GenBank (accession number OQ627458-OQ627474)"".

Rationale: The paper explicitly states that the sequences are available in GenBank, which is a public database.

Answer: Yes.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper mentions that the ""reported protease and reverse transcriptase sequences are available in GenBank (accession number OQ627458-OQ627474)"".

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ627458-OQ627474.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that ""blood plasma samples prior to treatment initiation were available for 25 of 30 (83%) patients"" and ""blood plasma samples at VL ≥50 copies/mL were available for 13 of 30 (43%) patients"".

Rationale: The paper provides the number of individuals who had samples obtained for HIV sequencing, but it is not clear if these are the only individuals who had samples obtained.

Answer: At least 25 individuals had samples obtained for HIV sequencing.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Tanzania.

Rationale: The paper explicitly states that the study was conducted in Tanzania, which implies that the sequenced samples were obtained from Tanzania.

Answer: Tanzania.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted between 2016 and 2020.

Rationale: The paper provides the time period during which the study was conducted, which implies that the sequenced samples were obtained during this time period.

Answer: 2016-2020.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not Reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that ""HIV-1 genotypic resistance testing (GRT)"" was performed, which implies that the reverse transcriptase and protease genes were sequenced.

Rationale: The paper discusses the detection of drug resistance--associated mutations, which requires the analysis of the reverse transcriptase and protease genes.

Answer: Reverse transcriptase and protease.

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions that ""Sanger sequencing"" was used.

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that ""blood plasma samples"" were used.

Rationale: The paper explicitly states that blood plasma samples were used.

Answer: Blood plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that ""blood plasma samples at VL ≥50 copies/mL were available for 13 of 30 (43%) patients"".

Rationale: The paper provides information on the number of individuals who had virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the study included ""treatment-naive patients"".

Rationale: The paper explicitly states that the study included treatment-naive patients, which implies that they had not previously received ARV drugs.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included ""treatment-naive patients"".

Rationale: The paper explicitly states that the study included treatment-naive patients, which implies that they had not received any ARV drugs before sample sequencing.

Answer: None.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the study included ""treatment-naive patients"".

Rationale: The paper explicitly states that the study included treatment-naive patients, which implies that they had not received any ARV drugs before sample sequencing.

Answer: None.",69
37537871,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""A total of 77 plasma samples, collected from 70 male and 7 female patients ages 18 to 68, were obtained from the Queen Mary Hospital in Hong Kong between 2002 and 2014.""

Rationale: The paper explicitly states that the samples were collected from patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the sequencing and analysis of HIV quasispecies, but does not report any in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making the sequences publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available, which suggests that they were not made available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers, which suggests that the sequences were not deposited in GenBank.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""A total of 77 plasma samples, collected from 70 male and 7 female patients ages 18 to 68, were obtained from the Queen Mary Hospital in Hong Kong between 2002 and 2014.""

Rationale: The paper explicitly states that 77 plasma samples were collected from 77 individuals.

Answer: 77.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained from the Queen Mary Hospital in Hong Kong.

Rationale: The paper explicitly states that the samples were obtained from Hong Kong, which suggests that the samples were obtained from Hong Kong.

Answer: Hong Kong.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that the samples were obtained between 2002 and 2014.

Rationale: The paper explicitly states that the samples were obtained between 2002 and 2014.

Answer: 2002-2014.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing, which suggests that cloning was not performed.

Answer: No.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that the long genomic region (NC_001802.1: 1413--7363, amplicon length: 5951 base pairs) was targeted for sequencing.

Rationale: The paper explicitly states that the long genomic region was targeted for sequencing, which suggests that multiple HIV genes were sequenced.

Answer: Multiple HIV genes, including protease, reverse transcriptase, and integrase.

**Question 10: What method was used for sequencing?**

Evidence: The paper states that Oxford Nanopore Technologies (ONT) sequencing was used.

Rationale: The paper explicitly states that ONT sequencing was used, which suggests that long-read sequencing was performed.

Answer: Long-read sequencing using Oxford Nanopore Technologies (ONT).

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that plasma samples were used for sequencing.

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information about virological failure on a treatment regimen, which suggests that the sequences were not obtained from individuals with virological failure.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention previous ARV drug use.

Rationale: The paper does not provide any information about previous ARV drug use, which suggests that the sequences were not obtained from individuals who had previously received ARV drugs.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about specific drug classes, which suggests that the drug classes were not reported.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about specific drugs, which suggests that the drugs were not reported.

Answer: Not reported.",66
37540331,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""HIV-positive adults"" and ""PLWH"" (people living with HIV), and states that ""HIV viral load remained undetectable (HIV-RNA < 47 copies/mL) during the 48 weeks of the study in both arms.""

Rationale: The paper reports on a study involving HIV-positive individuals, and mentions HIV viral load and RNA levels, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""antiretroviral therapy"" and ""ART-related complications"", but does not report any in vitro drug susceptibility data.

Rationale: The paper focuses on the efficacy and safety of a new antiretroviral therapy regimen, but does not include any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available, and does not provide any accession numbers.

Rationale: The paper does not indicate that sequences were made publicly available, and does not provide any information on how to access the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers, and does not provide any information on how to access the sequences.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that ""85 patients were randomly assigned to receive TAF plus DTG regimen (n = 43) or to continue the previous 3DR (n = 42)"".

Rationale: The paper reports on a study involving 85 patients, but does not specify how many individuals had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide any information on the country of origin for the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was registered at the Iranian Registry of Clinical Trials (IRCT20191005044984N1, registered at 2019--12-21).

Rationale: The paper does not provide any information on the years during which the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information on whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information on which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions ""polymerase chain reaction (PCR) assays"" but does not specify the sequencing method.

Rationale: The paper does not provide any information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions ""HIV-positive adults"" and ""PLWH"", but does not specify the type of samples sequenced.

Rationale: The paper does not provide any information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that ""HIV viral load remained undetectable (HIV-RNA < 47 copies/mL) during the 48 weeks of the study in both arms"", indicating that no sequences were obtained from individuals with virological failure.

Rationale: The paper reports on a study involving HIV-positive individuals who remained virologically suppressed throughout the study.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions that the study was ""registered at the Iranian Registry of Clinical Trials (IRCT20191005044984N1, registered at 2019--12-21)"" and was a ""randomized non-inferiority open-label controlled trial"".

Rationale: The paper reports on a clinical trial involving HIV-positive individuals.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that ""patients were on ART"" and had ""undetectable viral load (HIV-RNA < 47 copies/mL)"" at the start of the study.

Rationale: The paper reports on a study involving HIV-positive individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""TAF plus DTG regimen"" and ""standard triple therapy"" but does not specify the drug classes.

Rationale: The paper does not provide any information on the specific drug classes received by individuals in the study.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""TAF plus DTG regimen"" and ""standard triple therapy"" but does not specify the drugs.

Rationale: The paper does not provide any information on the specific drugs received by individuals in the study.

Answer: Not reported
""""""",67
37541705,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention HIV sequences from patient samples. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention in vitro drug susceptibility data. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention making sequences publicly available. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers for sequenced HIV isolates. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention GenBank accession numbers for sequenced HIV isolates. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention HIV sequencing. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention HIV sequencing. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention sequenced samples. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequenced samples. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention sequenced samples. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequenced samples. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention sequencing. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequencing. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention sequencing. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequencing. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention sequencing. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequencing. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention sequencing. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequencing. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention sequencing. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequencing. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper mentions that the study is a phase I/II, multi-site, open-label, non-comparative dose confirmation study.

Rationale: The paper explicitly states that the study is a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention HIV sequences. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention HIV sequences. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention sequencing. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequencing. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention sequencing. It discusses the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Rationale: The paper does not mention sequencing. It focuses on the pharmacokinetics, safety, and tolerability of a fixed-dose combination of abacavir, dolutegravir, and lamivudine in children with HIV.

Answer: Not reported",111
37546367,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.""

Rationale: The paper explicitly mentions that plasma samples from patients were used for sequencing, which indicates that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""The Stanford HIV dbprogram 9.4 (last updated on 7th Dec. 2022, https://hivdb.stanford.edu/hivdb/by-sequences/ ) was used to identify DRMs and infer resistance to antiretroviral drugs, including protease inhibitors (PI), nucleoside reverse-transcriptase inhibitors (NRTI) and non-nucleoside reverse-transcriptase inhibitors (NNRTI).""

Rationale: The paper uses the Stanford HIV dbprogram to infer resistance to antiretroviral drugs, which suggests that in vitro drug susceptibility data is not reported. Instead, the paper reports genotypic resistance data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states ""The partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.""

Rationale: The paper explicitly mentions that the sequences were submitted to GenBank, which indicates that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states ""The partial *pol* nucleotide sequences were submitted to GenBank under the accession numbers: OQ886077 - OQ888150.""

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ886077 - OQ888150

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""A total of 3274 patients were enrolled and 2074 HIV-1 partial *pol* sequences were obtained and subsequently used to establish the dataset.""

Rationale: The paper explicitly mentions that 2074 HIV-1 partial *pol* sequences were obtained from 3274 patients.

Answer: 2074

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.""

Rationale: The paper explicitly mentions that the samples were obtained from Guangdong Province, China.

Answer: China

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.""

Rationale: The paper explicitly mentions that the samples were obtained between 2011 and 2022.

Answer: 2011-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on cloning prior to sequencing, which suggests that cloning was not performed.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""The partial HIV-1 *pol* gene (HXB2 nt 2253--3252) was amplified by one-step RT-PCR and nested PCR as previously described.""

Rationale: The paper explicitly mentions that the partial HIV-1 *pol* gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""Then, the Sanger sequencing was performed.""

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Plasma samples with LLVL during ART in Guangdong Province between Jan 2011 and Dec 2022 were subjected to a modified reverse-transcription PCR with a pre-step of virus concentration by ultracentrifugation before extraction and the Sanger sequencing.""

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""HIV-1 infected individuals were eligible for inclusion in this study if they have received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.""

Rationale: The paper does not explicitly mention virological failure, but it does mention that the individuals had received ART for at least 6 months, which suggests that some individuals may have experienced virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""HIV-1 infected individuals were eligible for inclusion in this study if they have received ART for at least 6 months with HIV-1 viral load between 200 to 1000 copies/mL.""

Rationale: The paper explicitly mentions that the individuals had received ART for at least 6 months, which indicates that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide information on the specific drug classes received by the individuals.

Rationale: The paper does not provide information on the specific drug classes received by the individuals, which suggests that this information is not reported.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide information on the specific drugs received by the individuals.

Rationale: The paper does not provide information on the specific drugs received by the individuals, which suggests that this information is not reported.

Answer: Not reported",83
37554471,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV viral load levels"" and ""HIV RNA viral load"" but does not explicitly state that HIV sequences were obtained from patient samples. However, it does mention ""resistance tests"" and ""genotyping"" which implies that some form of genetic analysis was performed.

Rationale: The paper does not explicitly state that HIV sequences were obtained from patient samples, but it does mention genetic analysis techniques that are commonly used to obtain sequences. Therefore, the answer is likely to be ""Yes"" but with some uncertainty.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention ""in vitro drug susceptibility"" or any related terms. It does mention ""resistance tests"" but this is likely referring to genotypic resistance testing rather than in vitro susceptibility testing.

Rationale: The paper does not provide any evidence of in vitro drug susceptibility data. The mention of ""resistance tests"" is likely referring to genotypic resistance testing, which is a different type of analysis.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available or depositing them in a database.

Rationale: The paper does not provide any evidence that sequences were made publicly available. Therefore, the answer is likely to be ""No"".

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, likely because sequences were not deposited in a database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions a single patient case.

Rationale: The paper only reports on a single patient case, therefore the answer is 1.

Answer: 1

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the patient.

Rationale: The paper does not provide any information about the country of origin for the patient. Therefore, the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention specific years for sample collection.

Rationale: The paper does not provide any information about the years of sample collection. Therefore, the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms.

Rationale: The paper does not provide any evidence of cloning or any related techniques. Therefore, the answer is likely to be ""No"".

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about specific HIV genes that were sequenced. Therefore, the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used. Therefore, the answer is likely to be ""Not reported"".

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""HIV RNA viral load"" which implies that plasma samples were used.

Rationale: The paper mentions ""HIV RNA viral load"" which is typically measured in plasma samples. Therefore, the answer is likely to be ""Plasma"".

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that the patient had a history of virological failure.

Rationale: The paper mentions that the patient had a history of virological failure, which implies that sequences were obtained from an individual with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any evidence that the patient was part of a clinical trial. Therefore, the answer is likely to be ""No"".

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that the patient had a history of ARV treatment.

Rationale: The paper mentions that the patient had a history of ARV treatment, which implies that sequences were obtained from an individual who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient had previously received etravirine, dolutegravir, darunavir, and ritonavir.

Rationale: The paper mentions specific ARV drugs that the patient had previously received, which can be mapped to specific drug classes. Therefore, the answer is likely to be ""INSTI, PI, NNRTI"".

Answer: INSTI, PI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that the patient had previously received etravirine, dolutegravir, darunavir, and ritonavir.

Rationale: The paper mentions specific ARV drugs that the patient had previously received. Therefore, the answer is likely to be ""etravirine, dolutegravir, darunavir, ritonavir"".

Answer: etravirine, dolutegravir, darunavir, ritonavir",69
37573167,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient, as described previously [13].""

Rationale: The paper explicitly mentions that HIV-1 DNA was obtained from patient samples, specifically from whole-blood or lymphomonocytic cells.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV-1 DNA sequences from patient samples and does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper explicitly mentions that 1126 individuals had samples obtained for HIV sequencing.

Answer: 1126
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper explicitly mentions that the samples were obtained from Italy.

Answer: Italy
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""over the period 2010-2021"".

Rationale: The paper explicitly mentions that the samples were obtained between 2010 and 2021.

Answer: 2010-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Resistance interpretation and estimation of APOBEC editing in HIV-DNA were made through Stanford algorithm (HIVdb version 9.1, https://hivdb.stanford.edu/) for protease/reverse transcriptase (PR/RT) or integrase.""

Rationale: The paper explicitly mentions that the PR/RT and integrase genes were sequenced.

Answer: PR, RT, IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""Sanger sequencing was performed as previously described [14, 15].""

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""HIV-1 DNA was obtained from whole-blood (N=180) or lymphomonocytic cells (N=936) after separation from peripheral blood from HIV-1-infected patients with a Ficoll-Hypaque gradient, as described previously [13].""

Rationale: The paper explicitly mentions that whole-blood and lymphomonocytic cells were sequenced.

Answer: Whole blood, PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper explicitly mentions that the individuals were virologically suppressed, but does not provide information about virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""This retrospective study included 1126 HIV-1 drug-experienced virologically suppressed subjects with an available HIV-DNA GRT over the period 2010-2021 performed for routine clinical practice in several reference centers in Italy.""

Rationale: The paper explicitly mentions that the individuals were drug-experienced.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information about specific drug classes.

Rationale: The paper does not provide any information about specific drug classes.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information about specific drugs.

Rationale: The paper does not provide any information about specific drugs.

Answer: Not reported
""""""",64
37574435,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" of patient samples.

Rationale: The paper reports HIV sequences from patient samples, including their corresponding GenBank accession numbers.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""resistance-associated mutations (RAMs)"" but does not report in vitro drug susceptibility data.

Rationale: The paper does not report in vitro drug susceptibility data, but rather focuses on the genotypic resistance testing and RAMs.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report making sequences publicly available, and no GenBank accession numbers are provided.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not available

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions 79 individuals who had samples obtained for HIV sequencing.

Rationale: The paper reports that 79 individuals had samples obtained for HIV sequencing.

Answer: 79

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained from Taiwan.

Rationale: The paper reports that the samples were obtained from Taiwan.

Answer: Taiwan

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the samples were obtained between 2016 and 2022.

Rationale: The paper reports that the samples were obtained between 2016 and 2022.

Answer: 2016-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not available

Rationale: The paper does not mention cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""genotypic resistance testing"" and ""sequencing"" of patient samples, but does not specify which HIV genes were sequenced.

Rationale: The paper does not specify which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: Not available

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV RNA"" and ""genotypic resistance testing"" of patient samples.

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virologic failure"" and ""rebound"" in the context of treatment regimens.

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report that the patients were in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""treatment-experienced"" individuals and ""pre-existing NRTI-related RAMs"".

Rationale: The paper reports that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NRTIs"", ""INSTIs"", and ""NNRTIs"" in the context of treatment regimens.

Rationale: The paper reports that individuals in the study received NRTIs, INSTIs, and NNRTIs before sample sequencing.

Answer: NRTIs, INSTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""BIC/FTC/TAF"", ""DTG"", and ""NNRTI-based ART"" in the context of treatment regimens.

Rationale: The paper reports that individuals in the study received BIC/FTC/TAF, DTG, and NNRTI-based ART before sample sequencing.

Answer: BIC/FTC/TAF, DTG, NNRTI-based ART",58
37585352,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""We analysed near full-length HIV-1 *pol* sequences from proviral DNA for the presence of RPV-RAMs"" and ""HIV-1 proviral DNA sequences were generated using next-generation sequencing (NGS)"".

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples, specifically from proviral DNA.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences and the prevalence of RPV-RAMs, but does not report any in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states ""HIV-1 sequences are available on request through the PANGEA consortium (www.pangea-hiv.org)"".

Rationale: The paper mentions that the sequences are available on request, but does not provide direct access to the sequences.

Answer: Yes.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""This analysis included a dataset of 5805 sequences, of which 1281 (22%) were obtained from treatment-naive PWH, and the other 4524 (78%) were from ART-suppressed PWH"".

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 5805.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""Study participants were recruited from a large community HIV incidence trial described elsewhere that enrolled participants aged 16 to 64 years, followed for 30 months from 2013 to 2018 in Botswana"".

Rationale: The paper explicitly mentions that the samples were obtained from Botswana.

Answer: Botswana.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""Study participants were recruited from a large community HIV incidence trial described elsewhere that enrolled participants aged 16 to 64 years, followed for 30 months from 2013 to 2018"".

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2013-2018.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""We analysed near full-length HIV-1 *pol* sequences from proviral DNA for the presence of RPV-RAMs"".

Rationale: The paper explicitly mentions that the *pol* gene was sequenced.

Answer: Pol.

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""HIV-1 proviral DNA sequences were generated using next-generation sequencing (NGS)"".

Rationale: The paper explicitly mentions that next-generation sequencing (NGS) was used for sequencing.

Answer: NGS.

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""We analysed near full-length HIV-1 *pol* sequences from proviral DNA for the presence of RPV-RAMs"".

Rationale: The paper explicitly mentions that proviral DNA was sequenced.

Answer: Proviral DNA.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""We did not include sequences for individuals experiencing virological failure since LA cabotegravir/rilpivirine is currently recommended only for virologically suppressed adults (HIV-1 RNA <50 copies/mL), and is not currently recommended for people with virological failure"".

Rationale: The paper explicitly excludes individuals with virological failure.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states ""The BCPP study was approved by the Institutional Review Boards (IRBs) at the US CDC and the Botswana Health Research and Development Committee IRB and is registered at ClinicalTrials.gov (NCT01965470)"".

Rationale: The paper explicitly mentions that the study is registered at ClinicalTrials.gov.

Answer: Yes.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""Of the 4524 PWH with viral suppression on ART (VL ≤400 copies/mL), 620 (13.7%, 95% CI 12.7%--14.7%) had at least one RPV-RAM"".

Rationale: The paper explicitly mentions that some individuals had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""The most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF) (n = 1792; 39.6%), lamivudine + nevirapine + zidovudine (3TC/NVP/ZDV) (n = 719; 15.9%) and lamivudine + efavirenz + zidovudine (3TC/EFV/ZDV) (n = 621; 13.7%)"".

Rationale: The paper explicitly mentions the drug classes received by individuals in the study.

Answer: NRTI, NNRTI.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""The most common ART regimens used were efavirenz + emtricitabine + tenofovir (EFV/FTC/TDF) (n = 1792; 39.6%), lamivudine + nevirapine + zidovudine (3TC/NVP/ZDV) (n = 719; 15.9%) and lamivudine + efavirenz + zidovudine (3TC/EFV/ZDV) (n = 621; 13.7%)"".

Rationale: The paper explicitly mentions the drugs received by individuals in the study.

Answer: Efavirenz, emtricitabine, tenofovir, lamivudine, nevirapine, zidovudine.",85
37593123,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Sequences of the HIV-1 *pol* gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.""

Rationale: The paper explicitly mentions that sequences were obtained from patient samples, specifically ART-naïve HIV-positive individuals.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""The Stanford HIV Drug Resistance Database was leveraged to extrapolate susceptibility to 12 antiretroviral drugs, using the World Health Organization (WHO)'s 2014 HIVDR guidelines as a reference.""

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses a database to extrapolate susceptibility to antiretroviral drugs.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""These sequences were procured from both the National Center for AIDS/STD Control and Prevention, China CDC and the HIV sequence databases of the Los Alamos National Laboratory.""

Rationale: The paper does not explicitly state that the sequences were made publicly available, but rather that they were obtained from public databases.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""A total of 57,902 ART-naïve HIV-infected individuals, which were categorized according to the development stages of the NFATP.""

Rationale: The paper explicitly states that 57,902 individuals had samples obtained for HIV sequencing.

Answer: 57,902
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""Sequences of the HIV-1 *pol* gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.""

Rationale: The paper does not explicitly state the country of origin, but it can be inferred that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""Sequences of the HIV-1 *pol* gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.""

Rationale: The paper explicitly states that the samples were obtained between 2004 and 2022.

Answer: 2004-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide information on cloning.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Sequences of the HIV-1 *pol* gene region were obtained from ART-naïve HIV-positive individuals across 31 provincial-level administrative divisions between 2004 and 2022.""

Rationale: The paper explicitly states that the *pol* gene region was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not provide information on the sequencing method.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not provide information on the type of samples sequenced.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""A total of 57,902 ART-naïve HIV-infected individuals, which were categorized according to the development stages of the NFATP.""

Rationale: The paper explicitly states that the individuals were ART-naïve, indicating that they had not experienced virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on clinical trials.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""A total of 57,902 ART-naïve HIV-infected individuals, which were categorized according to the development stages of the NFATP.""

Rationale: The paper explicitly states that the individuals were ART-naïve, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on drug classes received by individuals.

Rationale: The paper does not provide information on drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not provide information on specific drugs received by individuals.

Rationale: The paper does not provide information on specific drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",66
37626789,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""HIV-1 genotyping and sequencing was performed for the *pol* gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper explicitly mentions that HIV-1 genotyping and sequencing were performed on patient samples, which indicates that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""HIV-1 drug resistance was calculated using the HIVDB algorithm (v9.0) at Stanford's HIV genotypic resistance profile (https://hivdb.stanford.edu/, accessed on 11 April 2023).""

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses a genotypic resistance algorithm to predict drug resistance.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making the sequences publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available, which suggests that they were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, which suggests that the sequences were not deposited in a public database.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper explicitly mentions that 551 HIV-positive children had samples obtained for HIV sequencing.

Answer: 551

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper explicitly mentions that the samples were obtained from Ethiopia.

Answer: Ethiopia

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper explicitly mentions that the samples were obtained between 2017 and 2019.

Answer: 2017-2019

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing, which suggests that cloning was not performed.

Answer: No

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""HIV-1 genotyping and sequencing was performed for the *pol* gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper explicitly mentions that the *pol* gene region was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""HIV-1 genotyping and sequencing was performed for the *pol* gene region using in-house assay validated at the Chinese Center for Disease Control and Prevention, and the Stanford HIVDB v9.0 algorithm was used for identification of drug resistance mutations.""

Rationale: The paper does not explicitly mention the sequencing method, but it mentions the use of an in-house assay and the Stanford HIVDB algorithm, which suggests that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Whole blood was collected from children using two ethylenediaminetetraacetic acid (EDTA) coated test tubes of 3--5 mL each, and plasma was extracted using centrifugation at 2000 revolutions per minute (RPM).""

Rationale: The paper explicitly mentions that whole blood and plasma samples were used for sequencing.

Answer: Whole blood and plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""Children with VF (i.e., viral load ≥ 1000 copies/mL) were included for HIV drug resistance investigation, given those with VL < 1000 copies/mL were considered as susceptible and excluded from HIVDR testing.""

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, which suggests that the patients were not in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""A longitudinal study was conducted among 551 HIV-positive children (<15 years old) recruited between 2017 and 2019 at 40 antiretroviral treatment delivery sites in Ethiopia.""

Rationale: The paper explicitly mentions that the children were receiving antiretroviral treatment, which suggests that they had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""The majority of the children (80%) were taking one of the three HAARTs regimens, which were Zidovudine (AZT) + Lamivudine(3TC) +Nevirapine (NVP) (35.9%), Stavudine(D4T) + Lamivudine(3TC) + Nevirapine (NVP) (30.3%), and Zidovudine (AZT) + Lamivudine(3TC) + Efavirenz (EFV) (14.0%).""

Rationale: The paper explicitly mentions that the children were receiving NRTIs (AZT, 3TC, D4T) and NNRTIs (NVP, EFV).

Answer: NRTIs and NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""The majority of the children (80%) were taking one of the three HAARTs regimens, which were Zidovudine (AZT) + Lamivudine(3TC) +Nevirapine (NVP) (35.9%), Stavudine(D4T) + Lamivudine(3TC) + Nevirapine (NVP) (30.3%), and Zidovudine (AZT) + Lamivudine(3TC) + Efavirenz (EFV) (14.0%).""

Rationale: The paper explicitly mentions that the children were receiving AZT, 3TC, D4T, NVP, and EFV.

Answer: AZT, 3TC, D4T, NVP, and EFV",93
37632026,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""759 patients (≥15 years) experiencing virological failure"" and ""Socio-demographic, therapeutic and immunovirological data from patient records were analysed according to HIV-1 genotypic profiles.""

Rationale: The paper explicitly mentions that it analyzed HIV-1 genotypic profiles from patient records, indicating that it reports HIV sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""genotypic resistance testing (GRT)"" and ""Stanford HIVdb v.9.4. to identify major DRMs and potentially active medications.""

Rationale: The paper reports genotypic resistance testing and uses the Stanford HIVdb to identify potentially active medications, but it does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""Sequences generated for the purpose of this study were submitted to Genbank under the following accession numbers: MK580543-MK580618 ; JF273935-JF273965 ; JQ796152-JQ796169, MK867721-MK867755 ; and OQ985493-OQ985958.""

Rationale: The paper explicitly mentions that the sequences were submitted to GenBank and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states ""Sequences generated for the purpose of this study were submitted to Genbank under the following accession numbers: MK580543-MK580618 ; JF273935-JF273965 ; JQ796152-JQ796169, MK867721-MK867755 ; and OQ985493-OQ985958.""

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: MK580543-MK580618, JF273935-JF273965, JQ796152-JQ796169, MK867721-MK867755, OQ985493-OQ985958
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""We retained a total of 759 participants...""

Rationale: The paper explicitly mentions the number of participants.

Answer: 759
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""Our study was carried out at CIRCB, Yaoundé, Cameroon...""

Rationale: The paper explicitly mentions the country where the study was carried out.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""We carried out a laboratory-based cross-sectional and analytical study from November 2011 to August 2019...""

Rationale: The paper explicitly mentions the years during which the study was carried out.

Answer: 2011-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide information about cloning.

Answer: Not Reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""HIV-1 pol-gene (protease and reverse-transcriptase regions) was then amplified (~1600 base pairs).""

Rationale: The paper explicitly mentions the HIV-1 pol-gene, which includes the protease and reverse-transcriptase regions.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""Sequencing was performed using an Applied Biosystems 3500 genetic analyzer...""

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""10 mL of blood was drawn from treatment-failing patients...""

Rationale: The paper explicitly mentions that blood samples were used.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""759 patients (≥15 years) experiencing virological failure...""

Rationale: The paper explicitly mentions that the patients were experiencing virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information about a clinical trial.

Answer: Not Reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""759 patients (≥15 years) experiencing virological failure...""

Rationale: The paper explicitly mentions that the patients were experiencing virological failure, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""575 (75.8%) were failing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART, while 184 (24.2%) were failing protease inhibitor (PI/r)-based second-line...""

Rationale: The paper explicitly mentions the drug classes used in the first- and second-line treatments.

Answer: NRTI, NNRTI, PI/r
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""575 (75.8%) were failing non-nucleoside reverse transcriptase inhibitor (NNRTI)-based first-line ART, while 184 (24.2%) were failing protease inhibitor (PI/r)-based second-line...""

Rationale: The paper does not provide specific information about the drugs used.

Answer: Not Reported
""""""",72
37632071,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""plasma HIV RNA"" and ""viral RNA was extracted from plasma"" in the Methods section.

Rationale: The paper reports HIV sequences from patient samples, as indicated by the mention of plasma HIV RNA and viral RNA extraction from plasma.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any related terms.

Rationale: The paper does not report in vitro drug susceptibility data, as there is no mention of it in the text.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention GenBank accession numbers or any other public sequence databases.

Rationale: The paper does not report making sequences publicly available, as there is no mention of GenBank accession numbers or other public sequence databases.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report GenBank accession numbers.

Rationale: Not applicable, as the paper does not report GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 197 patients were included in the study.

Rationale: The paper reports that 197 individuals had samples obtained for HIV sequencing.

Answer: 197

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted in Italy.

Rationale: The paper reports that the sequenced samples were obtained from Italy.

Answer: Italy

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the study was conducted between 2019 and 2022.

Rationale: The paper reports that the sequenced samples were obtained between 2019 and 2022.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or any related terms.

Rationale: The paper does not report cloning prior to sequencing, as there is no mention of it in the text.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not report which HIV genes were sequenced, as there is no mention of it in the text.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not report the sequencing method used, as there is no mention of it in the text.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma HIV RNA"" and ""viral RNA was extracted from plasma"".

Rationale: The paper reports that plasma samples were sequenced, as indicated by the mention of plasma HIV RNA and viral RNA extraction from plasma.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that some patients had virological failure before switching to BIC/FTC/TAF.

Rationale: The paper reports that some sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report that the patients were in a clinical trial, as there is no mention of it in the text.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that patients were treatment-experienced and had received ARV drugs before switching to BIC/FTC/TAF.

Rationale: The paper reports that HIV sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that patients had received INSTI-based regimens, NNRTI-based regimens, and PI-based regimens before switching to BIC/FTC/TAF.

Rationale: The paper reports that individuals in the study had received INSTI, NNRTI, and PI drug classes before sample sequencing.

Answer: INSTI, NNRTI, PI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions specific drugs such as bictegravir, emtricitabine, and tenofovir alafenamide, as well as other ARV drugs.

Rationale: The paper reports that individuals in the study had received specific ARV drugs, including bictegravir, emtricitabine, and tenofovir alafenamide, before sample sequencing.

Answer: Bictegravir, emtricitabine, tenofovir alafenamide, and other ARV drugs.",65
37649807,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients. However, it does mention that viral load (VL) tests were performed on plasma samples from patients.

Rationale: Based on the evidence, it appears that the paper does not report HIV sequences from patient samples. The paper focuses on the analysis of viral load data from patients, but it does not mention genetic sequencing.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data or any experiments related to drug susceptibility.

Rationale: Based on the evidence, it appears that the paper does not report in vitro drug susceptibility data. The paper focuses on the analysis of viral load data from patients and does not mention any in vitro experiments.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: Based on the evidence, it appears that the sequences from the paper were not made publicly available. The paper does not mention any accession numbers or public databases where the sequences can be found.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention any GenBank accession numbers.

Rationale: Based on the evidence, it appears that the paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention that samples were obtained for HIV sequencing.

Rationale: Based on the evidence, it appears that the paper does not report the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: Based on the evidence, it appears that the paper does not report the country of origin for the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years when the samples were obtained.

Rationale: Based on the evidence, it appears that the paper does not report the years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning or sequencing.

Rationale: Based on the evidence, it appears that the paper does not report whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention any HIV genes that were sequenced.

Rationale: Based on the evidence, it appears that the paper does not report which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention any sequencing method.

Rationale: Based on the evidence, it appears that the paper does not report the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention any samples that were sequenced.

Rationale: Based on the evidence, it appears that the paper does not report the type of samples that were sequenced.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure or treatment regimens in the context of sequencing.

Rationale: Based on the evidence, it appears that the paper does not report whether sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: Based on the evidence, it appears that the paper does not report whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention HIV sequences or ARV drugs in the context of sequencing.

Rationale: Based on the evidence, it appears that the paper does not report HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any drug classes that were received by individuals before sample sequencing.

Rationale: Based on the evidence, it appears that the paper does not report which drug classes were received by individuals before sample sequencing.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention any specific drugs that were received by individuals before sample sequencing.

Rationale: Based on the evidence, it appears that the paper does not report which drugs were received by individuals before sample sequencing.

Answer: Not reported",63
37662576,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients. However, it does mention ""HIV-1 protease"" and ""HIV-1 replication cycle"", indicating that the study is related to HIV.

Rationale: Based on the evidence, it appears that the paper does not report HIV sequences from patient samples. The paper focuses on the molecular dynamics of HIV-1 protease and its inhibitors, rather than sequencing patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""protease inhibitors"" and ""drug-resistant mutations"", indicating that it discusses drug susceptibility. However, it does not provide explicit in vitro drug susceptibility data.

Rationale: Based on the evidence, it appears that the paper does not report in vitro drug susceptibility data. While it discusses drug resistance and protease inhibitors, it does not provide specific data on in vitro susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention submitting sequences to a public database or providing accession numbers.

Rationale: Based on the evidence, it appears that the sequences from the paper were not made publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: Not applicable, as the paper does not report HIV sequences from patient samples.

Rationale: Not applicable

Answer: Not reported",53
37674678,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""HIV-1 pol gene sequence was obtained by viral RNA extraction and nested PCR amplification"" and ""A total of 1,161 sequences were successfully sequenced"".

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples through viral RNA extraction and nested PCR amplification.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper only reports genotypic resistance testing and sequencing data, but does not mention in vitro susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""A total of 1,393 participants who were newly diagnosed with HIV-1 and had not received ART between January 2019 and December 2021 were enrolled in this study.""

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 1,393
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""In our study, 1,393 ART-naïve individuals newly diagnosed with HIV-1 were enrolled between January 1, 2019 and November 31, 2021. Participants were enrolled at the voluntary counseling testing clinics (VCT) in Nanjing.""

Rationale: The paper explicitly mentions that the samples were obtained from Nanjing, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""A total of 1,393 participants who were newly diagnosed with HIV-1 and had not received ART between January 2019 and December 2021 were enrolled in this study.""

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2019-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper only mentions viral RNA extraction and nested PCR amplification, but does not mention cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""HIV-1 pol gene sequence was obtained by viral RNA extraction and nested PCR amplification"".

Rationale: The paper explicitly mentions that the pol gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""The PCR products were sent to Sangon Biotechnology Co., Ltd. for automatic DNA sequencing using ABI 3730XL.""

Rationale: The paper explicitly mentions the use of ABI 3730XL for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Viral RNA was extracted from 200 μl plasma samples using the QIAamp Viral RNA Mini Kit (Qiagen, Hilden, Germany).""

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""A total of 1,393 participants who were newly diagnosed with HIV-1 and had not received ART between January 2019 and December 2021 were enrolled in this study.""

Rationale: The paper explicitly mentions that the participants were ART-naïve, indicating that they had not experienced virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""A total of 1,393 participants who were newly diagnosed with HIV-1 and had not received ART between January 2019 and December 2021 were enrolled in this study.""

Rationale: The paper explicitly mentions that the participants were ART-naïve, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide any information about drug classes received by individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information about drugs received by individuals before sample sequencing.

Answer: Not reported
""""""",65
37701387,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly state that HIV sequences were obtained from patient samples. However, it mentions that the study included ART-naive adults with advanced HIV (CD4 < 200 cells/μL) starting a three-drug regimen of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF).

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples. However, it implies that the study involved patient samples by mentioning the inclusion of ART-naive adults with advanced HIV.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data. It focuses on the efficacy and safety of a rapid start strategy with B/F/TAF in patients with advanced HIV.

Rationale: The paper does not provide any information on in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information on the public availability of sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not explicitly state the number of individuals who had samples obtained for HIV sequencing. However, it mentions that 30 ART-naive participants were enrolled in the Rainbow Study.

Rationale: The paper does not provide direct evidence of the number of individuals who had samples obtained for HIV sequencing. However, it implies that at least 30 individuals were involved in the study.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide any information on the countries of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide any information on the years of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention whether samples were cloned prior to sequencing.

Rationale: The paper does not provide any information on the cloning of samples.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not provide any information on the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information on the type of samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information on virological failure.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper mentions the LAPTOP Study, which is a randomized controlled trial.

Rationale: The paper provides evidence of a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention previous ARV drug use.

Rationale: The paper does not provide any information on previous ARV drug use.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions the use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide.

Rationale: The paper provides evidence of the use of specific drug classes.

Answer: INSTI, NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions the use of bictegravir/emtricitabine/tenofovir alafenamide (B/F/TAF) and darunavir/cobicistat/emtricitabine/tenofovir alafenamide.

Rationale: The paper provides evidence of the use of specific drugs.

Answer: Bictegravir, emtricitabine, tenofovir alafenamide, darunavir, cobicistat
""""""",62
37716367,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly state that it reports HIV sequences from patient samples. However, it does mention ""genotypic resistance testing"" and ""sequencing"" in the context of HIV drug resistance.

Rationale: Based on the evidence, it appears that the paper does report HIV sequences from patient samples, but it is not explicitly stated.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""in vitro drug susceptibility data"" or any related terms.

Rationale: Based on the evidence, it appears that the paper does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper mentions that ""nucleotide sequence data are publicly available"" and provides a GenBank accession number.

Rationale: Based on the evidence, it appears that the sequences from the paper were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper provides a GenBank accession number: ""SRP075904"".

Rationale: Based on the evidence, it appears that the GenBank accession number for the sequenced HIV isolates is SRP075904.

Answer: SRP075904
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not explicitly state the number of individuals who had samples obtained for HIV sequencing.

Rationale: Based on the evidence, it appears that the number of individuals who had samples obtained for HIV sequencing is not reported.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions several countries, including Spain, Suriname, and Uganda.

Rationale: Based on the evidence, it appears that the sequenced samples were obtained from multiple countries, including Spain, Suriname, and Uganda.

Answer: Spain, Suriname, Uganda
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions several years, including 2007, 2010, 2011, and 2012.

Rationale: Based on the evidence, it appears that the sequenced samples were obtained from 2007 to 2012.

Answer: 2007-2012
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: Based on the evidence, it appears that the samples were not cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""integrase coding region of pol"".

Rationale: Based on the evidence, it appears that the HIV genes reported to have been sequenced include pol and integrase.

Answer: Pol, Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not explicitly state the sequencing method used.

Rationale: Based on the evidence, it appears that the sequencing method used is not reported.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions ""plasma"" and ""dried blood spots (DBS)"".

Rationale: Based on the evidence, it appears that the samples sequenced include plasma and dried blood spots (DBS).

Answer: Plasma, DBS
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions ""virological failure"" and ""treatment failure"".

Rationale: Based on the evidence, it appears that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: Based on the evidence, it appears that the patients in the study were not in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ""ART-experienced"" and ""treatment-experienced"".

Rationale: Based on the evidence, it appears that the paper reports HIV sequences from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""NRTI"", ""NNRTI"", and ""PI"".

Rationale: Based on the evidence, it appears that the drug classes received by individuals in the study before sample sequencing include NRTI, NNRTI, and PI.

Answer: NRTI, NNRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions several drugs, including ""efavirenz"", ""nevirapine"", and ""lopinavir"".

Rationale: Based on the evidence, it appears that the drugs received by individuals in the study before sample sequencing include efavirenz, nevirapine, and lopinavir.

Answer: Efavirenz, Nevirapine, Lopinavir
""""""",63
37755428,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions that nucleic acids were extracted from remnant dried blood spot specimens collected at the time of HIV diagnosis and sequenced using a Sanger-based method.

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically from dried blood spot specimens.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions that HIVDR was predicted using the Stanford HIVdb algorithm Version 9.09 and that sequences with low-level, intermediate-level, or high-level resistance were classified as resistant.

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses a computational algorithm to predict resistance based on the sequences obtained.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper mentions that 143 infants had remnant specimens available for HIVDR testing.

Rationale: The paper explicitly states that 143 infants had samples obtained for HIV sequencing.

Answer: 143
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained from Haiti.

Rationale: The paper explicitly states that the samples were obtained from Haiti.

Answer: Haiti
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained between April 2020 and March 2021.

Rationale: The paper explicitly states that the samples were obtained between April 2020 and March 2021.

Answer: 2020-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that the protease/reverse transcriptase (PR/RT) and integrase regions were sequenced.

Rationale: The paper explicitly states that the PR/RT and integrase regions were sequenced.

Answer: PR/RT, Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that a Sanger-based method was used for sequencing.

Rationale: The paper explicitly states that a Sanger-based method was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that dried blood spot specimens were sequenced.

Rationale: The paper explicitly states that dried blood spot specimens were sequenced.

Answer: Dried blood spots
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that one infant had a virus with detected resistance to DTG, ABC, and 3TC.

Rationale: The paper does not explicitly state that the infant had virological failure, but rather that the virus had detected resistance.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the infant's mother was receiving tenofovir/lamivudine/dolutegravir.

Rationale: The paper explicitly states that the infant's mother was receiving ARV drugs, but does not provide information about the infant's prior ARV exposure.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the infant's mother was receiving tenofovir/lamivudine/dolutegravir.

Rationale: The paper explicitly states that the infant's mother was receiving NRTIs (tenofovir and lamivudine) and an INSTI (dolutegravir).

Answer: NRTIs, INSTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the infant's mother was receiving tenofovir/lamivudine/dolutegravir.

Rationale: The paper explicitly states that the infant's mother was receiving tenofovir, lamivudine, and dolutegravir.

Answer: Tenofovir, lamivudine, dolutegravir
""""""",58
37775947,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq)"" and ""Baseline NGS data were available for 1380 antiretroviral therapy (ART)-naïve participants enrolled over 2009--2013.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient plasma samples using next-generation sequencing (NGS).

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences and their association with treatment failure, but does not report any in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available, and there is no mention of accession numbers or a public database.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not reported.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""Baseline NGS data were available for 1380 antiretroviral therapy (ART)-naïve participants enrolled over 2009--2013.""

Rationale: The paper explicitly states that 1380 individuals had samples obtained for HIV sequencing.

Answer: 1380.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""South America"", ""Africa"", ""Europe"", and ""USA"" as regions of enrolment.

Rationale: The paper does not provide a comprehensive list of countries, but mentions several regions where the study was conducted.

Answer: South America, Africa, Europe, USA.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""enrolled over 2009--2013"".

Rationale: The paper explicitly states that the samples were obtained between 2009 and 2013.

Answer: 2009-2013.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not reported.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""amino acid frequencies in the *pol* gene from amino acid position 1--935 where positions 1--99 encode protease protein, positions 100--659 encode reverse transcriptase protein, and positions 660--935 partially encode integrase protein"".

Rationale: The paper explicitly states that the *pol* gene, including protease, reverse transcriptase, and integrase, was sequenced.

Answer: Pol (protease, reverse transcriptase, integrase).

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq)"".

Rationale: The paper explicitly states that next-generation sequencing (NGS) using the Illumina MiSeq platform was used.

Answer: NGS (Illumina MiSeq).

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Stored plasma from participants with entry HIV RNA \>1000 copies/mL were analysed using NGS (llumina MiSeq)"".

Rationale: The paper explicitly states that plasma samples were sequenced.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""85 participants met our definition of primary endpoint of TF"" and ""the time of experiencing a single plasma HIV RNA \>200 copies/mL after \>6 months of therapy initiation"".

Rationale: The paper explicitly states that some individuals experienced virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states ""The START trial, conducted by the International Network for Strategic Initiatives in Global HIV Trials, enrolled ART-naïve participants with HIV between April 2009 and December 2013.""

Rationale: The paper explicitly states that the study was a clinical trial.

Answer: Yes.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""ART-naïve participants"" and ""Baseline NGS data were available for 1380 antiretroviral therapy (ART)-naïve participants enrolled over 2009--2013.""

Rationale: The paper explicitly states that the individuals were ART-naïve, meaning they had not previously received ARV drugs.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: Not reported.

Rationale: The paper does not provide any information about the drug classes received by individuals before sample sequencing.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: Not reported.

Rationale: The paper does not provide any information about the specific drugs received by individuals before sample sequencing.

Answer: Not reported.",69
37817087,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""Protease (PR) and reverse-transcriptase (RT) sequences were obtained from 4559 (39.6%) cases, and PR, RT and integrase (IN) sequences were obtained from 3097 (26.9%) cases.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically from plasma or serum.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper states ""Resistance was determined and assessed using the Stanford HIV Drug Resistance Database version 8.9 algorithm.""

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses a computational algorithm to determine resistance.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states ""All datasets including sequences are available from the corresponding author upon reasonable request.""

Rationale: The sequences are not publicly available, but can be obtained from the corresponding author upon request.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: None

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""Protease (PR) and reverse-transcriptase (RT) sequences were obtained from 4559 (39.6%) cases, and PR, RT and integrase (IN) sequences were obtained from 3097 (26.9%) cases.""

Rationale: The paper reports that samples were obtained from 4559 individuals for PR and RT sequencing, and from 3097 individuals for PR, RT, and IN sequencing.

Answer: 4559 (PR and RT), 3097 (PR, RT, and IN)

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""The study was partly funded by RKI Sonderforschungsmittel Molecular Surveillance (grant number 8321847).""

Rationale: The paper does not explicitly state the countries from which the samples were obtained, but it is implied that the samples were obtained from Germany.

Answer: Germany (implied)

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""From 2017 to 2020, 11,527 new HIV diagnoses were reported to the RKI.""

Rationale: The paper explicitly states that the samples were obtained from 2017 to 2020.

Answer: 2017-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: None

Rationale: The paper does not mention cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""The genomic regions of protease (PR, amino acids 9--99), reverse transcriptase (RT, amino acids 1-252) and integrase (IN, amino acids 1-279) were amplified according to previously published protocols.""

Rationale: The paper explicitly states that the PR, RT, and IN genes were sequenced.

Answer: PR, RT, IN

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""The amplicons were sequenced using an Illumina NGS method (MiSeq).""

Rationale: The paper explicitly states that Illumina NGS (MiSeq) was used for sequencing.

Answer: Illumina NGS (MiSeq)

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Viral RNA was isolated from the sample material (serum, plasma or spot elution) using the automated Biomerieux EasyMag platform.""

Rationale: The paper explicitly states that serum, plasma, or dried serum/plasma spots were used for sequencing.

Answer: Serum, plasma, dried serum/plasma spots

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: None

Rationale: The paper does not mention virological failure on a treatment regimen.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: None

Rationale: The paper does not mention a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: None

Rationale: The paper does not mention previous ARV drug use.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: None

Rationale: The paper does not mention previous ARV drug use.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: None

Rationale: The paper does not mention previous ARV drug use.

Answer: Not reported",62
37823653,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from 6,078 individuals, and ""proviral DNA templates were used for amplification, as the majority of participants were receiving ART.""

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, and the samples were obtained from individuals who were either ART-naive or ART-experienced.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", but it does mention ""FTR resistance-associated polymorphisms"" and ""predicted the tropism of the HIV-1 sequences"".

Rationale: The paper does not report in vitro drug susceptibility data, but it does report genotypic resistance data and predicted tropism.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not explicitly state that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"".

Rationale: The paper does not provide information on whether the sequences were made publicly available.

Answer: Not Reported
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide GenBank accession numbers.

Answer: Not Reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""a total of 6,078 participants with gp120 sequences were included in this study"".

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 6,078
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the study was conducted in Botswana.

Rationale: The paper explicitly states the country where the samples were obtained.

Answer: Botswana
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the participants were enrolled between 2013 and 2018.

Rationale: The paper explicitly states the years when the samples were obtained.

Answer: 2013-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not explicitly state that samples were cloned prior to sequencing, but it does mention ""proviral DNA templates were used for amplification"".

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not Reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that ""the generated sequences were from PWH aged 16--64 years residing in 30 communities in northern, central, and southern parts of Botswana who were randomly selected to participate in the Botswana Combination Prevention Project (BCPP) (4, 24--26). BCPP enrolled both PWH and HIV-negative individuals. HIV-positive status of participants was based on either written documentation provided (e.g., HIV test results and ART prescription) or HIV testing that was performed in the households according to the Botswana national guidelines by using two rapid HIV tests in parallel.""

Rationale: The paper does not explicitly state which HIV genes were sequenced, but it does mention that the sequences were generated from the gp120 region.

Answer: gp120
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states that ""the NGS was performed by the Biopolimers Facility at Harvard Medical School (https://genome.med.harvard.edu/) and through collaboration with PANGEA HIV consortium (24) at the Wellcome Trust Sanger Institute (Cambridge, UK; http://www.sanger.ac.uk/) with high-sequencing coverage and using Illumina platform MiSeq and HiSeq.""

Rationale: The paper explicitly states the method used for sequencing.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states that ""proviral DNA templates were used for amplification, as the majority of participants were receiving ART.""

Rationale: The paper explicitly states the type of samples that were sequenced.

Answer: Proviral DNA
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states that ""ART-experienced participants were further stratified to ART experienced and virally suppressed (VL ≤400 copies/mL) [4,526 (95.5%)] and ART experienced with VF (detectable VL >400 copies/mL at entry) [213 (4.5%)]"".

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper states that ""this study has been registered at ClinicalTrials.gov under registration no. NCT01965470"".

Rationale: The paper explicitly states that the study was registered at ClinicalTrials.gov.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states that ""most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016.""

Rationale: The paper explicitly states that the individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016.""

Rationale: The paper explicitly states the drug classes that were received by the individuals.

Answer: NNRTI, NRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states that ""most of the ART-experienced PWH were on efavirenz- or nevirapine-based ART which was the first-line regimen prior to dolutegravir-based first-line ART implementation in June 2016.""

Rationale: The paper explicitly states the drugs that were received by the individuals.

Answer: Efavirenz, Nevirapine, Dolutegravir
""""""",79
37872202,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from patients, and it reports accession numbers for GenBank.

Rationale: The paper explicitly states that it analyzed HIV sequences from patient samples, and it provides accession numbers for GenBank, which is a database of publicly available DNA sequences.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"", and it reports values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper explicitly states that it performed in vitro drug susceptibility assays and reports the results, including IC50 values.

Answer: Yes.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports accession numbers for GenBank, which is a database of publicly available DNA sequences.

Rationale: The paper explicitly states that the sequences were submitted to GenBank and provides accession numbers, which means that the sequences are publicly available.

Answer: Yes.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper reports accession numbers for GenBank, but the specific numbers are not provided in the text.

Rationale: The paper mentions that the sequences were submitted to GenBank, but it does not provide the specific accession numbers in the text.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not explicitly state the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not reported.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly state whether the samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""pol genotyping/sequencing"" and ""env"" sequencing.

Rationale: The paper explicitly states that it analyzed the pol and env genes of HIV.

Answer: Pol, Env.

**Question 10: What method was used for sequencing?**

Evidence: The paper does not explicitly state the method used for sequencing.

Rationale: The paper does not provide information on the method used for sequencing.

Answer: Not reported.

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not explicitly state the type of samples that were sequenced.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not explicitly state whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper does not provide information on whether any sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not explicitly state whether the individuals had previously received ARV drugs.

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly state which drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on which drug classes were received by individuals in the study before sample sequencing.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly state which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on which drugs were received by individuals in the study before sample sequencing.

Answer: Not reported.",71
37878637,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Sequencing of protease and reverse transcriptase regions was performed for participants experiencing virological failure, VF, (Plasma viral load, PVL ≥ 1000 RNA copies/ml)"" and ""HIV-1 RNA was extracted manually from 140 μL of plasma using the QIAGEN protocol"".

Rationale: The paper explicitly mentions sequencing of HIV-1 from patient samples, specifically from plasma.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report any in vitro drug susceptibility data, it only reports genotypic resistance testing and sequencing data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""The data underlying the results presented in the study are available from figshare (https://doi.org/10.6084/m9.figshare.22779836)"".

Rationale: The paper explicitly mentions that the sequences are available from figshare.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""Of the 141 participants in VF enrolled, the male-female ratio was 1:1; mean age was 15 (±3) years; and median [IQR] duration on ART was 51 [46--60] months.""

Rationale: The paper explicitly mentions that 141 participants had samples obtained for HIV sequencing.

Answer: 141
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""A cohort study was conducted from 2018--2020 among 311 adolescents living with perinatally acquired HIV (APHI) receiving antiretroviral therapy (ART) in one of the selected health facilities within the *""Resistance Evolution among Adolescents in Yaoundé and its surroundings"" (READY-study)* in the Centre region of Cameroon.""

Rationale: The paper explicitly mentions that the samples were obtained from Cameroon.

Answer: Cameroon
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""A cohort study was conducted from 2018--2020 among 311 adolescents living with perinatally acquired HIV (APHI) receiving antiretroviral therapy (ART) in one of the selected health facilities within the *""Resistance Evolution among Adolescents in Yaoundé and its surroundings"" (READY-study)* in the Centre region of Cameroon.""

Rationale: The paper explicitly mentions that the samples were obtained from 2018 to 2020.

Answer: 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report any cloning prior to sequencing, it only mentions PCR amplification and sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Sequencing of protease and reverse transcriptase regions was performed for participants experiencing virological failure, VF, (Plasma viral load, PVL ≥ 1000 RNA copies/ml)"".

Rationale: The paper explicitly mentions that the protease and reverse transcriptase regions were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""PCR products were sequenced using the Applied Biosystems 3500 genetic analyzer"".

Rationale: The paper explicitly mentions that the Applied Biosystems 3500 genetic analyzer was used for sequencing.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""HIV-1 RNA was extracted manually from 140 μL of plasma using the QIAGEN protocol"".

Rationale: The paper explicitly mentions that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Sequencing of protease and reverse transcriptase regions was performed for participants experiencing virological failure, VF, (Plasma viral load, PVL ≥ 1000 RNA copies/ml)"".

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report any information about a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Participants were recruited following consecutive, and exhaustive sampling. Included in the study were APHI; aged 10--19 years, receiving a standard reverse transcriptase inhibitor-based first- or ritonavir-boosted protease inhibitor-based second-line ART regimen for at least 6 months"".

Rationale: The paper explicitly mentions that the participants had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""Participants were recruited following consecutive, and exhaustive sampling. Included in the study were APHI; aged 10--19 years, receiving a standard reverse transcriptase inhibitor-based first- or ritonavir-boosted protease inhibitor-based second-line ART regimen for at least 6 months"".

Rationale: The paper explicitly mentions that the participants received reverse transcriptase inhibitors and protease inhibitors.

Answer: NRTI, PI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""Most of the participants (34.5%, 31.3%, and 31.7%) were on a TDF + 3TC + EFV-based regimen"".

Rationale: The paper explicitly mentions that the participants received TDF, 3TC, and EFV.

Answer: TDF, 3TC, EFV
""""""",78
37880705,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""HIV-1 pol sequences from studies conducted between 2003 and 2018 among ART-naïve Ethiopian individuals were retrieved from GenBank and analyzed for the presence of PDR mutations (PDRM) along with the analysis of HIV-1 variant dynamics.""

Rationale: The paper explicitly states that it analyzed HIV-1 pol sequences from patient samples, which were retrieved from GenBank.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV-1 pol sequences and the prevalence of PDR mutations, but does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""Sequences of the included studies were downloaded from GenBank if they were publicly available and, if they were not found online, study authors were contacted for the respective sequences.""

Rationale: The paper explicitly states that the sequences were downloaded from GenBank, which is a public database.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers.

Rationale: The paper does not provide specific GenBank accession numbers, but mentions that the sequences were downloaded from GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""We identified nine studies and analyzed 1070 retrieved HIV-1 pol sequences in this systematic review.""

Rationale: The paper explicitly states that 1070 HIV-1 pol sequences were analyzed, which implies that 1070 individuals had samples obtained for HIV sequencing.

Answer: 1070
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""HIV-1 pol sequences from studies conducted between 2003 and 2018 among ART-naïve Ethiopian individuals were retrieved from GenBank and analyzed for the presence of PDR mutations (PDRM) along with the analysis of HIV-1 variant dynamics.""

Rationale: The paper explicitly states that the samples were obtained from Ethiopia.

Answer: Ethiopia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""HIV-1 pol sequences from studies conducted between 2003 and 2018 among ART-naïve Ethiopian individuals were retrieved from GenBank and analyzed for the presence of PDR mutations (PDRM) along with the analysis of HIV-1 variant dynamics.""

Rationale: The paper explicitly states that the samples were obtained between 2003 and 2018.

Answer: 2003-2018
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""HIV-1 pol sequences from studies conducted between 2003 and 2018 among ART-naïve Ethiopian individuals were retrieved from GenBank and analyzed for the presence of PDR mutations (PDRM) along with the analysis of HIV-1 variant dynamics.""

Rationale: The paper explicitly states that HIV-1 pol sequences were analyzed, which implies that the pol gene was sequenced.

Answer: Pol
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not provide information on the type of samples sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""We identified nine studies and analyzed 1070 retrieved HIV-1 pol sequences in this systematic review.""

Rationale: The paper does not provide information on whether the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""ART-naïve Ethiopian individuals"".

Rationale: The paper explicitly states that the individuals were ART-naïve, which implies that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide information on which drug classes were received by the individuals before sample sequencing.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide information on which drugs were received by the individuals before sample sequencing.

Answer: Not reported
""""""",65
37896785,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""The study material was blood plasma samples from HIV-infected pregnant women: 31 women showed virological failure of ART, and 30 women had not previously received therapy.""

Rationale: The paper explicitly mentions that the study material was blood plasma samples from HIV-infected pregnant women, indicating that the sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""Analysis of HIV-1 genetic sequences for the presence of drug resistance mutations was performed using the Stanford database"" and ""The most common HIV drug resistance mutations to PIs and NNRTIs in the examined group are shown in Figure 2 and Figure 3, respectively.""

Rationale: The paper reports on the analysis of HIV-1 genetic sequences for the presence of drug resistance mutations, but it does not provide in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states ""The nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382).""

Rationale: The paper explicitly mentions that the nucleotide sequences were deposited in GenBank, indicating that the sequences are publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states ""The nucleotide sequences of 61 HIV-1 samples were obtained and deposited in GenBank (numbers OQ215322-OQ215382).""

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OQ215322-OQ215382

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""The study material was blood plasma samples from HIV-infected pregnant women: 31 women showed virological failure of ART, and 30 women had not previously received therapy.""

Rationale: The paper explicitly mentions that the study material was obtained from 61 HIV-infected pregnant women.

Answer: 61

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""The study material was blood plasma samples from HIV-infected pregnant women in Ho Chi Minh City, South Vietnam.""

Rationale: The paper explicitly mentions that the samples were obtained from Vietnam.

Answer: Vietnam

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""The study material was blood plasma samples collected in 2021 from 61 pregnant women in need of PMTCT in Ho Chi Minh City.""

Rationale: The paper explicitly mentions that the samples were collected in 2021.

Answer: 2021

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""HIV-1 genotyping was performed based on analysis of the nucleotide sequences of the 1285 nt *pol* gene region encoding the protease (PR) and part of the reverse transcriptase (RT) in the 2085--3369 nt region.""

Rationale: The paper explicitly mentions that the *pol* gene region was sequenced, which includes the protease (PR) and part of the reverse transcriptase (RT) genes.

Answer: Pol (PR and RT)

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""Sanger sequencing using the AmpliSens HIVResist-Seq (Central Research Institute of Epidemiology, Moscow, Russia) commercial kit.""

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""The study material was blood plasma samples from HIV-infected pregnant women.""

Rationale: The paper explicitly mentions that blood plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""31 women showed virological failure of ART.""

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""31 women showed virological failure of ART.""

Rationale: The paper explicitly mentions that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide information on the specific drug classes received by the individuals.

Rationale: The paper does not provide information on the specific drug classes received by the individuals.

Answer: Not Reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not provide information on the specific drugs received by the individuals.

Rationale: The paper does not provide information on the specific drugs received by the individuals.

Answer: Not Reported",69
37896860,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers (ThermoFisher Scientific, Nairobi, Kenya) at the KEMRI-CDC HIV Research and Sanger 3730xl at the Kenya National HIV Reference Laboratories.""

Rationale: The paper explicitly mentions that HIV DR testing was performed on plasma samples from patient participants, indicating that the paper reports HIV sequences from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences from patient samples and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available, and there is no mention of GenBank accession numbers or any other public sequence database.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not reported.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""A total of 704 children were enrolled in the study... During the 12-month study period, 190 study DRTs were requested for 106 (15%) participants across the two study groups.""

Rationale: The paper mentions that 106 participants had samples obtained for HIV sequencing.

Answer: 106

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""Children 1--14 years of age, enrolled at a study site, on or initiating ART, and with a consenting caregiver were enrolled to the study from five facilities in Kisumu County, Kenya...""

Rationale: The paper explicitly mentions that the samples were obtained from Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""Children were enrolled from March 2019 to December 2020...""

Rationale: The paper mentions the enrollment period, which indicates the years when the samples were obtained.

Answer: 2019-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not reported.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""HIV DR testing was performed on plasma samples using Sanger sequencing... to detect reverse transcriptase and PI mutations""

Rationale: The paper mentions that reverse transcriptase and PI mutations were detected, indicating that the pol gene was sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""HIV DR testing was performed on plasma samples using Sanger sequencing with Applied Biosystems 3130xl Genetic Analyzers...""

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Whole blood was collected from study participants for POC VL testing and separated into plasma for testing...""

Rationale: The paper mentions that plasma samples were used for sequencing.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""During the 12-month study period, 190 study DRTs were requested for 106 (15%) participants across the two study groups... All children with VF had some DR, the majority of whom had major DR.""

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper states ""The Optimizing Viral Suppression in Children on ART in Kenya (Opt4Kids) study protocol and primary findings have been described previously...""

Rationale: The paper mentions that the study is a clinical trial.

Answer: Yes

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""Children on ART for >2 years and those with a history of VF were significantly more likely to have major DR.""

Rationale: The paper mentions that some participants had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""First-line ART regimens in Kenya during the study period for children included lamivudine with either abacavir (preferred) or zidovudine (alternative) and lopinavir/ritonavir for those less than three years of age and lamivudine with either abacavir (preferred) or zidovudine (alternative) and efavirenz for those three years of age and older...""

Rationale: The paper mentions that participants received NRTIs, NNRTIs, and PIs.

Answer: NRTIs, NNRTIs, PIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""First-line ART regimens in Kenya during the study period for children included lamivudine with either abacavir (preferred) or zidovudine (alternative) and lopinavir/ritonavir for those less than three years of age and lamivudine with either abacavir (preferred) or zidovudine (alternative) and efavirenz for those three years of age and older...""

Rationale: The paper mentions that participants received lamivudine, abacavir, zidovudine, lopinavir/ritonavir, and efavirenz.

Answer: Lamivudine, abacavir, zidovudine, lopinavir/ritonavir, efavirenz",78
37910452,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention HIV sequences from patient samples. It discusses adherence to antiretroviral therapy among HIV patients in Ghana.

Rationale: The paper is focused on a systematic review and meta-analysis of adherence to antiretroviral therapy among HIV patients in Ghana. It does not mention HIV sequences from patient samples.

Answer: Not reported",82
37914679,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""All of the 76 HIV-1-infected patients with baseline plasma pre-existing low-frequency drug resistance mutations were detected by the MiSeq second-generation sequencing platform (Illumina, San Diego, CA, USA).""

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples using the MiSeq second-generation sequencing platform.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the detection of pre-existing low-frequency resistance mutations in HIV-1-infected patients using the MiSeq second-generation sequencing platform, but does not report in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information about the GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""All of the 76 HIV-1-infected patients with baseline plasma pre-existing low-frequency drug resistance mutations were detected by the MiSeq second-generation sequencing platform (Illumina, San Diego, CA, USA).""

Rationale: The paper explicitly mentions that 76 HIV-1-infected patients had samples obtained for HIV sequencing.

Answer: 76
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper does not provide any information about the country of origin for the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""HIV-1 ART-naïve patients attending the Second Hospital of Nanjing during January 1, 2018 to December 31, 2020...""

Rationale: The paper explicitly mentions the years during which the sequenced samples were obtained.

Answer: 2018-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""All of the 76 HIV-1-infected patients with baseline plasma pre-existing low-frequency drug resistance mutations were detected by the MiSeq second-generation sequencing platform (Illumina, San Diego, CA, USA).""

Rationale: The paper explicitly mentions that the MiSeq second-generation sequencing platform was used for sequencing.

Answer: NGS
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""All of the 76 HIV-1-infected patients with baseline plasma pre-existing low-frequency drug resistance mutations were detected by the MiSeq second-generation sequencing platform (Illumina, San Diego, CA, USA).""

Rationale: The paper explicitly mentions that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Thirty-eight patients who failed antiviral therapy were defined as the failure group according to the study definition criteria...""

Rationale: The paper explicitly mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""HIV-1 ART-naïve patients attending the Second Hospital of Nanjing during January 1, 2018 to December 31, 2020...""

Rationale: The paper explicitly mentions that the patients were ART-naïve, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",63
37920909,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""HIV-1 integrase genes of 601 cases were sequenced successfully"" and ""After RNA extraction, an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes"".

Rationale: The paper explicitly mentions that HIV-1 integrase genes were sequenced from patient samples, indicating that the answer is yes.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""We used the Stanford University HIV Drug Resistance Database (HIVDB Algorithm version 9.4.1) to examine mutations"" and ""Sequences with resistance levels classified as low, intermediate, and high were all regarded as resistant"".

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses a database to examine mutations and classify resistance levels.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available, so the answer is no.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, so the answer is not reported.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital"".

Rationale: The paper explicitly mentions that 629 individuals had samples obtained for HIV sequencing.

Answer: 629
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital"".

Rationale: The paper explicitly mentions that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital between January 1, 2020, and April 1, 2023"".

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2020-2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing, so the answer is no.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""After RNA extraction, an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes"".

Rationale: The paper explicitly mentions that HIV-1 integrase genes were sequenced.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""After RNA extraction, an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes"".

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""5 mL of blood was collected from the participants"" and ""After RNA extraction, an in-house genotyping method and standard Sanger sequencing were used to amplify and sequence HIV-1 integrase genes"".

Rationale: The paper explicitly mentions that blood samples were used for sequencing.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital"".

Rationale: The paper explicitly mentions that the individuals were ART-naïve, indicating that they had not experienced virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, so the answer is no.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""The current study recruited 629 ART-naïve individuals from Tianjin Second People's Hospital"".

Rationale: The paper explicitly mentions that the individuals were ART-naïve, indicating that they had not previously received ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any drug classes received by the individuals.

Rationale: The paper does not provide any information about drug classes received by the individuals, so the answer is none.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention any specific drugs received by the individuals.

Rationale: The paper does not provide any information about specific drugs received by the individuals, so the answer is not reported.

Answer: Not reported
""""""",62
37938856,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV DRM testing was performed at the two accredited centralized laboratories in Kenya using Sanger sequencing for participants in the intervention group with VL ≥ 1000 copies/ml.""

Rationale: The paper reports that HIV DRM testing was performed on patient samples using Sanger sequencing, which implies that HIV sequences were obtained from patient samples.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""HIV DRM testing was performed at the two accredited centralized laboratories in Kenya using Sanger sequencing for participants in the intervention group with VL ≥ 1000 copies/ml.""

Rationale: The paper reports that HIV DRM testing was performed, but it does not mention in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions ""820 women were enrolled, with 411 and 409 allocated to the intervention and control groups, respectively.""

Rationale: The paper reports that 820 women were enrolled, but it does not specify how many individuals had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions ""Kenya"" as the country where the study was conducted.

Rationale: The paper reports that the study was conducted in Kenya, which implies that the sequenced samples were obtained from Kenya.

Answer: Kenya

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions ""February 2019 to November 2022"" as the study period.

Rationale: The paper reports that the study was conducted from 2019 to 2022, which implies that the sequenced samples were obtained during this period.

Answer: 2019-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""Sanger sequencing for participants in the intervention group with VL ≥ 1000 copies/ml"" but does not specify which HIV genes were sequenced.

Rationale: The paper reports that Sanger sequencing was performed, but it does not specify which HIV genes were sequenced.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing"" as the method used for sequencing.

Rationale: The paper reports that Sanger sequencing was used for sequencing.

Answer: Sanger sequencing

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""plasma"" as the sample type used for VL testing.

Rationale: The paper reports that plasma was used for VL testing, which implies that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""participants in the intervention group with VL ≥ 1000 copies/ml"" which implies that sequences were obtained from individuals with virological failure.

Rationale: The paper reports that sequences were obtained from participants with VL ≥ 1000 copies/ml, which implies that sequences were obtained from individuals with virological failure.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""participants in the intervention group with VL ≥ 1000 copies/ml"" which implies that sequences were obtained from individuals who had previously received ARV drugs.

Rationale: The paper reports that sequences were obtained from participants with VL ≥ 1000 copies/ml, which implies that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""NNRTI-, PI-, and integrase-containing ART"" as the drug classes received by individuals in the study.

Rationale: The paper reports that individuals in the study received NNRTI-, PI-, and integrase-containing ART, which implies that these drug classes were received before sample sequencing.

Answer: NNRTI, PI, integrase inhibitors

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""efavirenz, lamivudine, tenofovir, dolutegravir, atazanavir, ritonavir"" as the drugs received by individuals in the study.

Rationale: The paper reports that individuals in the study received these drugs, which implies that these drugs were received before sample sequencing.

Answer: Efavirenz, lamivudine, tenofovir, dolutegravir, atazanavir, ritonavir",70
37941373,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022."" and ""Whole blood samples were harvested and centrifuged at 3000×g for 15 minutes to remove leucocytes, and then plasma (supernatant) was harvested for RNA extraction.""

Rationale: The paper explicitly states that plasma samples were obtained from HIV-1 patients, which indicates that the sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""phenotypic resistance testing"" and ""drug susceptibility assay"" in the methods section, but does not provide any in vitro drug susceptibility data.

Rationale: Although the paper mentions phenotypic resistance testing and drug susceptibility assay, it does not provide any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""Samples were harvested from 1080 patients, and successful amplification of the IN gene was achieved in 1032 samples"".

Rationale: The paper explicitly states that samples were obtained from 1080 patients, but successful amplification was achieved in 1032 samples.

Answer: 1032
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""Plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.""

Rationale: The paper explicitly states that the samples were obtained from patients at Chongqing Public Health Medical Center, which is located in China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""Plasma samples were obtained from HIV-1 patients at Chongqing Public Health Medical Center from July 2019 to August 2022.""

Rationale: The paper explicitly states that the samples were obtained from 2019 to 2022.

Answer: 2019-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""amplification of the target fragment by nested PCR. The HIV-1 IN gene was amplified by a validated In-house method.""

Rationale: The paper explicitly states that the HIV-1 IN gene was amplified.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""Whole blood samples were harvested and centrifuged at 3000×g for 15 minutes to remove leucocytes, and then plasma (supernatant) was harvested for RNA extraction.""

Rationale: The paper explicitly states that plasma samples were used for RNA extraction.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Among the seventeen patients with INSTI resistance, twelve were INSTI-treated (11.76%, 12/102), and five were INSTI-naive (1.38%, 5/363).""

Rationale: The paper explicitly states that some patients were INSTI-treated and had INSTI resistance, which indicates virological failure.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Among the seventeen patients with INSTI resistance, twelve were INSTI-treated (11.76%, 12/102), and five were INSTI-naive (1.38%, 5/363).""

Rationale: The paper explicitly states that some patients were INSTI-treated, which indicates previous receipt of ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The remaining patients on ART (45.06%, 465/1032) were treated with dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline and efavirenz, among others.""

Rationale: The paper explicitly states that patients were treated with INSTIs, NNRTIs, and NRTIs.

Answer: INSTIs, NNRTIs, NRTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The remaining patients on ART (45.06%, 465/1032) were treated with dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline and efavirenz, among others.""

Rationale: The paper explicitly states that patients were treated with dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, and efavirenz.

Answer: Dolutegravir, rilpivirine, lamivudine, tenofovir, crizaline, efavirenz
""""""",74
37946329,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""The partial pol gene sequences were also successfully amplified in all the patients whose INT genes were sequenced."" and ""The analysis included a total of 921 HIV-1 patients, with a median age of 43 (IQR, 30--53) years.""

Rationale: The paper explicitly states that the partial pol gene sequences were amplified from patient samples, indicating that HIV sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""Genotypic drug resistance testing was performed as described previously."" and ""DRMs and antiretroviral susceptibility were analyzed by submitting the identified sequences to the Stanford HIV-1 drug resistance database.""

Rationale: The paper does not report in vitro drug susceptibility data, but rather uses genotypic drug resistance testing and analysis of sequences to predict antiretroviral susceptibility.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available, so it is likely that they were not.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers, so it is not possible to answer this question.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""The analysis included a total of 921 HIV-1 patients, with a median age of 43 (IQR, 30--53) years.""

Rationale: The paper explicitly states that 921 HIV-1 patients had samples obtained for HIV sequencing.

Answer: 921
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""The Sixth People's Hospital of Zhengzhou from June 2018 to April 2022.""

Rationale: The paper does not explicitly state the country, but based on the hospital name, it is likely that the samples were obtained from China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""The Sixth People's Hospital of Zhengzhou from June 2018 to April 2022.""

Rationale: The paper explicitly states that the samples were obtained from June 2018 to April 2022.

Answer: 2018-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning.

Rationale: The paper does not provide any information about cloning, so it is likely that samples were not cloned prior to sequencing.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""The partial polymerase (pol) and complete integrase gene-coding sequences were amplified, sequenced, and analyzed to identify DRMs.""

Rationale: The paper explicitly states that the partial pol gene and complete integrase gene-coding sequences were sequenced.

Answer: Pol, Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not provide any information about the sequencing method, so it is not possible to answer this question.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""plasma samples derived from PLWH"".

Rationale: The paper explicitly states that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""A total of 1078 patients who failed in ART treatment, the partial pol gene sequence was successfully amplified in 921, and the integrase (INT) gene sequence in 751 patients.""

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, so it is likely that the patients were not in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""A total of 1078 patients who failed in ART treatment, the partial pol gene sequence was successfully amplified in 921, and the integrase (INT) gene sequence in 751 patients.""

Rationale: The paper explicitly states that sequences were obtained from individuals who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The incidence of DRMs was the highest in patients with NNRTI-based regimens (582/664, 87.7%), followed by PI (125/196, 63.8%) and INSTI (22/31, 71.0%)-based regimens.""

Rationale: The paper explicitly states that individuals received NNRTI, PI, and INSTI-based regimens before sample sequencing.

Answer: NNRTI, PI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The incidence of DRMs against lamivudine (3TC) was 63.4%."" and ""Dovato, a combination of 3TC/dolutegravir (DTG) in a single tablet, showed comparable efficacy in suppressing viremia even in the presence of DRMs against 3TC.""

Rationale: The paper explicitly states that individuals received lamivudine (3TC) and dolutegravir (DTG) before sample sequencing.

Answer: 3TC, DTG
""""""",71
37957382,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""Longitudinal single-genome sequencing of near-full-length proviruses and plasma HIV-1 *pol* - *env* RNA was performed.""

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples, specifically from plasma and PBMCs.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the analysis of HIV sequences and the characteristics of the viral reservoir, but does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""Sequence data were submitted to Genbank (BioProject: PRJNA973660).""

Rationale: The paper explicitly mentions that the sequences were submitted to GenBank, making them publicly available.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers.

Rationale: Although the paper mentions that the sequences were submitted to GenBank, it does not provide the specific accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""We enrolled eight participants with ongoing NSV...""

Rationale: The paper explicitly mentions that eight participants had samples obtained for HIV sequencing.

Answer: 8

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin of the samples.

Rationale: The paper does not provide information on the country of origin of the samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the specific years when the samples were obtained.

Rationale: The paper does not provide information on the specific years when the samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""Longitudinal single-genome sequencing of near-full-length proviruses and plasma HIV-1 *pol* - *env* RNA was performed.""

Rationale: The paper explicitly mentions that the *pol* and *env* genes were sequenced.

Answer: Pol, Env

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""We sequenced plasma HIV RNA as previously described.""

Rationale: The paper does not provide detailed information on the sequencing method, but it mentions that it was previously described.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""Extracted RNA was diluted to single viral genome levels to meet the criteria of single-genome sequencing of having no more than one template in each well...""

Rationale: The paper explicitly mentions that RNA was extracted from plasma and PBMCs.

Answer: Plasma, PBMCs

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""All participants were receiving at least two active antiretroviral drugs during the NSV episodes.""

Rationale: The paper does not provide information on whether the participants experienced virological failure on a treatment regimen.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""All participants were receiving at least two active antiretroviral drugs during the NSV episodes.""

Rationale: The paper explicitly mentions that the participants were receiving ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""All participants were receiving at least two active antiretroviral drugs during the NSV episodes.""

Rationale: The paper does not provide detailed information on the specific drug classes received by the individuals.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states that ""All participants were receiving at least two active antiretroviral drugs during the NSV episodes.""

Rationale: The paper does not provide detailed information on the specific drugs received by the individuals.

Answer: Not reported",70
37966701,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples, but it does mention that the study was conducted with data from the Observational Pharmaco-Epidemiology Research & Analysis (OPERA) cohort, which consists of prospectively captured, routine clinical data from electronic health records.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples, but it does mention the use of electronic health records, which may contain information about HIV sequences.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the administration and virologic outcomes of cabotegravir + rilpivirine long-acting injectable in a real-world setting, but it does not report any in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available, and it does not mention any accession numbers or databases where the sequences can be found.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not applicable.

Rationale: The paper does not mention GenBank accession numbers or any other type of accession number.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Not applicable.

Rationale: The paper does not mention HIV sequencing or the number of individuals who had samples obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Not applicable.

Rationale: The paper does not mention HIV sequencing or the countries where the samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Not applicable.

Rationale: The paper does not mention HIV sequencing or the years when the samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: Not applicable.

Rationale: The paper does not mention HIV sequencing or cloning.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Not applicable.

Rationale: The paper does not mention HIV sequencing or the specific genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: Not applicable.

Rationale: The paper does not mention HIV sequencing or the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Not applicable.

Rationale: The paper does not mention HIV sequencing or the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that 13% of initiators had a viral load ≥ 50 copies/mL at first injection, but it does not provide information about virological failure on a treatment regimen.

Rationale: The paper does not provide direct evidence of sequences obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial, and it appears to be a real-world study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the study included individuals who had previously received ARV drugs, but it does not provide information about HIV sequences.

Rationale: The paper does not provide direct evidence of HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included individuals who had previously received ARV drugs, but it does not provide information about specific drug classes.

Rationale: The paper does not provide direct evidence of specific drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the study included individuals who had previously received ARV drugs, but it does not provide information about specific drugs.

Rationale: The paper does not provide direct evidence of specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",55
37973713,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""The drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed based on a Sanger sequencing method with use of commercially available ViroSeq HIV-1 Genotyping System (Abbott Molecular, Des Plains, IL, USA).""

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples using a Sanger sequencing method.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper only reports genotypic resistance data and does not mention any in vitro susceptibility testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""The sequences were submitted to the Stanford University HIV Drug Resistance Database (http://hivdb.stanford.edu) in order to comparison of potential differences in the interpretation of the significance of genetic variants detected.""

Rationale: The paper explicitly mentions that the sequences were submitted to a public database.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""The inclusion and exclusion criteria met 117 patients.""

Rationale: The paper explicitly mentions the number of patients who had samples obtained for HIV sequencing.

Answer: 117
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""Among patients from eastern countries there were 58 patients (95.08%) from Ukraine (11 war refugees and 47 patients who arrived to Poland before the onset of war), 3 patients (4.92%) from: Belarus, Georgia and Kazakhstan.""

Rationale: The paper explicitly mentions the countries of origin for the sequenced samples.

Answer: Ukraine, Belarus, Georgia, Kazakhstan, Poland
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""The patients were recruited during 2 years period (2020--2022).""

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2020-2022
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning.

Rationale: The paper does not mention cloning, and the sequencing method used (Sanger sequencing) does not typically require cloning.

Answer: No
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""The drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed...""

Rationale: The paper explicitly mentions the genes that were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""The drug resistance genotyping of HIV-1 protease (PR) and reverse transcriptase (RT) coding region was performed based on a Sanger sequencing method...""

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not explicitly mention the type of samples sequenced.

Rationale: The paper does not mention the type of samples sequenced, but based on the context, it is likely that plasma or PBMC samples were used.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Among the analyzed groups of patients we assessed the applied antiretroviral therapy regimens.""

Rationale: The paper does not explicitly mention virological failure, but it does mention that the patients were assessed for antiretroviral therapy regimens.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper states ""The clinical trial received a positive opinion from the Bioethics Committee at the Medical University of Warsaw (Number of consent: AKBE/206/2020) and was registered on clinicaltrials.gov (Number: NCT04636736 ).""

Rationale: The paper explicitly mentions that the study was a clinical trial.

Answer: Yes
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Inclusion criteria were recent diagnosis with HIV-1 infection (newly recognized patients), no history of ART...""

Rationale: The paper explicitly mentions that the patients had no history of ART.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not mention specific drug classes, and the patients were ART-naive.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not mention specific drugs, and the patients were ART-naive.

Answer: None
""""""",63
37976080,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""Viral RNA was extracted from 200 µL plasma samples using the QIAamp viral RNA mini kit (Qiagen, Hilton, Germany) according to the operational instructions. Extracted RNA was used for first-round polymerase chain reaction, and the products were used for second-round polymerase chain reaction amplification; both rounds were performed in 25 µL volume reactions to amplify the HIV pol gene region (HXB2: 2253-3553 nt). This covered the PR region (4-99 amino acids) and the partial RT region (1-251 amino acids) [24]. The amplified products were sequenced by Sanger sequencing.""

Rationale: The paper explicitly states that HIV sequences were obtained from patient plasma samples using Sanger sequencing.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper only reports genotypic resistance testing and sequencing data, but does not provide in vitro susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making the sequences publicly available, such as submitting them to GenBank or other databases.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not mention GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""A total of 2869 HIV-positive individuals were initially recruited into the study. After removal of 16 HIV-positive individuals who were younger than 18 years and 9 individuals who had not started ART, the penultimate sample size was 2844. PDR test results were available for 90.3% (n=2568) of participants in RT/PR regions, thus yielding a final sample size of 2568.""

Rationale: The paper explicitly states that 2568 individuals had samples obtained for HIV sequencing.

Answer: 2568.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""We selected 8 provincial-level administrative divisions (PLADs) in China as the study area to conduct a large multicenter observational cross-sectional study.""

Rationale: The paper explicitly states that the samples were obtained from China.

Answer: China.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""Recruitment and specimen collection of HIV-positive individuals occurred in 2022 as individuals initiated ART.""

Rationale: The paper explicitly states that the samples were obtained in 2022.

Answer: 2022.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""Extracted RNA was used for first-round polymerase chain reaction, and the products were used for second-round polymerase chain reaction amplification; both rounds were performed in 25 µL volume reactions to amplify the HIV pol gene region (HXB2: 2253-3553 nt). This covered the PR region (4-99 amino acids) and the partial RT region (1-251 amino acids) [24].""

Rationale: The paper explicitly states that the PR and RT regions of the HIV pol gene were sequenced.

Answer: PR, RT.

**Question 10: What method was used for sequencing?**

Evidence: The paper states ""The amplified products were sequenced by Sanger sequencing.""

Rationale: The paper explicitly states that Sanger sequencing was used.

Answer: Sanger sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Viral RNA was extracted from 200 µL plasma samples using the QIAamp viral RNA mini kit (Qiagen, Hilton, Germany) according to the operational instructions.""

Rationale: The paper explicitly states that plasma samples were used.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""3.2% (n=81) of participants had prior ARV drug exposure.""

Rationale: The paper does not explicitly state that sequences were obtained from individuals with virological failure, but it does mention that some participants had prior ARV drug exposure.

Answer: Not reported.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""3.2% (n=81) of participants had prior ARV drug exposure.""

Rationale: The paper explicitly states that some participants had prior ARV drug exposure.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide any information about specific drug classes received by individuals before sample sequencing.

Answer: Not reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide any information about specific drugs received by individuals before sample sequencing.

Answer: Not reported.",72
37976185,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""We used NYC HIV surveillance and partner services data to measure the effect of PrEP use history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015--2022."" and ""Resistance-associated mutations were determined using the Stanford algorithm.""

Rationale: The paper reports HIV sequences from patient samples, specifically the M184I/V mutations, which were determined using the Stanford algorithm.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report making sequences publicly available.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not report GenBank accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""Of 4246 people with newly diagnosed HIV and a genotype obtained within ≤30 days of diagnosis...""

Rationale: The paper reports that 4246 individuals had samples obtained for HIV sequencing.

Answer: 4246

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""We used New York City surveillance and partner services data...""

Rationale: The paper reports that the sequenced samples were obtained from the United States, specifically New York City.

Answer: United States

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""We used NYC HIV surveillance and partner services data to measure the effect of PrEP use history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015--2022.""

Rationale: The paper reports that the sequenced samples were obtained from 2015 to 2022.

Answer: 2015-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report cloning prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""Resistance-associated mutations were determined using the Stanford algorithm.""

Rationale: The paper reports that the HIV genes sequenced were those associated with resistance to TDF/TAF or FTC, but does not specify which genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not report the sequencing method.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""We used NYC HIV surveillance and partner services data to measure the effect of PrEP use history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015--2022.""

Rationale: The paper reports that the samples sequenced were from people with HIV, but does not specify the type of sample.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not report sequences obtained from individuals with virological failure on a treatment regimen.

Answer: No

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report that the patients were in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""We used NYC HIV surveillance and partner services data to measure the effect of PrEP use history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015--2022.""

Rationale: The paper reports HIV sequences from individuals who had previously received ARV drugs, specifically PrEP.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""We used NYC HIV surveillance and partner services data to measure the effect of PrEP use history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015--2022.""

Rationale: The paper reports that the individuals in the study received PrEP, which includes the drug classes NRTI and NNRTI.

Answer: NRTI, NNRTI

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""We used NYC HIV surveillance and partner services data to measure the effect of PrEP use history on the baseline prevalence of M184I/V mutations in people with HIV diagnosed in 2015--2022.""

Rationale: The paper reports that the individuals in the study received PrEP, which includes the drugs TDF/TAF and FTC.

Answer: TDF/TAF, FTC",65
37993493,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""genotypic resistance testing"", ""genotyping"", or ""sequencing"" was performed on samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that genetic sequencing was performed on clinical samples from patients, which indicates that HIV sequences from patient samples are reported.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". The methods or results report values such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Rationale: The paper does not explicitly mention in vitro drug susceptibility data, but it does mention phenotypic susceptibility and resistance testing, which suggests that in vitro drug susceptibility data may be reported.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper reports that sequences were submitted to ""GenBank"", ""NCBI"", ""EMBL"", ""DDBJ"", ""ENA"", or the ""Short read archive (SRA)"". The paper also reports accession numbers for GenBank or any of the above databases.

Rationale: The paper explicitly mentions that sequences were submitted to GenBank, which indicates that sequences from the paper were made publicly available.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper reports accession numbers for GenBank, but the specific accession numbers are not provided in the text.

Rationale: The paper mentions that accession numbers were provided in a Supplementary Table or in the Data Availability statement, but the specific accession numbers are not provided in the text.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 600 individuals participated in the survey, and 598 samples were successfully genotyped.

Rationale: The paper explicitly mentions that 600 individuals participated in the survey, which indicates that samples were obtained from 600 individuals.

Answer: 600
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted in Tanzania, specifically in the Dar es Salaam Urban Cohort Study (DUCS) platform.

Rationale: The paper explicitly mentions that the study was conducted in Tanzania, which indicates that the sequenced samples were obtained from Tanzania.

Answer: Tanzania
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the study was conducted between February and May 2023.

Rationale: The paper explicitly mentions that the study was conducted between February and May 2023, which indicates that the sequenced samples were obtained in 2023.

Answer: 2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not explicitly mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions that protease, reverse transcriptase, and integrase genes were sequenced.

Rationale: The paper explicitly mentions that protease, reverse transcriptase, and integrase genes were sequenced.

Answer: Protease, reverse transcriptase, and integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper mentions that Sanger sequencing was used.

Rationale: The paper explicitly mentions that Sanger sequencing was used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions that plasma samples were used for sequencing.

Rationale: The paper explicitly mentions that plasma samples were used for sequencing.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions that sequences were obtained from individuals with unsuppressed viral loads (≥1000 copies/mL).

Rationale: The paper explicitly mentions that sequences were obtained from individuals with unsuppressed viral loads, which indicates that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not explicitly mention that the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions that the patients were treatment-experienced and had received antiretroviral therapy (ART) for at least one year.

Rationale: The paper explicitly mentions that the patients were treatment-experienced, which indicates that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients had received tenofovir, lamivudine, and dolutegravir as part of their treatment regimen.

Rationale: The paper explicitly mentions that the patients had received tenofovir, lamivudine, and dolutegravir, which indicates that they had received NRTIs, NNRTIs, and INSTIs.

Answer: NRTIs, NNRTIs, and INSTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions that the patients had received tenofovir, lamivudine, and dolutegravir as part of their treatment regimen.

Rationale: The paper explicitly mentions that the patients had received tenofovir, lamivudine, and dolutegravir.

Answer: Tenofovir, lamivudine, and dolutegravir
""""""",77
38005921,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""genotype--phenotype' datasets, which describe a relationship between a viral genotype and the phenotypic manifestation of resistance to protease, and reverse transcriptase and integrase inhibitors from the Stanford HIV Drug Resistance Database"".

Rationale: The paper reports HIV sequences from patient samples, as it uses genotype-phenotype datasets from the Stanford HIV Drug Resistance Database, which contains sequences from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""The experimental level of resistance provided in the dataset was determined using the Phenosense test system"".

Rationale: The paper reports in vitro drug susceptibility data, as it uses the Phenosense test system to determine the level of resistance.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states ""The datasets used for building models for the web-service is provided in Supplementary Materials"".

Rationale: The sequences from the paper are made publicly available, as they are provided in the supplementary materials.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""The total dataset contained 1958 protease inhibitor (PI) samples, 1707 nucleoside reverse transcriptase inhibitors (NRTI), and 1819 non-nucleoside reverse transcriptase inhibitors (NNRTI) samples"".

Rationale: The paper reports that samples were obtained from 1958 + 1707 + 1819 = 5484 individuals.

Answer: 5484
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not provide information on the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""The training set included the sequences from the Stanford HIV Drug Resistance Database that came from studies published no later than in 2018"".

Rationale: The paper reports that the sequenced samples were obtained from studies published no later than 2018.

Answer: Not reported (but mentioned that the studies were published no later than 2018)
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not provide information on whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on whether samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""The amino acid sequences of HIV enzymes: reverse transcriptase and protease"".

Rationale: The paper reports that the HIV genes that were sequenced are reverse transcriptase and protease.

Answer: Reverse transcriptase and protease
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states ""The sequences undergo processing according to the aforementioned algorithm, which is based on k-mer frequency"".

Rationale: The paper reports that the method used for sequencing is based on k-mer frequency.

Answer: K-mer frequency
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not provide information on the type of samples that were sequenced.

Rationale: The paper does not provide information on the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""The experimental level of resistance provided in the dataset was determined using the Phenosense test system"".

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen, as the Phenosense test system is used to determine the level of resistance.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not provide information on whether the patients were in a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""The experimental level of resistance provided in the dataset was determined using the Phenosense test system"".

Rationale: The paper reports that HIV sequences were obtained from individuals who had previously received ARV drugs, as the Phenosense test system is used to determine the level of resistance.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The total dataset contained 1958 protease inhibitor (PI) samples, 1707 nucleoside reverse transcriptase inhibitors (NRTI), and 1819 non-nucleoside reverse transcriptase inhibitors (NNRTI) samples"".

Rationale: The paper reports that the drug classes received by individuals in the study before sample sequencing are PI, NRTI, and NNRTI.

Answer: PI, NRTI, and NNRTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""The total dataset contained 1958 protease inhibitor (PI) samples, 1707 nucleoside reverse transcriptase inhibitors (NRTI), and 1819 non-nucleoside reverse transcriptase inhibitors (NNRTI) samples"".

Rationale: The paper reports that the drugs received by individuals in the study before sample sequencing are not specified, but the drug classes are PI, NRTI, and NNRTI.

Answer: Not reported
""""""",72
38020274,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states ""Genotypic resistance testing (GRT) was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C.""

Rationale: The paper reports that genetic sequencing was performed on clinical samples from patients, specifically on blood samples stored at -80˚C.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report any in vitro drug susceptibility data, such as IC50, EC50, EC90, fold-change in susceptibility, or reduced susceptibility.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention that sequences were made publicly available.

Rationale: The paper does not report that sequences were submitted to GenBank, NCBI, EMBL, DDBJ, ENA, or the Short read archive (SRA), or that accession numbers were provided.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: Not reported.

Rationale: The paper does not provide any GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states ""A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon.""

Rationale: The paper reports that 311 individuals had samples obtained for HIV sequencing.

Answer: 311

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper states ""A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon.""

Rationale: The paper reports that the sequenced samples were obtained from Cameroon.

Answer: Cameroon

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states ""A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon.""

Rationale: The paper reports that the sequenced samples were obtained from 2018 to 2020.

Answer: 2018-2020

**Question 8: Were samples cloned prior to sequencing?**

Evidence: Not reported.

Rationale: The paper does not mention whether samples were cloned prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states ""The sequences obtained were assembled and edited using Recall CDC Atlanta GA USA software and drug resistance mutations (DRMs) interpreted using Stanford HIVdb.v8.8; Subtyping was done using MEGA v10 for molecular phylogeny.""

Rationale: The paper reports that the HIV-1 polymerase and reverse transcriptase gene regions were sequenced.

Answer: Pol

**Question 10: What method was used for sequencing?**

Evidence: Not reported.

Rationale: The paper does not mention the sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper states ""Genotypic resistance testing (GRT) was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C.""

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states ""Genotypic resistance testing (GRT) was carried out at each time point among participants with plasma viral load (PVL) ≥1,000 RNA copies/ml using an in-house protocol as previously described by our working group (10) using blood samples stored at -80˚C.""

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: Not reported.

Rationale: The paper does not mention whether the patients were in a clinical trial.

Answer: Not reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states ""A cohort-study was conducted from 2018-2020 among 311 APHI receiving ART in Cameroon.""

Rationale: The paper reports that the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""Majority of our study participants were on first line RTI-based ART, with good adherence and median duration on ART of 36\[21-81\] months.""

Rationale: The paper reports that the individuals received RTI-based ART, which includes NRTIs and NNRTIs.

Answer: NRTIs, NNRTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper states ""Majority of our study participants were on first line RTI-based ART, with good adherence and median duration on ART of 36\[21-81\] months.""

Rationale: The paper does not mention specific drug names, but reports that the individuals received RTI-based ART.

Answer: Not reported",71
38022124,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly mention HIV sequences from patient samples. However, it does mention that the study analyzed the use of BIC/FTC/TAF for a one-year period, and 56.8% of those who received BIC/FTC/TAF were treatment-experienced patients.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples. However, it does mention the analysis of treatment-experienced patients, which may imply the use of HIV sequences.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the real-life efficacy and tolerability of BIC/FTC/TAF in HIV patients, and does not report any in vitro drug susceptibility data.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the public availability of sequences.

Rationale: The paper does not provide any information on the public availability of sequences, and it is unlikely that sequences were made publicly available given the lack of mention.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide any information on GenBank accession numbers, and it is unlikely that sequences were deposited in GenBank given the lack of mention.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information on the number of individuals who had samples obtained for HIV sequencing, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the samples.

Rationale: The paper does not provide any information on the country of origin for the samples, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years during which the samples were obtained.

Rationale: The paper does not provide any information on the years during which the samples were obtained, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information on cloning prior to sequencing, and it is unlikely that cloning was performed given the lack of mention.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not provide any information on the specific HIV genes that were sequenced, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method used, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information on the type of samples that were sequenced, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information on virological failure on a treatment regimen, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information on a clinical trial, and it is unlikely that the study was a clinical trial given the lack of mention.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not provide any information on HIV sequences from individuals who had previously received ARV drugs, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the drug classes received by individuals before sample sequencing.

Rationale: The paper does not provide any information on the drug classes received by individuals before sample sequencing, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not mention the specific drugs received by individuals before sample sequencing.

Rationale: The paper does not provide any information on the specific drugs received by individuals before sample sequencing, and it is unlikely that sequencing was performed given the lack of mention.

Answer: Not reported",68
38031075,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly mention HIV sequences from patient samples, but it does mention HIV RNA extraction and viral load determination.

Rationale: The paper focuses on HIV viral suppression and treatment outcomes, but it does not provide information on HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on HIV viral suppression and treatment outcomes, but it does not provide information on in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide information on making sequences publicly available, and it does not mention any accession numbers or databases.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: Not applicable.

Rationale: The paper does not provide GenBank accession numbers for sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: Not applicable.

Rationale: The paper does not provide information on HIV sequencing or the number of individuals with samples obtained for sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: Not applicable.

Rationale: The paper does not provide information on sequenced samples or their country of origin.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: Not applicable.

Rationale: The paper does not provide information on sequenced samples or their collection years.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: Not applicable.

Rationale: The paper does not provide information on sequencing or cloning methods.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: Not applicable.

Rationale: The paper does not provide information on HIV sequencing or the genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: Not applicable.

Rationale: The paper does not provide information on sequencing methods.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: Not applicable.

Rationale: The paper does not provide information on sequencing or sample types.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper mentions virological failure, but it does not provide information on sequencing.

Rationale: The paper focuses on HIV viral suppression and treatment outcomes, but it does not provide information on sequencing from individuals with virological failure.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on a clinical trial, and it appears to be an observational study.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper mentions ARV treatment, but it does not provide information on sequencing.

Rationale: The paper focuses on HIV viral suppression and treatment outcomes, but it does not provide information on sequencing from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions dolutegravir-based therapy and efavirenz-based therapy.

Rationale: The paper provides information on treatment regimens, but it does not provide information on sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions dolutegravir, efavirenz, tenofovir, and lamivudine.

Rationale: The paper provides information on treatment regimens, but it does not provide information on sequencing.

Answer: Not reported
""""""",50
38033131,"Here are the answers to the questions:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper does not explicitly mention HIV sequences from patient samples, but it does mention ""viral load monitoring"" and ""virological failure"" which implies that HIV sequences may have been obtained from patient samples.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, which suggests that HIV sequences may have been obtained from patient samples. However, the paper does not explicitly mention HIV sequences.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, which does not involve in vitro drug susceptibility testing.

Answer: No

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not mention submitting sequences to a public database or making them available for download.

Answer: No

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not mention submitting sequences to GenBank or providing accession numbers.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, but it does not mention the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the country of origin for the sequenced samples.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy in East Shewa hospitals, Oromia Region, Ethiopia, but it does not mention the country of origin for the sequenced samples.

Answer: Not reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years when the sequenced samples were obtained.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, but it does not mention the years when the sequenced samples were obtained.

Answer: Not reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not mention cloning or any other laboratory procedures related to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper does not mention which HIV genes were sequenced.

Rationale: The paper does not mention sequencing or any specific HIV genes.

Answer: Not reported

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not mention sequencing or any laboratory procedures related to sequencing.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper does not mention the type of samples sequenced.

Rationale: The paper does not mention sequencing or any laboratory procedures related to sequencing.

Answer: Not reported

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions virological failure, but it does not explicitly mention sequencing.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, which suggests that sequences may have been obtained from individuals with virological failure, but it is not explicitly mentioned.

Answer: Not reported

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, which does not suggest a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions antiretroviral therapy, but it does not explicitly mention sequencing.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, which suggests that sequences may have been obtained from individuals who had previously received ARV drugs, but it is not explicitly mentioned.

Answer: Not reported

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions antiretroviral therapy, but it does not explicitly mention specific drug classes.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, which suggests that individuals may have received various drug classes, but it is not explicitly mentioned.

Answer: Not reported

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions antiretroviral therapy, but it does not explicitly mention specific drugs.

Rationale: The paper focuses on the incidence and predictors of virological failure among HIV-infected children and adolescents on first-line antiretroviral therapy, which suggests that individuals may have received various drugs, but it is not explicitly mentioned.

Answer: Not reported",73
38058846,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper reports on three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance. The cases were managed directly by two of the authors, and a full file review, extensive search of the National Health Laboratory Services (NHLS) test results database, review of pharmacy ART pick-ups, and in-depth interviews with each woman were conducted.

Rationale: The paper reports on HIV sequences from patient samples, including their corresponding GenBank accession numbers. The sequences were obtained from the patients' plasma and were used to confirm high-level DTG resistance.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper reports on the development of dolutegravir resistance in three pregnant and breastfeeding women in South Africa. The cases were managed directly by two of the authors, and a full file review, extensive search of the National Health Laboratory Services (NHLS) test results database, review of pharmacy ART pick-ups, and in-depth interviews with each woman were conducted.

Rationale: The paper does not report in vitro drug susceptibility data. The resistance testing was done using clinical samples and not in vitro assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the sequences being made publicly available.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports on three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance.

Rationale: The paper reports on three individuals who had samples obtained for HIV sequencing.

Answer: 3
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper reports on three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance.

Rationale: The paper reports that the samples were obtained from South Africa.

Answer: South Africa
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper reports on three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance. The cases were managed directly by two of the authors, and a full file review, extensive search of the National Health Laboratory Services (NHLS) test results database, review of pharmacy ART pick-ups, and in-depth interviews with each woman were conducted.

Rationale: The paper reports that the samples were obtained between 2012 and 2023.

Answer: 2012-2023
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about the samples being cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper reports on the development of dolutegravir resistance in three pregnant and breastfeeding women in South Africa. The cases were managed directly by two of the authors, and a full file review, extensive search of the National Health Laboratory Services (NHLS) test results database, review of pharmacy ART pick-ups, and in-depth interviews with each woman were conducted.

Rationale: The paper reports that the integrase gene was sequenced.

Answer: Integrase
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the method used for sequencing.

Rationale: The paper does not provide any information about the method used for sequencing.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper reports on the development of dolutegravir resistance in three pregnant and breastfeeding women in South Africa. The cases were managed directly by two of the authors, and a full file review, extensive search of the National Health Laboratory Services (NHLS) test results database, review of pharmacy ART pick-ups, and in-depth interviews with each woman were conducted.

Rationale: The paper reports that plasma samples were sequenced.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports on three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance.

Rationale: The paper reports that all three individuals had virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about the patients being in a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports on three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance.

Rationale: The paper reports that all three individuals had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper reports on three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance. The cases were managed directly by two of the authors, and a full file review, extensive search of the National Health Laboratory Services (NHLS) test results database, review of pharmacy ART pick-ups, and in-depth interviews with each woman were conducted.

Rationale: The paper reports that the individuals received integrase inhibitors (dolutegravir) and nucleoside reverse transcriptase inhibitors (lamivudine, zidovudine, abacavir, tenofovir).

Answer: Integrase inhibitors, Nucleoside reverse transcriptase inhibitors
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper reports on three cases of pregnant and breastfeeding women in South Africa who developed dolutegravir resistance. The cases were managed directly by two of the authors, and a full file review, extensive search of the National Health Laboratory Services (NHLS) test results database, review of pharmacy ART pick-ups, and in-depth interviews with each woman were conducted.

Rationale: The paper reports that the individuals received dolutegravir, lamivudine, zidovudine, abacavir, tenofovir, emtricitabine, and darunavir.

Answer: Dolutegravir, Lamivudine, Zidovudine, Abacavir, Tenofovir, Emtricitabine, Darunavir
""""""",80
38072961,"Here are the answers to the questions based on the provided paper:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""CSF HIV RNA was 774 copies/mL, while plasma HIV RNA was undetectable"" and ""further HIV drug resistance tests of CSF and plasma (Sanger sequencing in Dongguan Medical Laboratory of Micro-scale and Presicion) presented identical results of major protease inhibitor (PI)-related mutations, nonnucleoside reverse transcriptase inhibitor (NNRTI)-related mutations, and nucleoside reverse transcriptase inhibitor (NRTI)-related mutations"".

Rationale: The paper reports HIV sequences from patient samples, specifically from CSF and plasma, and mentions Sanger sequencing as the method used.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""further HIV drug resistance tests of CSF and plasma (Sanger sequencing in Dongguan Medical Laboratory of Micro-scale and Presicion) presented identical results of major protease inhibitor (PI)-related mutations, nonnucleoside reverse transcriptase inhibitor (NNRTI)-related mutations, and nucleoside reverse transcriptase inhibitor (NRTI)-related mutations"".

Rationale: The paper reports genotypic resistance testing, but does not provide in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not provide any information about making sequences publicly available.

Answer: No.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions a single case report.

Rationale: The paper reports on a single individual with HIV sequencing.

Answer: 1.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that the patient is a Chinese Manchu male.

Rationale: The paper reports that the sample was obtained from China.

Answer: China.

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that the patient was diagnosed with HIV infection five years ago and that the events described in the paper occurred in 2022.

Rationale: The paper reports that the samples were obtained in 2022.

Answer: 2022.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide any information about cloning prior to sequencing.

Answer: Not reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""major protease inhibitor (PI)-related mutations, nonnucleoside reverse transcriptase inhibitor (NNRTI)-related mutations, and nucleoside reverse transcriptase inhibitor (NRTI)-related mutations"".

Rationale: The paper reports that the protease, reverse transcriptase, and integrase genes were sequenced.

Answer: Pol.

**Question 10: What method was used for sequencing?**

Evidence: The paper mentions ""Sanger sequencing in Dongguan Medical Laboratory of Micro-scale and Presicion"".

Rationale: The paper reports that Sanger sequencing was used.

Answer: Sanger sequencing.

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""CSF HIV RNA was 774 copies/mL, while plasma HIV RNA was undetectable"".

Rationale: The paper reports that both CSF and plasma samples were sequenced.

Answer: CSF and plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""treatment failure occurred one year later with plasma HIV RNA 2.19 × 10^5 copies/mL and CD4^+^ T-cell count 14 cells/μL"".

Rationale: The paper reports that the individual experienced virological failure on a treatment regimen.

Answer: Yes.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""he initiated ART with tenofovir, lamivudine, and efavirenz, but treatment failure occurred one year later"".

Rationale: The paper reports that the individual had previously received ARV drugs.

Answer: Yes.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""tenofovir, lamivudine, and efavirenz"" and ""lopinavir/ritonavir"".

Rationale: The paper reports that the individual received NRTIs, NNRTIs, and PIs before sample sequencing.

Answer: NRTIs, NNRTIs, and PIs.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""tenofovir, lamivudine, and efavirenz"" and ""lopinavir/ritonavir"".

Rationale: The paper reports that the individual received tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir before sample sequencing.

Answer: Tenofovir, lamivudine, efavirenz, and lopinavir/ritonavir.",68
38090027,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper mentions ""genotypic resistance testing"" and ""sequencing"" of patient samples, and reports GenBank accession numbers for the sequences.

Rationale: The paper states that ""genotypic resistance testing"" and ""sequencing"" were performed on patient samples, and provides GenBank accession numbers for the sequences, indicating that the sequences were obtained from patient samples.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper mentions ""genotypic resistance testing"" but does not report in vitro drug susceptibility data.

Rationale: The paper does not provide any information on in vitro drug susceptibility testing, such as IC50 or EC50 values, or describe any cell-based assays.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper reports GenBank accession numbers for the sequences.

Rationale: The paper provides GenBank accession numbers for the sequences, indicating that the sequences were deposited in a public database and are available for access.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers for the sequences.

Rationale: The paper does not provide specific GenBank accession numbers for the sequences, but mentions that the sequences were deposited in GenBank.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper reports that 1040 patients were included in the analysis.

Rationale: The paper states that 1040 patients were included in the analysis, and that samples were obtained from these patients for HIV sequencing.

Answer: 1040
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin of the samples.

Rationale: The paper does not provide any information on the country of origin of the samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper mentions that the samples were obtained between June 2019 and June 2021.

Rationale: The paper states that the samples were obtained between June 2019 and June 2021, indicating the time period during which the samples were collected.

Answer: 2019-2021
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information on cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions ""genotypic resistance testing"" but does not specify which HIV genes were sequenced.

Rationale: The paper does not provide any information on which HIV genes were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper mentions ""plasma HIV-RNA"" and ""PBMC HIV-DNA"" samples.

Rationale: The paper states that ""plasma HIV-RNA"" and ""PBMC HIV-DNA"" samples were used for sequencing.

Answer: Plasma, PBMC
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper reports that 44 patients experienced virological failure.

Rationale: The paper states that 44 patients experienced virological failure, indicating that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information on a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper reports that the patients were treatment-experienced.

Rationale: The paper states that the patients were treatment-experienced, indicating that they had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""integrase inhibitors"", ""NRTIs"", and ""NNRTIs"".

Rationale: The paper states that the patients were treated with integrase inhibitors, NRTIs, and NNRTIs before sample sequencing.

Answer: Integrase inhibitors, NRTIs, NNRTIs
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper mentions ""bictegravir"", ""emtricitabine"", ""tenofovir alafenamide"", ""elvitegravir"", ""darunavir"", and ""rilpivirine"".

Rationale: The paper states that the patients were treated with bictegravir, emtricitabine, tenofovir alafenamide, elvitegravir, darunavir, and rilpivirine before sample sequencing.

Answer: Bictegravir, emtricitabine, tenofovir alafenamide, elvitegravir, darunavir, rilpivirine
""""""",65
38140553,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states that genetic sequencing was performed on clinical samples from ""patients"", ""participants"", ""subjects"", ""blood donors"", ""newly diagnosed persons"", ""newly infected persons"", ""PWH"", ""PLWH"" or ""patient cohorts"". The paper also mentions ""genotypic resistance testing"", ""HIV sequencing"", ""Sanger"", ""Illumina"" ""MiSeq"", ""single-genome sequencing"".

Rationale: The paper explicitly mentions that the study was conducted on patient samples, and the sequencing methods used are typical for HIV sequencing studies.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention ""phenotypic susceptibility"", ""phenotypic resistance testing"", or ""drug susceptibility assay"". However, it does mention ""genotypic resistance testing"" and ""drug resistance mutations"".

Rationale: The paper does not report in vitro drug susceptibility data, but rather focuses on genotypic resistance testing and drug resistance mutations.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that ""All nucleotide sequences obtained in the study were deposited in the international database of the Los Alamos laboratory.""

Rationale: The paper explicitly mentions that the sequences were deposited in a public database.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide specific GenBank accession numbers.

Rationale: The paper does not provide specific GenBank accession numbers, but mentions that the sequences were deposited in the Los Alamos laboratory database.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states that ""The genotyping results of 3178 HIV-infected patients from seven Russian federal districts were examined.""

Rationale: The paper explicitly mentions the number of individuals who had samples obtained for HIV sequencing.

Answer: 3178
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states that the samples were obtained from ""seven Russian federal districts"".

Rationale: The paper explicitly mentions that the samples were obtained from Russia.

Answer: Russia
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states that the samples were obtained from ""2011 to 2020"".

Rationale: The paper explicitly mentions the years during which the samples were obtained.

Answer: 2011-2020
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states that the sequencing was performed on the ""HIV-1 protease (PR) and part of the reverse transcriptase (RT)"".

Rationale: The paper explicitly mentions the genes that were sequenced.

Answer: PR, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper states that ""Sanger-based sequencing of the HIV *pol* gene regions encoding the PR-RT (2253--3554 bp according to the HXB-2 strain, GenBank accession number K03455 ) was performed.""

Rationale: The paper explicitly mentions the sequencing method used.

Answer: Sanger sequencing
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states that the samples were obtained from ""blood plasma collections ( *n* = 2502), peripheral blood mononuclear cells (lymphocytes) collections ( *n* = 613), and frozen whole blood collections ( *n* = 63)"".

Rationale: The paper explicitly mentions the types of samples that were sequenced.

Answer: Plasma, PBMC, Whole Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not explicitly mention virological failure on a treatment regimen.

Rationale: The paper does not provide information on whether the sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not explicitly mention previous ARV drug use.

Rationale: The paper does not provide information on whether the individuals had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drug classes.

Rationale: The paper does not provide information on which drug classes were received by the individuals before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention specific drugs.

Rationale: The paper does not provide information on which drugs were received by the individuals before sample sequencing.

Answer: Not reported
""""""",67
38140649,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper states that ""HIV-1 RNA plasma samples were collected from newly diagnosed HIV patients"" and ""A total of 270 persons met the inclusion criteria."" The paper also mentions that ""Sequences were aligned and compared with the reference strain HIV-1 HXB2 (GenBank number K03455)"".

Rationale: The paper explicitly states that HIV sequences were obtained from patient samples, specifically from newly diagnosed HIV patients. The mention of GenBank accession numbers and the comparison with a reference strain further supports this.

Answer: Yes.

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic resistance testing"" and ""Stanford University HIV Drug Resistance Database, Genotypic Resistance Interpretation Algorithm version 9.5"" but does not report in vitro drug susceptibility data.

Rationale: Although the paper mentions resistance testing and genotypic interpretation, it does not provide in vitro drug susceptibility data.

Answer: No.

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper states that ""All sequences obtained in this study by SS were submitted to the GeneBank nucleotide sequence database under accession numbers OR605755-OR606279 and OR613869-OR613875"" and ""Sequences generated by DS are available from the ArrayExpress database at EMBL-EBI under accession number E-MTAB-13563"".

Rationale: The paper explicitly states that the sequences were submitted to public databases, including GenBank and ArrayExpress.

Answer: Yes.

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper states that ""All sequences obtained in this study by SS were submitted to the GeneBank nucleotide sequence database under accession numbers OR605755-OR606279 and OR613869-OR613875"".

Rationale: The paper provides the GenBank accession numbers for the sequenced HIV isolates.

Answer: OR605755-OR606279 and OR613869-OR613875.

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper states that ""A total of 270 persons met the inclusion criteria"".

Rationale: The paper explicitly states the number of individuals who had samples obtained for HIV sequencing.

Answer: 270.

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not explicitly state the countries of origin for the sequenced samples, but it mentions that ""most of the patients originated from and reported Croatia as the country of infection"".

Rationale: Although the paper does not provide a comprehensive list of countries, it suggests that the majority of the samples were obtained from Croatia.

Answer: Croatia (and possibly other countries, but not specified).

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper states that ""Data collection and analysis were performed on HIV-1 RNA plasma samples collected from newly diagnosed HIV patients over a four-year period during the diagnostic process and clinical follow-up at UHID. All newly diagnosed treatment-naïve PLHIV over 18 years who entered clinical care at UHID in the period between January 2019 and December 2022"".

Rationale: The paper explicitly states the time period during which the samples were collected.

Answer: 2019-2022.

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not explicitly state whether samples were cloned prior to sequencing.

Rationale: The paper does not provide information on cloning, so it is unclear whether samples were cloned prior to sequencing.

Answer: Not Reported.

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper states that ""Amplification of the HIV-1 *pol* gene was performed for two regions in two separate reactions: (1) sequencing of the HIV-1 protease and partial sequencing of the reverse transcriptase gene; and (2) sequencing of the HIV-1 integrase gene"".

Rationale: The paper explicitly states that the pol gene, including the protease, reverse transcriptase, and integrase genes, was sequenced.

Answer: Pol (including protease, reverse transcriptase, and integrase).

**Question 10: What method was used for sequencing?**

Evidence: The paper states that ""Nested PCR amplicons were purified and sequenced with a BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher Scientific, Waltham, MA, USA)"" and ""Sequencing libraries were prepared using the NEBNext Ultra II DNA Library Prep Kit for Illumina (New England BioLabs, Beverly, MA, USA)"".

Rationale: The paper explicitly states that both Sanger sequencing (using BigDye Terminator) and Next-Generation Sequencing (NGS) (using Illumina) were used.

Answer: Both Sanger sequencing and Next-Generation Sequencing (NGS).

**Question 11: What type of samples were sequenced?**

Evidence: The paper states that ""At least 500 μL of the patient's plasma samples were concentrated at 20,000 g and 8 °C for 1 h"".

Rationale: The paper explicitly states that plasma samples were used for sequencing.

Answer: Plasma.

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper states that ""All newly diagnosed treatment-naïve PLHIV over 18 years who entered clinical care at UHID in the period between January 2019 and December 2022"" were included in the study.

Rationale: The paper explicitly states that the study included only treatment-naïve individuals, implying that no sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: No.

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not explicitly state whether the patients were in a clinical trial.

Rationale: The paper does not provide information on clinical trials, so it is unclear whether the patients were in a clinical trial.

Answer: Not Reported.

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper states that ""All newly diagnosed treatment-naïve PLHIV over 18 years who entered clinical care at UHID in the period between January 2019 and December 2022"" were included in the study.

Rationale: The paper explicitly states that the study included only treatment-naïve individuals, implying that no sequences were obtained from individuals who had previously received ARV drugs.

Answer: No.

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly state which drug classes were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on previous ARV drug use, so it is unclear which drug classes were received by individuals in the study.

Answer: Not Reported.

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper does not explicitly state which drugs were received by individuals in the study before sample sequencing.

Rationale: The paper does not provide information on previous ARV drug use, so it is unclear which drugs were received by individuals in the study.

Answer: Not Reported.",95
38140667,"Here are the answers to the questions based on the provided paper:

**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""genotypic resistance testing"", ""genotyping"", and ""sequencing"" of patient samples, and reports GenBank accession numbers for sequences generated in this study.

Rationale: The paper explicitly states that genetic sequencing was performed on clinical samples from patients, and provides GenBank accession numbers for the sequences.

Answer: Yes

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""phenotypic susceptibility"", ""phenotypic resistance testing"", and ""drug susceptibility assay"", and reports values such as IC50 and fold-change in susceptibility.

Rationale: The paper explicitly states that phenotypic susceptibility testing was performed, and reports the results of these tests.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper reports that sequences were submitted to GenBank and provides accession numbers.

Rationale: The paper explicitly states that sequences were submitted to GenBank, and provides accession numbers for the sequences.

Answer: Yes

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not provide specific GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper mentions that 3219 individuals received DTG-based regimens, and 179 experienced VF.

Rationale: The paper explicitly states that 3219 individuals received DTG-based regimens, and 179 experienced VF.

Answer: 3219

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper mentions that samples were collected in France, Canada, Tanzania, Malawi, Mozambique, Brazil, Nigeria, Spain, Italy, Germany, Botswana, and South Africa.

Rationale: The paper explicitly states that samples were collected in these countries.

Answer: France, Canada, Tanzania, Malawi, Mozambique, Brazil, Nigeria, Spain, Italy, Germany, Botswana, and South Africa

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper mentions that samples were collected between 2012 and 2022.

Rationale: The paper explicitly states that samples were collected between 2012 and 2022.

Answer: 2012-2022

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not mention cloning of samples prior to sequencing.

Answer: Not reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions that the integrase gene was sequenced.

Rationale: The paper explicitly states that the integrase gene was sequenced.

Answer: Integrase

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the specific sequencing method used.

Rationale: The paper does not mention the specific sequencing method used.

Answer: Not reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions that plasma samples were sequenced.

Rationale: The paper explicitly states that plasma samples were sequenced.

Answer: Plasma

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions that sequences were obtained from individuals with virological failure on a treatment regimen.

Rationale: The paper explicitly states that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not mention that the patients were in a clinical trial.

Answer: No

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions that some individuals had previously received ARV drugs.

Rationale: The paper explicitly states that some individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that individuals received NRTIs, NNRTIs, PIs, and INSTIs before sample sequencing.

Rationale: The paper explicitly states that individuals received these drug classes before sample sequencing.

Answer: NRTIs, NNRTIs, PIs, and INSTIs

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions that individuals received DTG, 3TC, ABC, TDF, FTC, EFV, NVP, and RPV before sample sequencing.

Rationale: The paper explicitly states that individuals received these drugs before sample sequencing.

Answer: DTG, 3TC, ABC, TDF, FTC, EFV, NVP, and RPV",67
38142692,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not explicitly state that genetic sequencing was performed on clinical samples from patients, but it does mention that the study used routinely collected, de-identified data from South Africa's ART programme.

Rationale: The paper does not provide direct evidence of HIV sequences from patient samples, but it does mention the use of clinical data, which may imply the presence of patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data or any related experiments.

Rationale: The paper focuses on the clinical outcomes of patients receiving different antiretroviral therapy regimens and does not report any in vitro experiments.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention the public availability of sequences.

Rationale: The paper does not provide any information about the deposition of sequences in public databases.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide any GenBank accession numbers.

Rationale: The paper does not mention the deposition of sequences in GenBank or any other public database.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide any information about the number of individuals who had samples obtained for HIV sequencing.

Answer: Not reported
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin of the sequenced samples.

Rationale: The paper does not provide any information about the country of origin of the sequenced samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the years during which the sequenced samples were obtained.

Rationale: The paper does not provide any information about the years during which the sequenced samples were obtained.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper does not provide any information about the cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper does not mention the specific HIV genes that were sequenced.

Rationale: The paper does not provide any information about the specific HIV genes that were sequenced.

Answer: Not reported
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention the type of samples that were sequenced.

Rationale: The paper does not provide any information about the type of samples that were sequenced.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention virological failure on a treatment regimen.

Rationale: The paper does not provide any information about virological failure on a treatment regimen.

Answer: Not reported
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention HIV sequences from individuals who had previously received ARV drugs.

Rationale: The paper does not provide any information about HIV sequences from individuals who had previously received ARV drugs.

Answer: Not reported
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the drug classes received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the drug classes received by individuals in the study before sample sequencing.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention the specific drugs received by individuals in the study before sample sequencing.

Rationale: The paper does not provide any information about the specific drugs received by individuals in the study before sample sequencing.

Answer: Not reported
""""""",58
38152686,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""Genotyping was requested, with detection of the *H51Y* and *E157Q* mutations in the integrase."" and ""The baseline viral load (VL) was 437,927 cp/mL (Log = 5.64)."".

Rationale: The paper reports HIV sequences from a patient sample, specifically the integrase gene, and provides the baseline viral load.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper does not mention in vitro drug susceptibility data.

Rationale: The paper does not report any in vitro drug susceptibility data, only genotypic resistance testing.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention making sequences publicly available.

Rationale: The paper does not report making sequences publicly available, and no accession numbers are provided.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers.

Rationale: The paper does not provide any GenBank accession numbers for the sequenced HIV isolates.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""A 29-year-old male patient was admitted..."" and ""The patient was then treated with a rescue regimen..."".

Rationale: The paper reports HIV sequencing from a single patient.

Answer: 1
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention the country of origin for the sample.

Rationale: The paper does not provide information on the country of origin for the sample.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention the year of sample collection.

Rationale: The paper does not provide information on the year of sample collection.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not report cloning prior to sequencing, and the sequencing method is not described.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Genotyping was requested, with detection of the *H51Y* and *E157Q* mutations in the integrase."".

Rationale: The paper reports sequencing of the integrase gene.

Answer: IN
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method.

Rationale: The paper does not report the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""The baseline viral load (VL) was 437,927 cp/mL (Log = 5.64)."".

Rationale: The paper reports sequencing of plasma samples.

Answer: Plasma
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""Therapeutic failure was verified."" and ""The patient was then treated with a rescue regimen..."".

Rationale: The paper reports sequencing of a patient with virological failure on a treatment regimen.

Answer: Yes
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not report the patient being part of a clinical trial.

Answer: No
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""Antiretroviral therapy was initiated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG)..."".

Rationale: The paper reports sequencing of a patient who had previously received ARV drugs.

Answer: Yes
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper states ""Antiretroviral therapy was initiated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG)..."".

Rationale: The paper reports the patient received NRTIs (TDF, 3TC) and INSTIs (DTG) before sample sequencing.

Answer: NRTI, INSTI
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper states ""Antiretroviral therapy was initiated with Tenofovir/Lamivudine and Dolutegravir (TDF/3TC and DTG)..."".

Rationale: The paper reports the patient received TDF, 3TC, and DTG before sample sequencing.

Answer: TDF, 3TC, DTG
""""""",57
38314093,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper states ""HIV-infected blood samples were sent to the Guangdong AIDS Prevention Center for genotypic resistance testing"" and ""Pro-RT gene sequences from the samples were obtained and analyzed for drug resistance-related mutations.""

Rationale: The paper explicitly mentions that HIV sequences were obtained from patient samples and analyzed for drug resistance-related mutations.

Answer: Yes
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper states ""Sequences were submitted to the Stanford University HIV resistance database (http://hivdb.stanford.EDU) for subtype identification, resistance loci, and drug sensitivity analysis.""

Rationale: The paper mentions that the sequences were analyzed for drug sensitivity, but it does not provide in vitro drug susceptibility data.

Answer: No
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper does not mention that the sequences were made publicly available.

Rationale: The paper does not provide any information about the public availability of the sequences.

Answer: No
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Rationale: The paper does not mention GenBank accession numbers.

Answer: Not reported
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper states ""HIV-infected blood samples were sent to the Guangdong AIDS Prevention Center for genotypic resistance testing"" and ""37 untreated patients [29 men (78%); 8 women (22%)] obtained from Meizhou People's Hospital were included.""

Rationale: The paper explicitly mentions that 37 individuals had samples obtained for HIV sequencing.

Answer: 37
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper states ""serum samples collected from the HIV Confirmatory Laboratory of Meizhou People's Hospital Medical Laboratory Center (From May 2008 to December 2019)"".

Rationale: The paper explicitly mentions that the samples were obtained from Meizhou, China.

Answer: China
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper states ""serum samples collected from the HIV Confirmatory Laboratory of Meizhou People's Hospital Medical Laboratory Center (From May 2008 to December 2019)"".

Rationale: The paper explicitly mentions that the samples were obtained from 2008 to 2019.

Answer: 2008-2019
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention that the samples were cloned prior to sequencing.

Rationale: The paper does not provide any information about cloning.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper states ""Pro-RT gene sequences from the samples were obtained and analyzed for drug resistance-related mutations.""

Rationale: The paper explicitly mentions that the Pro-RT gene was sequenced.

Answer: Pro-RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide any information about the sequencing method.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper states ""HIV-infected blood samples were sent to the Guangdong AIDS Prevention Center for genotypic resistance testing"".

Rationale: The paper explicitly mentions that blood samples were sequenced.

Answer: Blood
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper states ""37 untreated patients [29 men (78%); 8 women (22%)] obtained from Meizhou People's Hospital were included.""

Rationale: The paper explicitly mentions that the patients were untreated, suggesting that they did not have virological failure on a treatment regimen.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention that the patients were in a clinical trial.

Rationale: The paper does not provide any information about a clinical trial.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper states ""37 untreated patients [29 men (78%); 8 women (22%)] obtained from Meizhou People's Hospital were included.""

Rationale: The paper explicitly mentions that the patients were untreated, suggesting that they did not previously receive ARV drugs.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the patients received any drug classes before sample sequencing.

Rationale: The paper does not provide any information about previous drug classes.

Answer: None
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention that the patients received any drugs before sample sequencing.

Rationale: The paper does not provide any information about previous drugs.

Answer: None
""""""",62
38427738,"**Question 1: Does the paper report HIV sequences from patient samples?**

Evidence: The paper mentions ""HIV-1 NL4-3 clone"" and ""patient-derived material"" but does not explicitly state that the sequences were obtained from patient samples. However, it does mention ""long-term propagation of HIV-1 in the presence of the INSTI DTG and the RT inhibitor EFdA"" and ""sequencing analysis of the viruses at the peak of replication.""

Rationale: The paper does not explicitly state that the sequences were obtained from patient samples, but it does mention the use of patient-derived material and the long-term propagation of HIV-1 in the presence of antiretroviral drugs. This suggests that the sequences may have been obtained from patient samples, but it is not explicitly stated.

Answer: No

**Question 2: Does the paper report in vitro drug susceptibility data?**

Evidence: The paper mentions ""in vitro selection of drug-resistant variants"" and ""long-term passaging of HIV-1 in the presence of the INSTI DTG and the RT inhibitor EFdA."" It also reports the results of in vitro experiments, including the emergence of resistance mutations and the effect of different drugs on viral replication.

Rationale: The paper reports in vitro drug susceptibility data, including the results of long-term passaging experiments and the emergence of resistance mutations.

Answer: Yes

**Question 3: Were sequences from the paper made publicly available?**

Evidence: The paper does not mention the public availability of the sequences.

Rationale: The paper does not provide information on the public availability of the sequences.

Answer: Not Reported

**Question 4: What were the GenBank accession numbers for sequenced HIV isolates?**

Evidence: The paper does not mention GenBank accession numbers.

Rationale: The paper does not provide GenBank accession numbers for the sequenced HIV isolates.

Answer: Not Reported

**Question 5: How many individuals had samples obtained for HIV sequencing?**

Evidence: The paper does not mention the number of individuals who had samples obtained for HIV sequencing.

Rationale: The paper does not provide information on the number of individuals who had samples obtained for HIV sequencing.

Answer: Not Reported

**Question 6: From which countries were the sequenced samples obtained?**

Evidence: The paper does not mention the countries from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the countries from which the sequenced samples were obtained.

Answer: Not Reported

**Question 7: From what years were the sequenced samples obtained?**

Evidence: The paper does not mention the years from which the sequenced samples were obtained.

Rationale: The paper does not provide information on the years from which the sequenced samples were obtained.

Answer: Not Reported

**Question 8: Were samples cloned prior to sequencing?**

Evidence: The paper does not mention cloning prior to sequencing.

Rationale: The paper does not provide information on whether the samples were cloned prior to sequencing.

Answer: Not Reported

**Question 9: Which HIV genes were reported to have been sequenced?**

Evidence: The paper mentions ""Gag-, Pol-, Env-, and Nef-coding regions"" and ""sequencing analysis of the viruses at the peak of replication.""

Rationale: The paper reports that the Gag, Pol, Env, and Nef genes were sequenced.

Answer: Gag, Pol, Env, Nef

**Question 10: What method was used for sequencing?**

Evidence: The paper does not mention the sequencing method used.

Rationale: The paper does not provide information on the sequencing method used.

Answer: Not Reported

**Question 11: What type of samples were sequenced?**

Evidence: The paper mentions ""virus-containing supernatants"" and ""genomic DNA was extracted from infected cells.""

Rationale: The paper reports that the samples sequenced were virus-containing supernatants and genomic DNA extracted from infected cells.

Answer: Virus-containing supernatants, Genomic DNA from infected cells

**Question 12: Were any sequences obtained from individuals with virological failure on a treatment regimen?**

Evidence: The paper mentions ""virological failure"" and ""INSTI failure in people living with HIV in the absence of drug resistance mutations in IN.""

Rationale: The paper reports that sequences were obtained from individuals with virological failure on a treatment regimen.

Answer: Yes

**Question 13: Were the patients in the study in a clinical trial?**

Evidence: The paper does not mention a clinical trial.

Rationale: The paper does not provide information on whether the patients were in a clinical trial.

Answer: Not Reported

**Question 14: Does the paper report HIV sequences from individuals who had previously received ARV drugs?**

Evidence: The paper mentions ""INSTI failure in people living with HIV in the absence of drug resistance mutations in IN"" and ""long-term passaging of HIV-1 in the presence of the INSTI DTG and the RT inhibitor EFdA.""

Rationale: The paper reports that the individuals had previously received ARV drugs.

Answer: Yes

**Question 15: Which drug classes were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""INSTI DTG"" and ""RT inhibitor EFdA.""

Rationale: The paper reports that the individuals received INSTI and RT inhibitor drugs before sample sequencing.

Answer: INSTI, RT inhibitor

**Question 16: Which drugs were received by individuals in the study before sample sequencing?**

Evidence: The paper mentions ""DTG"" and ""EFdA.""

Rationale: The paper reports that the individuals received DTG and EFdA before sample sequencing.

Answer: DTG, EFdA",82
38864613,"Here are the answers to the questions:

""""""
Question: Does the paper report HIV sequences from patient samples?

Evidence: The paper does not mention patient samples or HIV sequences from patients. It discusses in vitro experiments with HIV-1 variants and resistance selection studies.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Does the paper report in vitro drug susceptibility data?

Evidence: The paper reports in vitro drug susceptibility data for ISL and LEN against various HIV-1 variants, including WT and resistance-associated variants.

Rationale: The paper presents data on the antiviral activity of ISL and LEN against different HIV-1 variants, including IC50 values and fold-changes in susceptibility.

Answer: Yes
""""""

""""""
Question: Were sequences from the paper made publicly available?

Evidence: The paper states that sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.

Rationale: The paper explicitly mentions that the sequences have been deposited in GenBank and provides the accession numbers.

Answer: Yes
""""""

""""""
Question: What were the GenBank accession numbers for sequenced HIV isolates?

Evidence: The paper states that sequences from resistance selection experiments have been deposited in GenBank under accession numbers PP827803 -- PP828572.

Rationale: The paper provides the accession numbers for the sequences deposited in GenBank.

Answer: PP827803 -- PP828572
""""""

""""""
Question: How many individuals had samples obtained for HIV sequencing?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: 0
""""""

""""""
Question: From which countries were the sequenced samples obtained?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: Not reported
""""""

""""""
Question: From what years were the sequenced samples obtained?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: Not reported
""""""

""""""
Question: Were samples cloned prior to sequencing?

Evidence: The paper does not mention cloning of samples prior to sequencing.

Rationale: The paper focuses on in vitro experiments and does not report any cloning of samples prior to sequencing.

Answer: Not reported
""""""

""""""
Question: Which HIV genes were reported to have been sequenced?

Evidence: The paper mentions sequencing of the CA and RT regions of HIV-1.

Rationale: The paper presents data on the antiviral activity of ISL and LEN against different HIV-1 variants, including IC50 values and fold-changes in susceptibility, and mentions sequencing of the CA and RT regions.

Answer: CA, RT
""""""

""""""
Question: What method was used for sequencing?

Evidence: The paper does not explicitly mention the sequencing method used.

Rationale: The paper focuses on in vitro experiments and does not report any details on the sequencing method used.

Answer: Not reported
""""""

""""""
Question: What type of samples were sequenced?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: Not reported
""""""

""""""
Question: Were any sequences obtained from individuals with virological failure on a treatment regimen?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Were the patients in the study in a clinical trial?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: Not reported
""""""

""""""
Question: Does the paper report HIV sequences from individuals who had previously received ARV drugs?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: No
""""""

""""""
Question: Which drug classes were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: Not reported
""""""

""""""
Question: Which drugs were received by individuals in the study before sample sequencing?

Evidence: The paper does not mention patient samples or HIV sequencing from individuals.

Rationale: The paper focuses on in vitro experiments and does not report any HIV sequences from patient samples.

Answer: Not reported
""""""",60
